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Abstract 
The role of prion protein (Prpc) as a crucial factor in the pathogenesis of the 
Transmissible Spongiform Encephalopathies (TSE's) is weIl known. However, the 
physiologic role of this highly conserved protein in vivo is thus far, largely unknown. 
In vitro evidence shows that Prpc may have a neuroprotective role, inhibiting Bax-
mediated apoptosis, by preventing the conformational change of Bax, which is one of 
the early steps leading to Bax activation and subsequently, apoptosis. In vivo 
evidence indicates that in sorne transgenic mouse models overexpressing a mutant 
prion protein that result in neuronal death, the simulataneous expression of PrP 
protects against this neuronal death. The pathogenesis of the neuronal death in these 
in vivo models is unknown. Our objective was to determine if Prpc could protect 
against Bax-mediated cell death in vivo. We used two experimental paradigms to 
investigate this neuroprotective role of Prpc in vivo. 
The first paradigm involved an external in suit (ethanol injection) to 7 day old mice, 
which induces massive Bax-mediated neuronal death. We then quantified the number 
of active caspase 3 positive ceIls, as a downstream marker of Bax activation, induced 
in mice on various genetic backgrounds, PrP overexpressors (PrPOexp), PrP wild-type 
(PrP+/+) and PrP knockout (PrpO/o). We also examined Bax activation by 
immunoprecipitation of subcellular fractions, as weIl as total Bax activation and 
cytochrome c release directly in ex-vivo mouse brains. In addition, we examined the 
insertion of active Bax into the rnitochondrial membrane, also using subcellular 
fractionation. 
The second paradigm involves an internaI in suIt (physiological Bax-mediated 
neuronal death during embryonic development). This insult results in massive Bax-
mediated cell death in embryonic mi ce that do not express the natural antagonist of 
Bax i.e. BclxL • We have therefore created 3 lines of transgenic mice expressing 
Syrian Hamster PrP (SHaPrP) under the control of the Bclx promoter, to cross with 
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Bclx+'- mice to see if the SHaPrP can assume the role of Bclx in Bclx knockout mice 
and rescue the neuronal cell death. 
In the first paradigm, greater numbers of neurons undergoing apoptosis following 
ethanol insult were seen in PrpO/O th an in PrP+1+ mice, although the differences were 
not statistically significant. The ex-vivo examination of mouse brains did not provide 
definitive results. 
In the second paradigm, 3 lines of transgenic mice have been created and are in 
various stages of breeding to obtain the required genotypes to test our hypothesis. 
The level of expression of SHaPrP in these mice is below the level of detection via 
western blot or immunoprecipitation. 
The trend shown in our results suggests that in vivo, Prpc may provide sorne 
protection for neurons from Bax-mediated cell death as a result of an external insult. 
Research is ongoing to see if Prpc can protect neurons in vivo against developmental 
Bax-mediated cell death. The work presented here highlights the variability and 
technical difficulty inherrent with in vivo studies, particularly when the available 
knowledge of the biochemical pathways involved is incomplete. 
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Résumé 
Le rôle que joue la protéine prion (Prpc) dans la pathogenèse des maladies 
Encéphalopathies Spongiforme Transmissibles (ESTs) est bien connu. Cependant, le 
rôle physiologique de cette protéine largement exprimée in vivo reste toujours 
inconnu. Des évidences in vitro indiquent que Prpc joue un rôle neuroprotecteur 
contre l'apoptose provoquée par Bax. Prpc empêche le changement de conformation 
de Bax, qui est l'une des étapes menant à l'activation de Bax et à l'apoptose. De plus, 
des évidences in vivo montrent que dans certains modèles de souris transgéniques qui 
surexpriment une protéine prion et qui est toxique pour les neurones, l'expression 
simultanée de Prpc protège contre la mort de ces neurones. Les mécanismes de la 
mort neuronale dans ces modèles in vivo ne sont pas connus. L'objectif de notre 
étude était de déterminer si Prpc peut protéger in vivo contre la mort cellulaire induite 
par Bax. Nous avons utilisé deux modèles pour tester ce rôle neuroprotecteur de Prpc 
in vivo. 
Le premier modèle consistait en un dommage externe (l'injection d'éthanol) à des 
souris âgées de 7 jours, pour induire une mort cellulaire sous la médiation de Bax. 
Par la suite, nous avons quantifié le nombre de cellules positives pour la caspase 3 
active, qui est un marqueur de l'activation de Bax, chez des souris surexprimant PrP 
(PrpOexP), des souris de type sauvage (Prpc), et des souris déficientes en protéine prion 
(PrpO'o). Nous avons également examiné l'activation de Bax par immunoprécipitation 
dans les fractions subcellulaires ainsi que la Bax totale et la libération du cytochrome 
c dans le cerveau de souris ex-vivo. De plus, nous avons examiné l'insertion de Bax 
dans les membranes mitochondriales par fractionnement subcellulaire. 
Le deuxième modèle consistait en une lésion interne (la mort neuronale 
physiologique induite par Bax pendant le développement embryonnaire). Cette lésion 
induit la mort de plusieurs cellules provoquée par Bax chez les souris embryonnaires 
qui n'expriment pas l'antagoniste naturel de Bax i.e. BclxL . Pour cela, nous avons 
créé 3 lignées de souris transgéniques afin qu'elles expriment la PrP du hamster 
IV 
syrien de la PrP (SHaPrP) sous le contrôle du promoteur de Bclx. Ces souris seront 
croisées avec des souris Bclx+'- afin de déterminer si SHaPrP peut remplacer la 
fonction de Bclx chez des souris n'exprimant pas Bclx et ainsi empêcher la mort 
neuronale. 
Dans le premier modèle, suite à l'injection d'éthanol, nous avons constaté un plus 
grand nombre de neurones apoptotiques chez les souris PrpOlO que les souris Prp+/+, 
mais les différences n'étaient pas statistiquement significatives. L'examen des 
cerveaux des souris ex-vivo n'a pas fourni de résultats concluants. 
Dans le deuxième modèle expérimental, 3 lignées de souris transgéniques sont en 
production, et le~ croisements des diverses lignées afin de générer les génotypes 
requis pour vérifier notre hypothèse sont en cours. Toutefois, les niveaux 
d'expression de la protéine SHaPrP sont indétectables par immunobavardage ou 
immunoprécipitation. Les études se poursuivent afin de tester si Prpc peut protéger 
les neurones de la mort cellulaire développementale sous la médiation de Bax. 
Nos résultats du premier modèle n'étaient pas statistiquement significatifs, mais 
montraient une nette tendance à appuyer notre hypothèse en accord avec d'autres 
études in vitro. Le travail présenté dans cette thèse démontre les difficultés associées 
aux études in vivo, en particulier quand les connaissances des voies biochimiques 
impliquées sont limitées. 
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Chapter 1 General Introduction 
1.1 Historical Perspective 
The prototypic prion disease is a naturally occurring disease of sheep and goats called 
"scrapie" that was first described in the literature in 1732 (Wechselberger et al. 2002). 
The prion diseases have since come to be known as transmissible spongiform 
encephalopathies and have been reported in a large number of animal species. These 
other diseases include, transmissible mink encephalopathy (Collinge 2001), chronic 
wasting disease of mule deer and elk (Williams and Young 1980), bovine spongiform 
encephalopathy (BSE) (Wells et al. 1987), and feline spongiform encephalopathy 
(Wyatt et al. 1991). Spongiform encephalopathies have also been described in a 
number of zoo animaIs including; kudu, nyala, Arabian oryx, Scimitar horned oryx, 
eland, gemsbok, bison, ankole, tiger, cheetah, ocelot and puma, which have 
developed coincident with the emergence of BSE (Collinge 2001). Human prion 
diseases include Creutzfeldt-lakob disease (ClD), Gerstmann-Straussler-Scheinker 
disease (GSS), kuru (Collinge 2001) and fatal familial insomnia (FFI) (Belay 1999). 
In 1995, a novel human prion disease, variant OD (vOD) was identified and 
subsequently found to be caused by the same prion strain that causes BSE in cattle 
(Collinge 1999). This finding has fueled fears that dietary exposure to BSE prions 
may lead to a major epidemic of vClD in the UK and other countries (Collinge 1999), 
and has understandably stimulated considerable research interest in these diseases. 
Scrapie was demonstrated to be a transmissible disease by inoculation experiments in 
sheep and goats in 1936 (Collinge 2001). Scrapie was initially believed to be caused 
by a "slow virus" infection, due to the prolonged incubation period (Collinge 2001). 
Investigation into an epidemic of a neurodegenerative disease known as kuru, 
affecting members of the Fore linguistic group in the Eastern Highlands of Papua 
New Guinea, incriminated cannibalistic feasts in the transmission of the disease 
(Gajdusek et al. 1957). Subsequently, kuru, OD and GSS were ail successfully 
transmitted to chimpanzees, confirming the transmissible nature of these diseases 
(Gajdusek et al. 1966, Collinge 2001). 
1.1.1 Classification of prion diseases 
The prion diseases are classified etiologically, as acquired, inherited and sporadic. 
Acquired cases have resulted from cannibalism (Gajdusek et al. 1957), accidentaI 
exposure to infected tissues during medical or surgi cal procedures, such as via 
contaminated stereotactic electroencephalogram electrodes (Bernoulli et al. 1977), 
corne al transplants (Duffy et al. 1974), dura mater grafts (Thadani et al. 1988), and 
the use of human pituitary-derived gonadotrophin (Cochius et al. 1990). 
Epidemiological studies do not provide evidence for a link between scrapie and ClD 
in humans (Brown et al. 1987). Dietary exposure to BSE has been responsible for an 
increasing number of vClD cases, and no doubt this number will continue to increase 
as the incubation period is unknown (Collinge 1999). 
Approximately 15% of human cases of prion disease are inherited and associated with 
mutations in the prion protein gene (PRNP) (Collinge 1997). Over 20 distinct 
mutations in the PRNP gene have thus far been identified (Prusiner 1998a). These 
occur as missense mutations (Goldfarb et al. 1992a, Goldfarb et al. 1992b), non-sense 
mutations (Finckh et al. 2000), or insertions in the octapeptide repeat region (Owen et 
al. 1989). 
The overwhelming majority of human pnon cases, nearly 85%, have no clear 
evidence of a genetic mutation in PRNP or documented exposure to an infectious 
agent and so are termed sporadic (Collinge 2001). The majority of these cases are 
CJD (Parchi et al. 1996), although sporadic forms of GSS (Prusiner 1998b) and FI 
(Mastrianni et al. 1999) have been described. 
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1.2 Clinical Features and Pathology 
Clinically Kuru and GSS cases present with ataxia, referable to the cerebellum, 
whereas, classieal CJD presents as a rapidly progressive, multifocal dementia, usually 
with myoclonus (Collinge 2001). Variant CJD is however, dominated by behavioral 
and psychiatrie signs (Collinge 2001). Scrapie in sheep is also marked in its early 
stages by behavioral abnormalities (i.e. withdrawal from normal flock societal 
behavior, nervousness, aggression) and pruritis, with progressive ataxia and trembling 
when excited (Lampert et al. 1972). 
The classical triad of histopathological features of the prion diseases, spongiform 
vacuolation, neuronal loss and astrocytosis, are common to both animal and human 
diseases (Bell and Ironside 1993). Amyloid plaques have also been described in 
sorne cases (Bell and Ironside 1993). The incubation period, type, severity and 
distribution of these pathological changes, when scrapie strains are inoculated into a 
given strain of mice, are sufficiently specifie to allow the identification of 
approximately 20 specifie strains of scrapie (Bruce and Fraser 1991). 
1.2.1 Vacuolation 
Vacuolation is found within the perikarya and within neuronal processes (Jeffrey et 
al. 1995a). It is a relatively common and prominent finding in both BSE and scrapie, 
though it is not invariably present (Wells et al. 1989, Zlotnik 1962). In BSE, 
vacuolation is predominantly found in the nucleus of the solitary tract, the nucleus of 
the spinal tract of the trigeminal nerve, within the reticular formation, periaqueductal 
gray matter, in the paraventricular area of the hypothalamus and in the thalamus 
(Wells et al. 1991). In pigs infected with the BSE agent, vacuolation is most 
prominent rostral to the medulla, in the thalamus, striatum and in the frontal cerebral 
cortex, although it can also be found in the periaqueductal gray matter, and tectum, 
with occasional vacuoles in the cerebellum (Ryder et al. 2000). The brainstem is also 
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the area most commonly affected in sheep with scrapie, although the severity of the 
vacuolation varies with the breed of sheep (Wells 1993). The most consistent lesions 
are described in the lateral cuneate nucleus, reticular formation, and dorsal nucleus of 
the vag us nerve, and when the spinal cord is affected, in the dorsal horn and 
intermediate gray matter (Wells 1993). Vacuolar change is an infrequent finding in 
transmissible mink encephalopathy (Jeffrey et al. 1995a). Vacuolation may also be 
inconspicuous in cases of classical CJD (Manuelidis et al. 1978). 
In murine models of scrapie, vacuolation is not prominent early in the disease process 
but increases rapidly in the terminal stages of the disease (Jeffrey et al. 1991). The 
location of the vacuolation varies with scrapie strain in mou se models, however, the 
cerebellum is generally affected as a late event (Fraser and Dickinson 1968), with the 
exception of a single strain, 22L (Bruce and Fraser 1991), but may also be affected 
when mice are inoculated with the BSE strain (Lasmézas et al. 1997). 
Vacuoles may also occur in oligodendrocyte cytoplasm (Jeffrey et al. 1991), within 
the myelin sheath (Sato et al. 1980) and in astrocytes (Kim and Manuelidis 1983, 
1986). The vacuoles may be single membrane bound (Baker et al. 1990), double 
membrane bound (Sato et al. 1980), unbound (Kim and Manuelidis 1983, 1986) or 
any combination of these in the same mou se model of the disease (Jeffrey et al. 
1991). Baker et al. (1990) concluded that the single membrane bound vacuoles most 
likely originate in the smooth endoplasmic reticulum. Jeffrey et al. (1995a) reported 
that vacuoles may also originate from, mitochondria, or from within processes formed 
by the disassembly of microtubules and neurofilaments. Liberski et al. (1994) 
demonstrated that the intraocular injection of tumor necrosis factor produced lesions 
in the mou se optic nerve similar to the changes seen in the myelin sheaths of 
panencephalopathic type of CJD. The appearance of the vacuoles is not closely 
linked with clinical disease as agent replication and tissue infectivity precede 
vacuolation (Bruce 1985, Lasmézas et al. 1997, Prusiner 1982) and nonvacuolated 
areas of the brain may still be infectious (Baringer et al. 1983). In hamster models of 
scrapie, clinical signs may precede the appearance of vacuolation (Prusiner 1982). 
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Vacuolation is reduced in mink with the Chediak-Higashi gene (Marsh et al. 1976) 
and in beige mice (Jeffrey et al. 1995b). These mutations are associated with 
abnormalities in membrane bound organelles, including melanosomes and lysosomes, 
as weIl as a deficiency of lysosomal enzymes (Jeffrey et al. 1995b). Vacuolation is 
also a feature of accelerated aging in mice (Y agi et al. 1989) and has also been 
reported in experimental rabies infections in skunks and foxes (Bundza and Charlton 
1988), as weIl as in retroviral infections in mice (Sharpe et al. 1990). Taken together, 
these findings suggest that the vacuolation in transmissible spongiform 
encephalopathies (TSEs), one of the cardinal signs of the disease, is not the result of a 
pathologic change in a specific organelle but rather a more general feature of 
degeneration within the nervous system. The variable appearance of vacuolation and 
its lack of specific consistent temporal relationship with infectivity or clinical signs 
also suggest that it is a marker of degeneration rather than the specific cause of the 
pathological changes or clinical signs. 
1.2.2 Neuronalloss 
Neuronal loss is considered to be part of the classical triad of features of the TSEs, 
however, reliable documented evidence of this change is difficult to find. In many 
cases of GD and GSS, neuronalloss has not been objectively assessed (Jeffrey et al. 
1995a). Neuronal loss has not been unequivocaIly described in natural scrapie 
(Jeffrey et al. 1995a). It has however, been described in BSE (Jeffrey et al. 1992) and 
in murine scrapie (Jeffrey et al. 1994a). Several features described in CJD may 
suggest neuronal injury including; irregular dendrites with reduced spines, dendrites 
with constrictions and dilations along their processes, axonal dystrophy, frequent 
formation of ubiquitin protein conjugates and neuronal autophagy (Jeffrey et al. 
1995a). Neurofilament proteins are often abnormally phosphorylated (Jeffrey et al. 
1995a). These findings suggest that neuronal loss is not the major cause of the 
clinical signs noted in the TSEs, but rather indicates that ceIl death is the result of a 
pathological process during which the neuron loses its ability to perform its function. 
Therefore, the pathological process in the disease is degeneration rather than ceIl 
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death or apoptosis. The neuronal loss described in BSE, as weIl as in scrapie and 
BSE inoculated mice, may suggest a more virulent pathogen or more susceptible ho st. 
In these cases, the time for degeneration of the neurons prior to cell death is 
extremely short. 
1.2.3 Astrocytosis 
Although part of the "c1assical tri ad" of TSE pathologie findings, astrocytosis is a 
variable but sometimes prominent feature (MacKenzie 1983). Mild astrocytosis is 
present in many natural cases of scrapie and in sorne GSS patients, though it can be 
severe in many cases of CJD (Hudson et al. 1983). Astrocytosis is present in most 
neurodegenerative diseases and is one of a limited repertoire of responses to in jury in 
the central nervous system (CNS) (Jeffrey et al. 1995a). Ultrastructural and 
immunohistochemical features of astrocytosis include increased expression of glial 
fibrillary acidic protein (GFAP), vimentin and the accumulation of glycogen, features 
that are typical of reactive cells (Norenberg 1994). Therefore, astrocytosis is most 
likely a response to the degenerative process induced by the TSE agent, rather than a 
specifie response to the TSE agent itself. 
Many reports indicate that there is no significant inflammatory response with scrapie 
infection (Berg 1994). However, in cases with vacuolation or disease specifie PrP 
accumulation, increased numbers of microglial cells have been reported (Jeffrey et 
al. 1995a) and confirmed in mouse scrapie models (Williams et al. 1994a). 
Upregulation of HLADR expression in microglia has been reported (lronside et al. 
1993). Scrapie infection in mice results in induction of IL-lj3 and TNFa in glial cells 
(Williams et al. 1994b), as weIl as NF-KB, the major transcription activator for 
inflammatory cytokines (Kim et al. 1999). These findings do not rule out a more 
subtle inflammatory response in the CNS, perhaps mediated by activated microglia 
and cytokines. 
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1.2.4 Amyloid plaques 
Amyloid plaques were first described in kuru and were reported most consistently in 
the cerebelIum (Klatzo et al. 1959) and may be seen in GSS (Hudson et al. 1983). 
However, they are only rarely found in scrapie and BSE, and when present, are 
usually present in perivascular locations (Wells et al. 1991). Immunohistochemical 
studies have demonstrated that the se plaques contain amyloid fibrils composed of PrP 
(DeArmond et al. 1985) and astrocytic and microglial processes (Wisniewski et al. 
1990). The celI processes bec orne a more prominent component of the plaques over 
time (Jeffrey et al. 1995b). Ultrastructural and immunocytochemical studies have 
shown that PrP accumulates in astrocytic and microglial lysosomes, suggesting that 
these celIs are involved in the phagocytosis and removal of abnormal or excess PrP, 
rather than in its production (Jeffrey et al. 1995b). 
1.3. Etiologie Agent 
1.3.1 Protein-only theory 
Numerous transmission studies have indicated that these diseases are caused by an 
infectious agent. The long incubation period between inoculation and the 
development of the disease led to the concept of a "slow virus" being the causative 
agent (Collinge 2001). Alper et al. (1966) used the ability of ionizing radiation to 
inactivate biological activity, and determined that the agent may not contain nucleic 
acid and if it did, it must contain less than 800 bases. Subsequently, Patti son and 
Jones (1967) suggested that the agent may be associated with a small basic protein. 
More recently, based on titration and transmission studies, the scrapie agent has 
demonstrated resistance to man y treatments that degrade nucleic acids. It is resistant 
to wide changes in pH, nucleases, phosphodiesterases, ultraviolet irradiation at 254 
nm, divalent cation hydrolysis with Zn(N03)2' photochemical inactivation with 
psoralens and inactivation by hydroxylamine (Prusiner 1982). While there are viruses 
that are resistant to sorne of these procedures, there is no known virus resistant to 
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themall (Prusiner 1982). However, the se findings do not rule out the possibility of a 
virus-like agent. In contrast, infectivity of the agent is reduced following treatments 
that denature proteins, such as; digestion with proteinase K or trypsin, chemical 
modification with diethylpyrocarbonate, treatment with sodium dodecyl sulfate 
(SDS), chaotropic salts such as guanidinium thiocyanate, phenol, and urea (Prusiner 
1982). Taken together, the se observations led Stanley Prusiner to propose that the 
agent responsible for the TSEs was devoid of nucleic acids and was composed solely 
of protein, the "protein-only" hypothesis. This was clearly a unique concept. 
Prusiner (1982) introduced the term "prion" to de scribe the agent. The purported 
prion protein was subsequently isolated and found to be a sialoglycoprotein, 
containing a 27 to 30 kDa core that was resistant to proteases, which became known 
as Prp27-30 (Bolton et al. 1982). Partial ami no acid sequencing and cDNA isolation led 
to the discovery that the prion protein was encoded by a single-copy chromosomal 
gene rather than the DNA of an infectious agent (Oesch et al. 1985). The prion 
protein gene (PRNP) encodes a 33-35 kDa protein (Prpc) that is sensitive to proteases 
(Caughey and Raymond 1991). The Prp27-30 protease-resistant form is known as the 
scrapie protein (PrPSC) and has the sa me amino acid sequence as the normal cellular 
form PrpC , from which it is derived by posttranslational modification (Borchelt et al. 
1990, Caughey and Raymond 1991). Comparison of PrpC and PrpSc structure reveals 
that Prpc contains 42% u-helix and only 3% (3-sheet, whereas PrpSc contains 43% (3-
sheet and 30% u-helix (Pan et al. 1993). The protein-only hypothesis proposes that 
PrpSc acts as a template to change the conformation 9f Prpc into the PrpSc form and 
PrpSc is inextricably linked with the disease state (Prusiner 1998a, Telling et al. 1996, 
Westaway et al. 1998). The theory has been modified to suggest that another protein, 
"Protein X" may act as a facilitator in this conversion (Telling et al. 1995, Westaway 
et al. 1998). While the protein only theory has gained wide acceptance, the theory 
that the scrapie agent contains a virus-like nucleic acid is still championed by sorne 
researchers. 
Resistance to UV and ionizing radiation does not prove that the scrapie agent does not 
contain nucleic acid, only that it must be small (Alper et al. 1966, Rohwer 1984). 
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Narang (2002) reviewing the resistance data, states that the data does not preclude the 
presence of a virus and since conventional viruses depend on their protein coat for 
their integrity and infectivity, decreased infectivity as a result of treatments that 
denature proteins does not prove that nucleic acid is not present. Moreover, Narang 
interprets the data as being supportive of the presence of nucleic acid in the agent, as 
DNA is known for its tremendous stability and biologically active DNA has been 
amplified from fossils and tissues that have been fixed in formalin and maintained in 
a paraffin block for over 40 years, conditions that proteins cannot withstand. 
UltrastructuraIly, scrapie-associated fibrils (SAF) and tubulofilamentous virus-like 
particles (nemavirus particles NVP) are consistently seen in TSEs (Narang 2002). 
These are interpreted to be ultrastructural markers whereas PrPsc is stated to be a 
protein marker of the agent (Narang 2002). Narang (2002) argues that the protein-
only hypothesis is based on negative and indirect evidence and further, that PrP post-
translational modification is a pathological process and that PrPsc is a by-product of 
the disease process rather th an the agent itself. Narang (2002) proposes that the agent 
contains a nucleic acid that encodes the "protein X", the protein now believed to be 
required by the Prusiner group to facilitate conversion of Prpc to Prpsc. Single 
stranded DNA (ssDNA) of 1.2 kb has been purified from homogenized scrapie-
infected hamster brain tissue using standard phenol/chloroform extraction and 
alkaline gel electrophoresis (Narang 1998). This ssDNA has a multi-palindromic 
structure that may explain its tremendous stability (Narang 2002). Narang claims that 
this ssDNA has been purified and injected into hamsters, and has reproduced the 
disease (Narang 2002). He suggests that the ssDNA with the help of a carrier protein 
transmits the disease and that incorporation of the ssDNA into host DNA could 
explain the familial inheritance of scrapie in sheep, as weIl as inherited cases of CJD 
and GSS. 
Perhaps the most serious challenge to the protein-only theory has been raised as a 
result of the observation that the prion from a donor species, passaged in other species 
and then reisolated and injected into mice, retains its original amino acid sequence 
and phenotypic properties, and does not acquire the amino acid sequence of the Prpc 
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from the intervening specles (Kimberlin et al. 1989, Somerville 2002). Thus far, 
approximately 20 distinct scrapie strains have been identified via mouse inoculation 
tests (Bruce and Fraser 1991). As these strains can be identified by passage through 
mice of a single genotype, strain variation must be specified by the agent and be 
independent of the host (Bruce and Fraser 1991). These observations are difficult to 
reconcile with a single Prpsc. The Prusiner group argues that the different strains can 
be explained by different posttranslational modifications of the Prpc and structures 
induced by the PrpSc (Prusiner 1998a). 
1.3.2 Toxin or metabolic disorder theory 
Another interpretation of the data by Rico (2003) yields an alternative theory 
regarding the agent. Rico argues that when considering PrpSc, one must also consider 
the way that water interacts with globular proteins, as water participates in the 
macromolecular structure of proteins. PrpSc is strongly hydrophobic, water insoluble 
and surrounded by a microanhydrous environment, and probably a 1 nm thick gas 
cap, that is most likely composed of CO2 (Rico 2003). Rico argues that the absence 
of water inhibits interaction with proteases and chemical deactivators that function in 
an aqueous medium, and also explains the resistance to heat and radiation. Rico 
suggests that PrpSc interacts with Prpc to disrupt the post-translational modification of 
the protein following its endocytosis and recycling from the membrane location. 
Structural rigidity and hydrophobicity may also explain the absence of an 
immunological reaction (Rico 2003). Based on the se interpretations, Rico proposes 
that the inherited or sporadic spongiform encephalopathies should be considered as 
metabolic disorders and the acquired transmissible spongiform encephalopathies as 
intoxications. This is a conceptually different interpretation of the data that may also 
explain the inability to definitively detect nucleic acid in the agent. 
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1.3.3 Virino or virus theory 
The "virino" hypothesis suggests that the agent has an infoimational molecule, most 
likely ribonucleic acid (RNA), that is independent of the host, and that host derived 
PrP provides the protein component to prote ct the genetic material (Kimberlin 1982). 
Heat inactivation of TSE infectivity exhibits biphasic properties, and is consistent 
with a theory whereby the agent contains two components (Somerville 2002). In 
addition, Lasmézas et al. (1997) reported that 55% of mice inoculated with a 
homogenate of BSE-infected cattle brai n, exhibited clinical signs and infectivity, even 
with three subsequent passages, however, there was no detectable abnormal form of 
PrP. These results suggest that infectivity and the abnormal prion protein can be 
dissociated and led Lasmézas et al. (1997) to suggest that there may be an infectious 
agent in addition to PrP and that this agent may be a nucleic acid. Lasmézas et al. 
(1997) concluded that the abnormal prion accumulation was related to adaptation to a 
new host species, and that vacuolation and gliosis were linked to the abnormal protein 
accumulation. These transmission studies need to be replicated by other researchers 
in order to fully evaluate their significance. In addition, lack of sensitivity of the 
detection methods must be ruled out as a cause of the inability to detect abnormal 
prion protein in these transmission studies. 
Manuelidis and Manuelidis (1993) inoculated hamsters with buffy coat samples 
(peripheral blood white cell fractions) from healthy human volunteers with no family 
history of CJD and were able to produce spongiform changes in the brain of 
inoculated animaIs. Brain samples from similar healthy humans did not produce 
disease in hamsters. The authors interpreted these findings as suggestive of a viremia 
being present in most people within circulating leukocytes, but CNS disease only 
being seen in a very small number of people (Manuelidis and Manuelidis 1993). 
Subsequent work using centrifugation in various solutions and treatment with 
guanidine hydrochloride or sodium dodecyl sulfate (SDS) on CJD infected brain 
samples led the authors to conclude that the CJD "agent" is a virus (Manuelidis et al. 
1995). 
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Clearly, the exact nature of the scrapie agent has not been universally accepted at this 
point, and so one must keep an open mind. 
1.4 Pathogenesis 
1.4.1 Sporadic and inherited forms of disease 
The spongiform encephalopathies are thought to be the result of the accumulation of 
an abnormal isoform of the cellular prion protein, PrpSc (Taraboulos et al. 1990). In 
the inherited diseases, the abnormal isoform accumulates as a result of an autosomal 
dominant genetic mutation in the PRNP gene, presumably resulting in a protein with 
a propensity to misfold into the abnormal isoform, however, direct experimental 
evidence to support this theory is lacking (Swietnicki et al. 1998). The sporadic 
diseases account for the majority of the human cases of spongiform encephalopathy 
and are believed to be caused by a rare biochemical event that initiates the misfolding 
of the Prpc into the pathologic isoform (Mastrangelo and Westaway 2001). Proposed 
initiating metabolic events include misrouting to the cytoplasm (Ma and Lindquist 
1999), deamidation (Qin et al. 2000) and interaction with bivalent manganese ions 
(Brown et al. 2000). 
1.4.2 Acquired forms of disease 
Regardless of the nature of the etiologic agent of TSEs, it is transmissible between 
hosts. Understanding the mechanism of transmission is an important step towards 
understanding the pathogenesis of the disease. In cases of accidentaI transmission via 
medical or surgical procedures involving contaminated tissue, or in cases of 
experimental injection into the cerebrospinal fluid (CSF), direct transmission from 
nervous tissue to nervous tissue is obvious. However, in TSEs believed to be 
transmitted via the oral route, such as BSE, vClD and transmissible mink 
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encephalopathy, the route of neuroinvasion is less clear (Klein et al. 1997). Recent 
evidence suggests that after absorption from the gastrointestinal (GI) tract, the agent 
is carried via the systemic circulation to the spleen, where it invades mature follicular 
dendritic cells (FDC) of the white pulp (Glatzel et al. 2001). FDCs are a prominent 
site of PrpSc deposition (Nicotera 2001). Maturation of the FDCs is directed by 
cytokines released by B lymphocytes and so both cell types are critical for the 
propagation of the agent (Glatzel et al. 2001). In fact, depletion of FDCs pre vents 
neuroinvasion (Montrasio et al. 2000) and various B lymphocyte defects inhibit 
neuroinvasion (Klein et al. 1997). From the FDCs, the agent is believed to enter 
sympathetic nerves and from there, disseminate to the CNS (Nicotera 2001). 
Consistent with these observations, hyperinnervation of the spleen results in 
significantly greater repli cation and neuroinvasion, whereas, denervation of the 
spleen delays or prevents neuroinvasion (Nicotera 2001). Beekes et al. (1998) have 
suggested that following absorption from the GI tract, neuroinvasion via the vagal 
nerve to the dorsal motor nucleus is another possibility. 
According to the most widely accepted protein-only hypothesis of Prusiner, Prpc acts 
as substrate for PrpSc-mediated conversion of Prpc into PrpSc, with "Protein X" acting 
as a catalyst in the process. The requirement for a species specifie protein required to 
facilitate the conversion of Prpc to PrpSc was deemed necessary on the basis of studies 
with miee expressing either mou se Prpc al one, mouse Prpc and human Prpc and miee 
expressing a chimeric mouse/human PrP with or without expression of mouse Prpc 
(Telling et al. 1995). The catalyst protein termed "Protein X" provided the best 
explanation for the transmission studies in the se mice (Telling et al. 1995). Two 
models have been proposed to explain how Prpc may be converted to PrpSc. The first 
is the template-directed model, whereby a PrpSc mono mer would initiate the 
conversion, perhaps aided by protein X. In this model, PrpSc would be more stable 
than Prpc, but kinetically inaccessible (Prusiner 1991). The second model is the 
nucleation-seeding model. In this model, a nucleus of aggregated PrpSc initiates 
polymerization and conversion of Prpc, perhaps aided by protein X. In this model, 
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monomeric PrpSc would be less stable th an Prpc, but would be stabilized upon joining 
the PrpSc aggregate (Jarrett et al. 1993). 
Prpe has been converted into a protease-resistant form by denaturation and incubation 
with PrpSc, however the product has not been demonstrated to be infectious (Riesner 
et al. 1996). More recently, Prpe has been converted to a protease resistant form 
(Prpes) in vitro using the incubation of Prpes with normal brain homogenate 
(therefore containing Prpc) and then subjecting the mix to repeated cycles of 
sonication via a protein misfolding cyclic amplification assay (PM CA) (Castilla et al. 
2005). The in vitro generated product has demonstrated infectivity when inoculated 
into wild-type hamsters (Castilla et al. 2005). Curiously however, the "purified" 
product is less infectious than the same quantity of infectious crude brain extract 
(Castilla et al. 2005). These experiments, although showing that Prpe can be 
converted to prpes were done with the continued addition of normal brain 
homogenate and therefore do not rule out the presence of another factor in the brain 
homogenate that may be required for disease. In the protein-only theory, Prpe is 
required to provide a substrate to form the pathologic isoform PrpSc, as has been 
demonstrated in the Prnp knockout studies (Bueler et al. 1993). Reducing the amount 
of available Prpe via introducing antibodies or inhibitors therefore, seems a logical 
therapeutic rationale, however, before such an approach should be undertaken, the 
physiological functions of Prpe must be thoroughly investigated. 
In order to investigate the neurotoxicity of PrpSc, Brandner et al. (1996,1998) grafted 
brain tissue expressing PrpC into the brains of PrnpOIO mi ce, which do not express 
Prpe, then inoculated scrapie prions intracerebrally. The grafts developed severe 
neurodegenerative lesions as would be expected in a wild-type mouse, however, 
despite high levels of PrPsc in the grafted tissue and throughout the brain, no 
pathological changes were found in the adjacent brain not expressing Prpe (Brandner 
et al. 1996). The PrpSc isolated from these brains was demonstrated to be infectious 
(Brandner et al. 1996). Brandner et al. (1996) concluded that PrpSc, by itself, is not 
neurotoxic. Interestingly, when they used an intraperitoneal route of infection, they 
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were not able to demonstrate prions in the spleen and there was no sign of disease in 
the grafted bniin tissue (Blattler et al. 1997). They concluded that a PrpC expressing 
tissue is required to facilitate the invasion of prions into the brain. Irradiation of the 
bone marrow of these Prnp% mice, followed by bone marrow grafts from wild-type 
mice, was able to elicit infectivity in the spleen following intraperitoneal challenge, 
but no disease or infectivity was found in the Prpü/o brain (Blattler et al. 1997). They 
concluded that transfer from the spleen to the CNS requires another tissue, most 
likely the peripheral nervous system. Other experiments in severe combined 
immunodeficiency (SCID) mice, reconstituted with wild-type spleen grafts restored 
susceptibility to scrapie after peripheral inoculation (Fraser et al. 1996). Other 
experiments with various models of immunodeficiency demonstrated that 
differentiated B lymphocytes play a crucial role in neuroinvasion, whereas, there was 
no requirement for T lymphocytes (Klein et al. 1997). The same group demonstrated 
that the role of B cells seemed to be related to their role in inducing maturation of the 
follicular dendritic cells (FDCs), as prion immunoreactivity was localized to the 
FDCs and not the B cells (Klein et al. 1998). Overall, these findings suggest that 
components of the immune system are required for neuroinvasion of scrapie and that 
the FDCs are the most likely prion reservoir in the immune system. 
ln experimental scrapie infections of mice the first demonstrable indication of the 
presence of the agent is the extracellular accumulation of disease-specific PrPsc in the 
hippocampus at around day 70 post-infection (Jeffrey et al. 2000). Ultrastructural 
evidence of synaptic loss is present around day 84 post-infection, with axonal 
terminal degeneration and vacuolation occurring around day 98 post-infection 
(Jeffrey et al. 2000). The synaptic disruption was also associated with the loss of 
dendritic spines and abnormal dendritic morphology (Belichenko et al. 2000). Siso et 
al. (2002) found an overall decrease of proteins associated with synaptic function, 
such as synaptophysin, SNAP-25, syntaxin-1, a-synuclein, and j3-synuclein in 
scrapie-infected mice. Taken together, the se data provide evidence for both pre and 
post-synaptic pathological changes associated with the disease, which would disrupt 
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neuronal circuitry, perhaps leading to neuronal degeneration and eventuaIly, 
apoptosis. 
Treating mou se embryo derived cortical neurons with a synthetic peptide containing 
amino acids 106-126 of PrpC, a region conserved in aIl prion isoforms, increased the 
activity of glycogen synthase kinase 3 (GSK-3), an enzyme involved in 
phosphorylating sorne microtubule-associated proteins including Tau and microtubule 
associated protein 2 (Perez et al. 2003). Hyperphosphorylation of these proteins may 
initiate the disruption of the cytoskeleton and lead to the disorganization of neurites 
with subsequent synaptic disruption (Perez et al. 2003). The authors did not report if 
this peptide has ever been reported under physiological conditions and so the 
significance of this finding is unknown, however, if PrpSc is able to increase activity 
of GSK-3, this could suggest a mechanism linking PrpSc with synaptic degeneration. 
1.5 Prion protein (Pr pC) is ubiquitously expressed 
1.5.1 Prnp gene 
1.5.1.1 Normal prion protein (Prpc) 
Isolation of the 27 to 30 kDa protease resistant prion protein (PrP), and its partial 
amino acid sequencing, followed by cDNA isolation, led to the discovery that the 
Hamster prion protein was encoded by a single-copy chromos omal gene rather than 
an infectious agent (Oesch et al. 1985). Subsequently, Kretzschmar et al. (1986) 
cloned the human PRNP gene, which is located on the short arm of chromosome 20 
(Puckett et al. 1991). The human gene locus contains a 134 bp exon 1 and a 2355 bp 
exon II, separated by a 12,696 bp intron (Lee et al. 1998). The entire coding region is 
located in the second exon (Kretzschmar et al. 1986). The PRNP promoter region is 
typical for a housekeeping gene, with a CpG island extending from -235 to +167 bp 
within intron 1 and lacks a canonical T AT A box and an initiator element (Mahal et al. 
2001). Based on the sequence of the promoter, binding sites for transcription factors 
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such as nuclear-factor interleukin 6 (NF-IL6), muscle-specifie factor MyoD, SpI, heat 
shock factor (HSF), AP-1, AP-2 are present, and many are weIl conserved among 
mammalian species (Mahal et al. 2001). The presence of the NF-IL6 binding site 
may suggest that proinflammatory cytokines may play a role in Prpc expression. 
Using functional analysis of the promoter region, deletion of the region from -148 to 
-114 resulted in a 62% drop in gene expression in human neuronal (embryonic 
retinal) cells but not in HeLa (human uterine carcinoma) cells (Mahal et al. 2001), 
suggesting that this region may be particularly important in neuronal cells. A 
schematic diagram of the murine promoter region is shown in Figure 1.1 below. 
1.5.1.2 Familial mutations and polymorphism influence disease 
A number of ami no acid (AA) mutations in Prpc in humans appear to influence the 
onset and phenotype of human inherited prion diseases (Prusiner 1998a). Over 20 
AA mutations are reported, most of which are proposed to destabilize the Prpc 
structure (Prusiner 1998a). However, studies on the thermodynamic stability of sorne 
of these mutations do not support this hypothesis (Liemann et al. 1999, Swietnicki et 
al. 1998). However, prion proteins with insertional mutations (3 or 5 additional 
octapeptide repeats) have a more exposed N terminal and are more susceptible to 
oxidative damage (Yin et al. 2006). Apetri et al. (2004) found that increased 
thermodynamic stability of an intermediate form in the fol ding process of the prion 
protein (relative to the wild-type protein) is present in 7 out of 9 familial mutations 
examined. They suspect that this maybe a crucial factor in the conversion of these 
proteins to a disease associated form. However, the intermediate form for 2 out of the 
9 (E200K and P102L) did not show this increased stability, indicating that this 
property is not consistent and so its relationship to the disease state may be 
coincidental rather than causative. 
A polymorphism at position 129 has also been reported in humans, where 
approximately 40% of Caucasians are homozygous for methionine, 10% homozygous 
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Figure 1.1: Schematic diagram of the murine PrP promoter region. The numbers 
correspond to the position where the binding site for the respective promoter 
elements, which are listed above. NF-IL6, Apl, Ap2, Myo D, p53. -230 to +167 
represents the CpG island region. 
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for valine and 50% heterozygous (Zimmennann et al. 1999). Homozygosity at 
position 129 appears to predispose to sporadic ClD (Palmer et al. 1991). 
Interestingly, aIl clinical cases of variant Creutzfeldt-lakob Disease (vCJD) thus far 
identified, are homozygous for Met 129 (Collinge et al. 1996). A single preclinical 
case in a heterozygous Met/Val at codon 129 patient, who died from a ruptured 
abdominal aortie aneurysm 5 years after receiving a blood transfusion from a patient 
who had subsequently developed vClD has been identified (Peden et al. 2004). This 
patient had Prprt's present in the spleen, but not in the central nervous system, nor was 
there evidence of pathological features associated with vClD (Peden et al. 2004). An 
aspartate substitution for an asparagine at position 178 is also associated with either 
Fatal Familial Insomnia (FFI) or familial Creutzfeldt-lakob Disease (fCJD) , 
depending on whether there is a methionine or a valine at position 129, respectively 
(Goldfarb et al. 1992b). Heterozygosity at codon 129 appears to delay the onset of 
inherited prion diseases (Baker et al. 1990) and these data suggest that it may also be 
protective against vCJD (Zimmennann et al. 1999). 
Predictably, other structural changes are also associated with diseases. For example, 
a higher number of octapeptide repeats is associated with earlier onset of disease 
(Collinge 1999) characterized by dementia and ataxia (Chiesa et al. 1998). 
1.5.2 PrP protein 
1.5.2.1 Protein expression 
The Prpc protein is expressed in a wide variety of tissues including the brain, spleen, 
Iymph nodes, kidney, pancreas, salivary gland, adrenal gland, liver, thymus 
(Bendheim et al. 1992, Brown et al. 2000), testes, lung (Oesch et al. 1985) and 
muscle (Brown et al. 1998a). It is present in at least 27 mammalian species, birds 
(Wopfner et al. 1999) and reptiles (Simonie et al. 2000). A unique form of Prpc, 
truncated at the C-termÏnus is expressed only in rodent, caule and human 
spermatozoa (Shaked et al. 1999). The expression of Prpc increases with age in miee 
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(Williams et al. 2004). Human Prpc is a 253 amino acid (AA) precursor protein 
encoded from an intronless open reading frame (van Rheede et al. 2003) and has a 
molecular weight of 25 to 35 kDa (Hegde et al. 1998). The protein contains 254 AA 
in the mouse (Lee et al. 1998). 
Not only is PrpC ubiquitously expressed, but key elements of the protein structure are 
also highly conserved. The human protein has 4 identical proline and glycine-ri ch 
tandemly repeated octapeptides (ORs) at the N-terminus (Chiesaet al. 1998), a 
central transmembrane domain and a stop transfer effector domain (STE) (Borchelt et 
al. 1990, Hegde et al. 1998). However, the number of ORs in homozygous 
individuals varies among species from 4 in humans (Chiesa et al. 1998) and golden 
mole, up to 7 in the gymnure and leaf-nosed bat (van Rheede et al. 2003). Many 
motifs involved in post-translational modification of the protein (see below) are also 
conserved among species; glycosylation sites, the hydrophobie transmembrane 
domain, structural elements for N and C-terminal processing and attachment of the 
GPI anchor to the outer cell membrane (van Rheede et al. 2003). 
1.5.2.2 Post-translational modification 
PrpC is directed cotransiationally into the lumen of the endoplasmic reticulum (ER), a 
process that is mediated by a 22 amino acid (AA) N-terminal signal peptide 
(Nunziante et al. 2003). Within the ER, the N-terminal signal sequence is removed, 
as is a 23 AA C-terminal sequence, which facilitates the addition of the GPI anchor 
for attachment to the cell membrane (Nunziante et al. 2003). A disulphide bond 
between Cys 178 and Cys 213 is essential for proper folding of the protein (Stahl and 
Prusiner 1991). 
A particularly important post-translational modification involves N-glycosylation, 
which has been mapped to Asn 180 and Asn 196 in the human protein (Rudd et al. 
1999). High-mannose glycosylation and addition of the GPI anchor occur concurrent 
with or soon after translation and translocation of polypeptides into the lumen of the 
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ER (Caughey et al. 1989). The N-linked oligosaccharide chains that are added in the 
ER are rich in mannose and as such, are sensitive to endoglycosidase H digestion 
(Harris 2003). These oligosaccharides are later modified by the addition of sialic acid 
in the Golgi and are resistant to digestion with endoglycosidase H (Harris 2003). 
Final maturation of glycosylation requires transit to the Golgi apparatus where N-
acetylneuraminic acid is added to the GPI anchor (Stahl et al. 1992). Caughey et al. 
(1989) described 3 main glycoforms of the protein, full y glycosylated, 
monoglycosylated and unglycosylated, which can readily be identified by western 
blotting of protein extracts. However, given that glycosylation occurs in the ER as 
the protein is being translated, and transit to the Golgi is required to add N-
acetylneuraminic acid, these 3 main glycoforms are more likely mature glycosylated 
and various immature glycosylated forms. Glycosylation is thought to play an 
important role in intracellular trafficking of the protein (Rudd et al. 2002), and may 
also play a role in the folding or misfolding of the protein (Wiseman et al. 2005). 
Indeed, N-glycosylation is believed to help stabilize the normal structure of PrPc 
(Ermonval et al. 2003). 
Three topological forms of Prpc have been identified (Hegde et al. 1998). Using cell-
free translation systems containing ER-derived microsomal membranes, Hegde et al. 
(1998) identified a C-transmembrane form (CtmPrP) where the C-terminal is within the 
ER lumen and following the normal maturation and transit of the protein through the 
Golgi apparatus, would be expressed on the extracellular surface, an N-
transmembrane form (NtmPrP), where the N-terminal is within the ER lumen and 
would be expressed on the extracellular surface, and a secreted form, entirely within 
the ER lumen, where it would be attached to the cell surface via the GPI anchor. The 
authors suggested that CtmprP may be associated with disease. Hegde et al. (1998) 
also described the secreted PrP (Prpe) and CtmprP forms as being glycosylated and the 
NtmprP form as being unglycosylated. 
Other post-translationally modified forms of PrP have also been described. Stahl et 
al. (1992) identified 6 different glycoforms via a two-dimensional immunoblot 
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technique. Using a similar technique, Pan et al. (2002) identified 7 Prpc forms based 
on molecular weight (MW) alone. Each of these generated from 3 to 14 distinct spots 
on a gel as a result of different charges on the molecule (Pan et al. 2002). These 
different electrical charges could be due to different glycans, slight differences in the 
primary structure due to truncations etc., or due to differences in the composition of 
the GPI anchor. 
Clearly, there is a potential for a bewildering array of PrP forms arising from a single 
primary structure, due to post-translational modification of the protein. Glycosylation 
in particular is thought to play an important role in the normal trafficking of PrP and 
perhaps in the relationship of Prpc to disease (see below). A schematic diagram of 
the PrP protein illustrating the most significant regions is shown in Figure 1.2 below. 
1.5.2.3 Normal trafficking of PrP 
Following translation, glycosylation and the addition of the GPI anchor, in 
neuroblastoma lines, approximately 90% of the protein is transported to the cell 
surface where it is attached via the GPI anchor (Borchelt et al. 1990) to the outer cell 
membrane (van Rheede et al. 2003). Also in neuroblastoma ceIls, the half-life on the 
cell surface is approximately 3 to 6 hours (Caughey et al. 1989). The Prpc molecules 
are transported to the cell surface in association with cholesterol rafts (Naslavsky et 
al. 1997) and indeed, cholesterol is required for cell surface localization (Gilch et al. 
2006). Rather than being simply a transport vesicle however, lipid rafts may have a 
role in the folding of Prpc (Critchley et al. 2004). 
From the cell surface, sorne of the Prpc is internalized into an endosome, from where 
a C-terminal fragment may be recycled to the surface (Borchelt et al. 1992), however, 
Shyng et al. (1993) reported that most of the protein is recycled without degradation. 
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Figure 1.2: Schematic diagram of the murine prion protein with the N and C 
terminal fragments shown in black. The numbers give the amine acid number where 
the structure listed below is found. N terminal signal peptide 1-22, octapeptide 
repeats between AA 51-91, cysteines at AA 178 and 213 that form a disulfide bond, 
asparagines at AA180 and 196 where glycosylation occurs. 
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This endocytosis may be initiated by copper binding via the octapeptide repeats 
(Paul y and Harris 1998, Lee et al. 2001) or not require copper binding (Sunyach et al. 
2003). Internalization occurs via clathrin-coated pits (Shyng et al. 1995) and/or 
caveolae-like membranous domains (Vey et al. 1996) or sphingolipid/cholesterol rafts 
(Sunyach et al. 2003). The N-terminal may play a role in modulating endocytosis 
(Nunziante et al. 2003, Sunyach et al. 2003). Clathrin-mediated endocytosis involves 
the recruitment of clathrin and adaptor proteins, such as AP-2 at phosphoinositides in 
the membrane (Gaidarov and Keen 1999). However, impairment of clathrin-
mediated endocytosis with protein mutants did not affect the internalization of the 
GPI suggesting that this mechanism may not be the major mechanism for aIl GPI 
anchored proteins (Nichols et al. 2001). Shyng et al. (1994) used hypertonie media to 
disrupt clathrin lattices and thereby impair endocytosis via clathrin and reported 
impaired Prpc internalization, suggesting that Prpc may not behave like other GPI 
anchored proteins. Internalization of proteins through caveolae has been suggested to 
di vert proteins from the endosomal/lysosomal pathway (Pelkmans et al. 2001). 
Nichols et al. (2001) showed that GPI anchored proteins may use caveolae to traffic 
from the cell membrane to the Golgi. Prpc has been reported in endosomes 
containing transferrin receptors in adult mouse sensory neurons and N2a 
neuroblastoma cells (Sunyach et al. 2003). Aiso in neurons, Prpc has been 
demonstrated both in the Golgi and within cytoplasmic organelles resembling 
endosomes (Laine et al. 2001). From the endoplasmic reticulum, misfolded or excess 
Prpc may be delivered to the cytoplasm and degraded by the proteasome system (Ma 
and Lindquist 2001, Yedidia et al. 2001). 
Although the majority of Prpc is expressed on the cell surface (Borchelt et al. 1990, 
Mironov et al. 2003), significant amounts are present within the cytoplasm of a 
subpopulation of neurons in the cortex, hippocampus and thalamus (Mironov et al. 
2003). The proportion of Prpc that is normally present in the endolysosomal 
compartment (Arnold et al. 1995) or in the proteasome and endoplasmic reticulum 
associated degradative (ERAD) pathway (Yedidia et al. 2001) has thus far not been 
determined. 
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Taken together, these data indicate that there are several pathways by which Prpc can 
be recycled from the cell surface and several subcellular compartments where PrpC 
could be present and could conceivably interact with the disease associated form of 
the protein. The role of copper in the process of internalization of Prpc has also not 
been definitively confirmed. The seemingly conflicting results from various studies 
may represent differences among neoplastic cell lines, primary cell cultures, in vivo 
systems, as weIl as experimental methods to block components of the system being 
studied. 
1.6 Proposed Physiological Functions of PrP 
The physiologie role of Prpc has been the subject of considerable debate. Prpc is 
attached to the outer cell surface and found throughout the cell surface (Laine et al. 
2001) and specifically at synaptic areas in neurons (Salès et al. 1998, Brown 2001), 
which may suggest both a generalized role in cell metabolism and perhaps a specifie 
role in synaptic transmission. Prpc is also found within the cytoplasm (Mironov et al. 
2003). Therefore, physiological roi es for PrPc within the cytoplasm, at the cell 
membrane and at synapses in neurons aIl seem possible. The physiological roles of 
Prpc must be thoroughly investigated before reducing Prpc availability should be 
considered as a potential therapy in the prion diseases. The generation of the subtle 
phenotype reported in Prnp homozygous knockout mice, does not definitively rule out 
a role for the loss of function of Prpc in the development of the disease, as a 
phenotype generated by knockout procedures only demonstrates those deficits that 
cannot be compensated for by other systems. The post-natal knockout using the Cre-
loxP system, knocking out PrP in neurons after 9 weeks, is more convincing 
(Mallucci et al. 2002), although the loss of Prpc function via the loss of gene 
expression may not reproduce exactly the loss of Prpc function by a pathogen, after 
the protein has been translated. If no protein is translated, there is at least the 
potential that the situation may be recognized and compensatory measures taken. 
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The physiologie role for Prpc within the cytoplasm is also controversial, as it has 
been reported to have a neuroprotective role (Roucou et al. 2003, 2005) or a 
neurotoxic role (Ma et al. 2002). Mironov et al. (2003) observed cytosolic PrP in a 
subpopulation of neurons that had no signs of degeneration and concluded that PrP 
may be non-toxic in sorne neurons but toxic in others. 
1.6.1 Copper metabolism and anti-oxidant role 
Divalent copper binds to Prpc via the octapeptide repeats present in the N-terminal 
region (Brown et al. 1997b). Two of these binding sites may be physiologically 
relevant with Kd values around 10-14 and 4 x 10-14 M, which are comparable to other 
copper binding proteins such as superoxide dismutase and ceruloplasmin (Jackson et 
al. 2001). However, van Rheede et al. (2003) reported that not only do the number of 
octapeptide repeats vary among species, but also the number of histidine residues, 
which are implicated in Cu2+ binding vary, which suggests that copper binding may 
not be the primary function of the Prpc protein. 
Copper binding to Prpc is thought to stimulate its internalization (Pauly and Harris 
1998), perhaps via a clathrin-mediated mechanism (Shyng et al. 1995), and has been 
proposed as the determining factor in Prpc internalization (Haigh et al. 2005). 
Copper binding appears to be pH dependent, which combined with the internalization 
following binding, suggests a role in Cu2+ absorption (Jackson et al. 2001). Prpc has 
been proposed as a modulator of the activity of Copper (Cu2+)/Zinc (Zn2+) superoxide 
dismutase, a key intracellular antioxidant enzyme (Brown et al. 1998b). Moreover, 
levels of Prpc seem to correlate with Cu/Zn superoxide dismutase activity (Brown et 
al. 1998b, Rachidi et al. 2003) and glutathione reductase activity (Rachidi et al. 
2003). However, other researchers do not find that Prpc has dismutase activity and 
conclude that if it has a role in the protection against oxidative stress, it is an indirect 
one (Jones et al. 2005). 
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Neuronal cell cultures from Prnp% mice are more susceptible to oxidative stress than 
are wild-type (PrP+/+) cells (Brown et al. 1997a, White et al. 1999). The PrpOlO 
neurons had significantly lower glutathione reductase activity that appeared to be 
modulated by Prpc expression (White et al. 1999). Indeed Pereira et al. (2001) 
speculated that impaired brain anti-oxidant defenses may be a significant factor in the 
lower threshold for seizure activity noted in Prnp% mice. In addition, spermatozoa 
from Prnp% mice are more susceptible to copper toxicity than are spermatozoa 
expressing Prpc, suggesting a protective role for copper binding by PrpC (Shaked et 
al. 1999). PrpOlO cell lines are also more sensitive to copper toxicity (Brown 2001). 
Brown (2001) suggested that PrPc deficient cells may be able to compensate for the 
lack of the protein by using other copper uptake proteins, such as copper transporting 
receptor (CTR) proteins. 
Brown (2001), noting the synaptic concentration of Prpc in neurons and the copper 
binding affinity, proposed that Prpc has a protective role at the synapse rather than a 
direct role in neurotransmission. A possible anti-oxidant protective role at the 
synapse may be particularly significant in light of the fact that the earliest lesions in 
the prion diseases have been noted at the synapse (Belichenko et al. 2000, Jeffrey et 
al. 2000, Siso et al. 2002). 
Overall, the data suggest that PrPc expression may contribute to Cu2+ binding and/or 
uptake, increased Cu/Zn superoxide dismutase and glutathione reductase activity and 
increased resistance to oxidant stress, moreover, the loss of function of Prpc may 
contribute to the pathogenesis of the prion diseases. However, given that a role for 
Prpc in the protection against oxidative stress is not uniformly accepted (Jones et al. 
2005), Prpc may not be concentrated at the synapse (Mironov et al. 2003) and even 
that Prpc may be involved in Zn transport and homeostasis rather th an Cu (Watt and 
Hooper 2003), a significant role for Prpc in copper metabolism and as an anti-oxidant 
remain to be proved. 
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1.6.2 Signal transduction and growth 
PrpC binds to a large number of proteins inc1uding, heat shock protein (HSP)60 
(Edenhofer et al. 1996), heparin-like compounds (Gabizon et al. 1993), neuronal 
phosphoprotein synapsin lb, a still uncharacterized prion interactor 1 (Pi nt!) 
(Spielhaupter et al. 2001), as well as the carboxy-terminal decapeptide in the y-1 
chain of laminin, the most highly conserved of aIl laminin types (Graner et al. 2000). 
Indeed, the 37 kDa laminin receptor protein (LRP) has been proposed to act as a 
receptor for Prpc (Rieger et al. 1997). This interaction is important for both extension 
and maintenance of neurites in PC12 and hippocampal neurons in culture (Graner et 
al. 2000). Furthermore, cultured neurons from PrnpO/O rnice extend fewer neurites 
th an wild-type cultures when grown on media containing laminin, which are 
unaffected when exposed to anti-Prpc antibodies, a procedure that inhibits neurite 
growth in wild-type cultures, suggesting that those neurons that do form do not 
express Prpc (Graner et al. 2000). 
A fusion protein of mouse Prpc and the Fc region of human IgG interacting with 
cerebeIlar granule neurons derived from C57BL/6 mice expressing the GPI-anchored 
form of mouse Prpc, stimulated increased neuronal survival and neurite outgrowth 
compared to controls (Chen et al. 2003). Moreover, Chen et al. (2003) also found 
that different members of the Src kinase family were involved in neurite outgrowth 
and neuron survival. More recently, Steele et al. (2006) found that neuronal 
differentiation is delayed in vitro and in vivo if Prpc is absent and suggest that Prpc 
may be a positive regulator of neuronal precursor proliferation. 
However, anti-PrPc antibodies inducing crosslinking of Prpc molecules triggered 
apoptosis of hippocampal neurons in vivo (Solforosi et al. 2004). Whether this 
apoptosis was the result of the loss of a cell survival signal from Prpc or the 
transmission of a ceIl death signal was not evaluated. 
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Prpe is also reported to play a role in known cell-signaling pathways. PrpC binds to 
the adaptor protein (growth factor receptor binding protein) Grb2, which is involved 
in activating ERK1I2 and MAP kinases (Spielhaupter et al. 2001). In a murine 1C11 
neuronal differentiation model, prpe activates the Src family member tyrosine kinase 
Fyn via a caveolin-1-dependent mechanism, suggesting a role in signal transduction 
(Mouillet-Richard et al. 2000). prpe activation of the cAMP/PKA pathway is 
neuroprotective (Chiarini et al. 2002). The outcome of ERK-mediated or Fyn-
mediated signaling is currently unknown. Zanata et al. (2002) speculated that (stress 
inducible protein 1) STIl may be the protein that binds to PrpC and facilitates its 
conversion to the disease-associated form and therefore be the "protein X" of 
Prusiner's protein-only theory (Telling et al. 1995). Interestingly, a mutated form of 
prpe (PrP106-126) or a sheep scrapie agent activates the JNK-c-Jun pathway 
resulting in murine cortical neuronal apoptosis in vitro (Carimalo et al. 2005). 
Whether this represents a loss of function of prpe and therefore the loss of an 
inhibitor of the JNK pathway is open to speculation. 
OveraIl, these data indicate that Prpe is capable of binding to a variety of ligands and 
potentially be involved in regulating a variety of signal transduction pathways, which 
affect cell growth and differentiation. Conclusive evidence for su ch a role for prpe 
has not thus far been elucidated, but this appears to be a very active area of research. 
The expression of Prpe in a wide variety of tissues may indicate that Prpe is 
performing a similar role in other tissues by transmitting signaIs from the 
extracellular compartment to the intracellular milieu. 
1.6.3 Homeostatic functions 
1.6.3.1 Calcium metabolism and regulating neuronal activity 
Observations made on PrpO'o mice suggest that Prpe may be involved in regulating 
circadian rhythms and sleep patterns (Tobler et al. 1996), as weIl as memory retenti on 
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in aging rodents (Coitinho et al. 2003). PrpOlO mice are also known to have a lower 
threshold for seizure activity than their wild-type counterparts, which is believed to 
be related to an increased susceptibility to oxidative stress (Walz et al. 1999, Pereira 
et al. 2001). Recently, it has been proposed that PrP may play a role in the formation 
of long-term memory in humans (Papassotiropoulos et al. 2005). 
Evaluation of these observations at the electrophysiological level has implicated the 
regulation of calcium in their pathogenesis. In hippocampal slices from PrpO/O mice, 
Ca2+ activated K+ currents are disrupted (Colling et al. 1996). These channels are 
involved in late after hyperpolarizations and therefore may be important in long-term 
potentiation and memory consolidation, and may also have a role in the lower 
threshold for seizures reported in PrpO/O mice. Similarly, Herms et al. (2000) 
examined cerebellar granule cells and found alterations in both the basal Ca2+ 
concentration and the changes in Ca2+ concentration with K+ depolarization in tissue 
slices from PrpO/O rnice. Herms et al. (2001) examined Purkinje cells in cerebellar 
slices and found a correlation between Prpc expression level and the amplitude of 
maximum calcium concentration after depolarization. It has therefore been proposed 
that PrP may play a role in regulating synaptic activity (Collinge et al. 1994, Mallucci 
et al. 2002). 
However, another group has disputed this proposed role as they have failed to find the 
same electrophysiological abnormalities (Uedo et al. 1996). In addition, PrpC does 
not appear to be concentrated at the synapse, as was previously thought (Mironov et 
al. 2003). Moreover, most of the electrophysiological abnormalities have been 
reported in the hippocampus, which is not involved in the "retenti on" of memory. 
Other neurobehavioral studies in rnice have suggested subtle differences between 
PrpOlO and PrP+/+ mice (Roesler et al. 1999), however, no attempt was made to 
interpret the findings and identify the location of any possible lesion. Given the 
inconsistency of purely descriptive neurobehavioral studies, the significance of these 
findings must be questioned. Overall the se data suggest that Prpc may have a role in 
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regulating neuronal activity, perhaps via Ca2+ gated K+ channels, but this proposaI 
requires further study. 
Aiso related to Ca2+ metabolism, Kristensson et al. (1993) infected mouse 
neuroblastoma cells with PrpSc and noted a disruption of mitogen-activated increases 
in intracellular calcium concentration. The authors interpreted the se findings to 
suggest that PrpC may be involved in regulating intracellular Ca2+ concentration. 
However, following PrpSc infection, neuroblastoma cells may undergo the process of 
degeneration and degenerating cells would not be expected to be "normal" with 
respect to their physiological processes. These findings could therefore be the effect 
of the degeneration rather th an the cause. 
1.6.3.2 Nucleic acid binding 
PrP also binds to nucleic acids and induces the production of large nucleoprotein 
complexes when mixed with viral nucleic acids in vitro (Gabus et al. 2001). Human 
or ovine Prpc is able to functionally replace HIV -1 nucleocapsid protein NCP7 
nucleic acid chaperoning during the retrovirallife cycle (Gabus et al. 2001). NCP7 is 
required for the initiation of reverse transcription (Huang et al. 1998). An anti-
retroviral role for Prpc has therefore been proposed (Derrington and Darlix 2002). 
However, Prpc binding to nucleic acids may also have a negative side. Human 
recombinant PrpC binds to synthetic small highly structured RNAs under in vitro 
though, physiological conditions (Adler et al. 2003).· The Prpc then becomes resistant 
to digestion by proteinase K and the RNA in the nucleoprotein complexes becomes 
resistant to digestion by ribonuclease A (Adler et al. 2003). Moreover, Deleault et al. 
(2003) found that the addition of mammalian RNA species to normal brain 
homogenate seeded with prion-infected brain homogenate amplified the conversion 
of Prpc to PrpeS. a form of PrP that may be associated with disease. This 
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amplification was inhibited by the addition of RNase in a dose-dependent manner 
(Deleault et al. 2003). 
Taken together these findings may suggest that Prpc could play a protective role 
against retroviral repli cation in the celI, but could also be a key element in the 
amplification of the disease-associated form of PrP. Clearly, considerably more 
research will be required to confirm the validity of these experimental results. 
1.6.3.3 Involvement in the immune response 
ln addition to being abundantly expressed in the brain, PrpC is also expressed in cells 
of the immune system (Bendheim et al. 1992). Treatment with the T lymphocyte 
mitogen concanavalin A induced significantly greater proliferation in T cells from 
PrP+1+ mice compared to PrpO/O mice (Mabbott et al. 1997). Concanavalin A treatment 
also resulted in greater production of interferon (lFN)-y and interleukin (IL)-2 in 
splenocytes from PrP+1+ mice or splenocytes from PrpO/O mice that had been 
transfected with a PrP expressing plasmid than splenocytes from PrpO/O mice 
(Bainbridge and Walker 2905). These two cytokines are critical in the type 1 immune 
response. Treatment with anti-PrpC suppressed mitogen-induced lymphocyte 
activation (Cashman et al. 1990). 
The culture of CD14+ monocytes in the presence of IFN-y resulted in increased 
expression of PrpC (Durig et al. 2000), suggesting that Prpc may be related to 
increased activation of monocyte/macrophage cells. In contrast however, de Almeida 
et al. (2005) found that macrophages not expressing Prpc were more efficient at 
phagocytosis using an in vivo peritonitis model than Prpc expressing macrophages 
and concluded that Prpc is a negative regulator of phagocytosis. 
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Expression of Prpc was down-regulated upon differentiation of hematopoietic cells 
along the granulocyte lineage (Dodelet and Cashman 1998). Zhang et al. (2006) 
also examined Prpc expression in hematopoietic cells and found that Prpc expression 
in stem cells is important in their self-renewal following seriaI transplantation, 
however, they found no differences in progenitor cell or terminally differentiated 
hematopoietic cell numbers in Prp+I+ or PrpO/O mice in vivo. These findings suggest 
that the lack of PrpC expression is overcome in PrpO'° mice, or perhaps defects may 
only be seen in aged mice or that Prpc expression may be important in the 
experimental paradigm but less so in vivo. 
Taken together, these data suggest that PrpC may play an important role in the 
regulation of the type 1 adaptive immune response, a response that is obviously 
critical to survival of the organism. However, evidence for a role in the innate 
immune response or in hematopoietic differentiation and proliferation is inconsistent 
and no firm conclusions can be made at this time. 
1.6.4 Cell survival 
It is generally accepted that the disease-associated form of the prion protein has either 
a direct or an indirect role in the neurodegeneration culminating in neuronal death 
that is a feature of the transmissible spongiform encephalopathies. It is therefore, 
somewhat ironic that the normal form of the protein Prpc may be associated with 
neuronal survival, however there is increasing evidence that this may be the case. 
Using a model for traumatic brain injury, Hoshino et al. (2003) reported that PrpO/O 
mice had a significantly larger lesion volume than did PrP+1+ mice and also that the 
breakdown in the blood brain barrier in PrpO/O mice was more extensive one month 
after the event. Similarly, in rodent models of cerebral ischemia, the ischemic 
penumbra was larger in PrpOlO mice than Prp+/+ mice (McLennon et al. 2004). In the 
early phase following either ischemic injury (McLennon et al. 2004, Weise et al. 
2004) or traumatic brain injury (Marciano et al. 2004) Prpc was markedly 
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upregulated. In addition, Spudich et al. (2005) reported larger infarcts in PrpO/o mice 
th an in PrP+/+ controls and also found increased activities of ERKl/2, ST AT -1 and 
caspase 3 in the PrpOlO ischemic brains, suggesting a possible signaling mechanism 
through Prpc that may provide neuroprotection. In an in vivo model involving the 
injection of anti-PrP antibodies into the hippocampus, massive neuronal apoptosis 
was noted 24 hours after treatment (Solforosi et al. 2004). This may suggest that PrpC 
is involved in transmitting survival or anti-apoptotic signaIs into the neuron. 
These findings suggest that PrpC may provide a neuroprotective role in vivo and may 
be particularly important in the early period after the ischemic or traumatic event. 
The promoter region of PrP contains binding sites for heat shock transcription factors 
(Shyu et al. 2000, Mahal et al. 2001), which could therefore provide another possible 
mechanism for upregulation due to cell stress and subsequent neuroprotection. 
Neuroprotection could also be related to protection against oxidative stress or related 
to apoptosis via an anti-Bax function. There is abundant in vitro evidence that Prpc 
has an anti-Bax function and the demonstration of an in vivo anti-Bax role for Prpc is 
the objective of the work described in this thesis (see below). 
ln contrast to these cell survival functions of Prpc however, Paitel et al. (2002) using 
stably transfected cell lines found that overexpression of Prpc rendered cells more 
sensitive to apoptosis, mediated by caspase 3 activation. 
1.6.4.1 Involvement with Bcl-2 family and anti-Bax function 
Further investigation by Chen et al. (2003) revealed that their fusion protein (mouse 
PrpC-human IgGFc see signal transduction section 1.6.2 above) that resulted in 
increased cerebellar granule cell neurite survival also increased antiapoptotic B cell 
leukemia 2 (Bcl-2) levels and decreased proapoptotic Bax levels, suggesting that Prpc 
may be influencing neurite survival via a Bcl-2 family mediated mechanism. 
Kuwahara et al. (1999) found that Prp+/+ hippocampal cell lines survive serum-
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deprivation induced apoptosis better than Prp-/- cell tines. Kuwahara et al. (1999) 
were unable to demonstrate direct binding between PrpC and Bel-2, however, 
apparently pretiminary experiments suggested a functional interaction between the 
two proteins. In addition, neuronal cultures derived from PrpO/O mice were more 
susceptible to apoptosis induced by serum deprivation than Prp+/+ neuronal cultures, 
an effect that was abrogated by the reintroduction of PrP to the PrpO/O neurons (Kim et 
al. 2004). Moreover, Kurschner and Morgan (1996) demonstrated that PrpC interacts 
with the C-terminal 37 amino acids of Bel-2. They suggested that Bcl-2 may be the 
"protein X" presumed to be involved in converting PrpC to PrpSc in Prusiner's protein-
only theory (Telling et al. 1995), however, the antiapoptotic nature of Prpc was not 
known at that time. Perhaps an alternative explanation may be that Prpc may 
facilitate the interaction of Bel-2 with Bax and therefore, contribute to the 
antiapoptotic function of Bel-2. Consistent with this explanation, Bounhar et al. 
(2001) found that Prpc protects human neuronal cells in culture from Bax-mediated 
ceIl death, and Roucou et al. (2003) found that the cytosolic form of Prpc prevents 
Bax-mediated death in human primary neurons. SpecificalIy, PrP inhibits the 
proapoptotic conformational change of Bax, which is an early event in the initiation 
of apoptosis (Roucou et al. 2005). However, at least in Saccharomyces cerevisiae 
prion protein does not require other Bel-2 family proteins to prote ct against Bax-
mediated cell death (Bounhar et al. 2006 in press). OveralI, these data suggest that 
Prpc may be influencing neuronal survival by inhibiting Bax activation, however, the 
manner of this interaction or the involvement of other Bel-2 proteins, is thus far 
unknown. In addition, Prpc overexpression in a human breast carcinoma cell tine 
(MCF-7) induced resistanee to tumor neerosis factor (TNF)-a-induced ceIl death 
(Diarra-Mehrpour et al. 2004). 
1. 7 Apoptosis Introduction 
Apoptosis, literalIy, "dropping off', is a physiologieal proeess of programmed cell 
death whereby eells die as a result of exposure to a physiologie or pathologie stimulus 
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(Kerr et al. 1972). The classic histological and ultrastructural slgns include 
membrane blebbing, cell shrinkage, nuclear condensation and DNA fragmentation 
(Kerr etaI. 1972). The process does not initiate an inflammatory response (Kerr et al. 
1972). During apoptosis, DNA is cleaved into approximately 180 bp fragments 
(Wyllie 1980) and phosphatidylserine is externalized to the cell membrane as a 
prelude to phagocytosis by neighboring cells (Fadok et al. 1992). Apoptosis differs 
from necrosis, a process that is initiated by pathologic stimuli, results in cell swelling 
and disruption of organelles, involves random diffuse DNA breakdown, A TP 
depletion, membrane injury and free radical damage and often initiates an 
inflammatory reaction (Cotran et al. 1994). 
Apoptosis is essential in multicellular organisms during development, to remove 
extraneous cells, is essential for tissue homeostasis and for the removal of infected or 
damaged cells (Vaux and Korsmeyer 1999). The importance of the process is 
underscored when the process is impaired, and is then associated with neoplasia, 
autoimmunity, neurodegenerative disease, hematopoeitic deficiencies and infertility 
(Vaux and Korsmeyer 1999). Apoptosis is a highly conserved process in 
multicellular organisms and has been studied in Caenorhabditis elegans (Ellis et al. 
1991) and Drosophila melanogaster (Abrams 1999). 
A group of enzymes called caspases, which are normally present in the cell as 
inactive precursors called procaspases, are the key effectors of the cell death process 
(Ranger et al. 2001). Caspases comprise two functional families: initiator caspases 
(eg. caspase 8, 9), which are the upstream regulators of the process, and effector 
caspases (eg. caspase 3, 6, 7), which are directly responsible for cell breakdown 
(Ranger et al. 2001). Two major pathways leading to apoptosis have been described, 
one via death receptors (eg. CD95, TNF-RI, Dr3) that ultimately activate caspase 8 
(Ranger et al. 2001). Caspase 8 may then activate the effector caspase, caspase 3 
directly, but also activates Bcl-2 family member (described below) Bid (tBid), which 
translocates to the mitochondria, where it is able to initiate or contribute to the second 
major pathway to apoptosis, the mitochondrial pathway (Ranger et al. 2001). The 
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importance of this mitochondrial amplification loop of caspase 8 is cell type-
dependent (Ranger et al. 2001). 
The mitochondrial pathway is largely dependent upon the activation of caspases, 
however, a caspase-independent pathway via Apoptosis-inducing factor (AIF) has 
also been described (Susin et al. 1999). The B cell leukemia 2 (Bcl-2) family 
members are important regulators of physiological cell death and are involved in 
regulating caspase activity (Gross et al. 1999). A schematic diagram of these 
pathways is shown in Figure 1.3 below. 
1.7.1 Bel-2 family 
Bcl-2 family members may have pro or antiapoptotic functions (Gross et al. 1999) 
and it is often the balance between these that determines the final outcome for the cell 
(Oltvai et al. 1993). Anti-apoptotic members contain Bel-2 homology domains 1 and 
2 (BHl, BH2), a carboxy-terminal hydrophobie transmembrane (TM) domain, and 
may also contain Bel-2 homology domain 3 (BH3) (Ranger et al. 2001). Pro-
apoptotic members contain the BH3 domain and the TM domain, but may also 
contain BHl and/or BH2 domains (Ranger et al. 2001). Anti-apoptotic Bel-2 family 
members inelude Bel-2, Belxu Belw, Mell, Al/Bftl, Boo/Diva and Nrl3 (Ranger et 
al. 2001). The pro-apoptotic multi-domain members inelude Bax, Bak, Bok/Mtd and 
the BH3 only domain members inelude Bid, Bad, Bik/Nbk, Blk, Hrk, Bim/Bod, 
Bnip3, Nix and Noxa (Ranger et al. 2001). 
1.7.2 Proapoptotic Bax 
Bax is a proapoptotic Bel-2 family member that contains the BHl, BH2, BH3 and 
TM domains (Ranger et al. 2001), and is particularly important in inducing neuronal 
cell death in the developing nervous system (Deckwerth et al. 1996). In fact, 
developmental neuronal cell death is reduced in Bax-deficient mice (Deckwerth et al. 
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1996), an effect that is abrogated in mice deficient in both Bax and BclxL, (Shindler et 
al. 1997). When activated, Bax undergoes a pH-dependent conformational change 
(Khaled et al. 1999), which exposes the N and C-termini of the protein (Nechushtan 
et al. 1999). Bax then translocates to the mitochondria and oligomerizes to form 
pores in the membrane, releasing proapoptotic proteins from within (Eskes et al. 
2000). Alternatively, Bax induces the opening of the permeability transition pore 
(PTP) and thus releases the intramitochondrial proteins (Martinou and Green 2001) or 
renders the high-conductance mitochondrial apoptosis-induced channel (MAC) 
permeable to cytochrome c (Guo et al. 2004). The proapoptotic proteins thereby 
released include, Smac/Diablo (Du et al. 2000), cytochrome c (Korsmeyer et al. 
2000), endonuclease G (Ott et al. 2002) and apoptosis-inducing factor (AIF) (Susin et 
al. 1999), which facilitate the execution phase of apoptosis. 
When released from the mitochondria to the cytoplasm, cytochrome c binds to 
apoptosis activating factor-1 (Apaf-1), thereby increasing the affinity of Apaf-1 for 
dATP/ ATP 10 fold, which induces oligomerization of Apaf-lIcytochrome c 
complexes to form the apoptosome (Wang 2001). The apoptosome then recruits and 
activates pro-caspase 9 to caspase 9, which then activates the effector caspase 3 
(Wang 2001). The apoptosome contains an N-terminal caspase recruitment domain 
(CARD) a middle nucleotide binding and oligomerizing domain, and aC-terminal 
cytochrome c binding domain (Kim et al. 2005). Executioner caspases are known to 
activate or inactivate over 100 proteins including the nuclease responsible for the 
nucleosomal ladder, proteases responsible for cleavage of nuclear lamins that are 
required for nuclear shrinkage, and proteases responsible for the cleavage of critical 
cytoskeletal proteins fodrin and gel solin (Hengartner 2000). 
Proapoptotic and antiapoptotic members of the Bcl-2 family readily homodimerize 
and heterodimerize (Adams and Cory 2001). Bax dimerizes with BclxL , blocking the 
ability of BclxL to prevent apoptosis (Sedlak et al. 1995). BH3 proteins kill by 
binding to other members of the Bcl-2 family, although Bax-like proteins may also be 
able to kill cells via an alternative mechanism (Adams and Cory 2001). For example, 
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BH3 proteins may result in the release of AIF or endonuclease (endo) G from the 
mitochondria, which may th en go on to induce chromatin condensation and apoptosis 
(Ott et al. 2002). Mitochondrial membrane permeabilization (MMP) as a result of 
various stimuli, including Bcl-2 family members may also result in increased 
production of reactive oxygen species (ROS) and altered Ca2+ homeostasis, which 
may also trigger the activation of other cell death pathways, including calpains and 
the oxidation of ceramide metabolites, resulting in noncaspase-mediated apoptosis 
(Hail Jr et al. 2006). 
1.7.3 Anti-apoptotic Bcl-2 members 
Antiapoptotic members of the Bcl-2 family share four homology domains (BH1, 
BH2, BH3 and BH4) and a membrane anchor domain (Adams and Cory 2001). 
Antiapoptotic members, such as Bcl-2 and BclxL act by blocking the oligomerization 
of BH3 domain containing proteins, such as Bax and Bak (Wei et al. 2001). This 
oligomerization is required to induce the release of critical proapoptotic proteins from 
the mitochondria (Wei et al. 2001). The loss of anti-apoptotic BclxL function in Bclx 
knockout mice results in embryolethality due to excessive Bax-mediated cell death in 
the developing hematopoietic system (Motoyama et al. 1995). The antiapoptotic 
activity of BclxL is particularly important in the developing brain and hematopoietic 
systems (Motoyama et al. 1995). 
1.8 Mouse Models 
1.8.1 Prpc knockout mice (PrpO/o) 
Prusiner (1982) proposed that the agent responsible for the transmissible spongiform 
encephalopathies was devoid of nucleic acid and composed only of protein (PrPSC). 
This was based largely on the resistance of the agent to numerous treatments that 
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Figure 1.3: Schematic diagram of the major apoptosis pathways. Extrinsic receptor-
mediated pathway and the intrinsic cell stress induced Bax-mediated pathway leading 
to caspase 3 activation. 
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destroy nucleic acid, the small size constraints imposed on the agent, the inability to 
demonstrate nucleic acid, and the reduced infectivity induced by treatments that 
de grade proteins (Prusiner 1982). In an attempt to find more conclusive evidence to 
support their theory, Bueler et al. (1992) succeeded in disrupting one mouse Prnp 
allele of murine embryonic stem (ES) cells by homologous recombination with a 4.8-
kilobase (kb) DNA fragment in which codons 4 to 187 of the 254-codon open reading 
frame were replaced by a neomycin phosphotransferase (neo) gene under the control 
of the herpes simplex virus thymidine kinase (HSV TK) promoter. Blastocysts from 
C57BL/6J mice were injected with the clone and implanted into foster mothers 
(Bueler et al. 1992). The resulting offspring were screened with polymerase chain 
reaction (PCR) and Southern analysis to confirm the presence of the disrupted gene 
and these heterozygotes mated to generate homozygous PrnpOIO knockout mice 
(Bueler et al. 1992). The genotype of these mice was also confirmed by PCR and 
Southern analysis (Bueler et al. 1992). Manson et al. (1994) also produced a 
disruption of the gene. A schematic diagram of the murine Prnp gene is shown in 
Figure 1.4 below. Both groups found that, contrary to expectation, the mice survived 
and developed normally (Bueler et al. 1992, Manson et al. 1994). These homozygous 
null mice (Prnpo/O) did not develop spongiform encephalopathy after inoculation with 
PrpSc. and did not demonstrate infectivity (Bueler et al. 1993). These findings were 
consistent with the protein-only hypothesis, and demonstrate that Prpc is crucial to 
the development of and transmission of the disease, but do not prove that PrpSc is the 
actual agent. Interestingly, mice heterozygous for the Prnp knockout expressing 
reduced levels of Prpc developed disease, but had prolonged incubation times (Bueler 
et al. 1994). 
44 
Figure 1.4: Schematic diagram of the murine Prnp gene (a) and disrupted gene (b) 
containing the neo gene cassette. The entire open reading frame of the mouse Prnp is 
within exon 3. Adapted from Bueler et al. 1992. 
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PrnpO/O mice are reported to have altered circadian rhythms and sleep patterns (Tobler 
et al. 1996). They may also have impaired memory retenti on with aging (Coitinho et 
al. 2003). Abnormal synaptic activity involving gamma aminobutyric acid (GABAA) 
type A receptors in the CAl region of the hippocampus was reported by Collinge et 
al. (1994), although no effects on synaptic function were found by Ueda et al. (1996). 
Significant reductions in afterhyperpolarizations (AFPs) in hippocampal CAl cells 
were also reported in a post-natal knockout of prion protein targeted to neurons in the 
adult mouse, suggesting a role for Prpc in regulating neuronal excitability (Mallucci 
et al. 2002). Clearly, there is no consensus at this time, regarding the effect of PrpC 
on synaptic activity. 
PrnpO/O mice are also reported to have demyelination in the peripheral nervous system, 
although no clinical signs have been noted in the Zurich strain developed by Bueler's 
group (Nishida et al. 1999). The clinical signs described in other knackout strains 
and not in the Zurich strain, are believed to be related to variable disruption of the 
gene in different strains (Nishida et al. 1999). 
Cells from PrnpO/O mice also have alterations in superoxide dismutase activity (SOD-
1) and therefore increased susceptibility to oxidative stress (Brown et al. 1997a) and 
defects in copper metabolism (Brown et al. 1997b). PrnpO/O mice are more susceptible 
to seizures than their wild-type counterparts, which is also thought to be related to 
increased susceptibility to oxidative stress (Walz et al. 1999). Brown et al. (2002) 
examined numerous biochemical parameters and found increased activity of nuclear 
factor NF-KB, increased activity of manganese superoxide dismutase, perhaps in 
response to decreased p53, as weIl as decreased Cu/Zn superoxide dismutase activity. 
They concluded that PrnpO/O mice, or cells derived from them, have increased neuronal 
sensitivity to oxidative stress. 
Another Prnp knockout generated by Sakaguchi et al. (1996) led to the 
overexpression of a gene downstream from the Prnp gene, a Prpc-like protein called 
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Doppel (DpI), and progressive ataxia and cerebellar Purkinje cell degeneration by 70 
weeks of age (Moore et al. 1999). This phenotype is rescued by the coexpression of 
Prpe (Moore et al. 2001). Purkinje cell degeneration is not a feature of the 
transmissible spongiform encephalopathies (TSEs) in mice, suggesting that this 
Doppel-induced disease is a distinct entity and unrelated to the TSEs. Interestingly, 
an N-terminally truncated form of PrP, similar to Doppel, when targeted to Purkinje 
cells, also leads to Purkinje cell loss and is also rescued by the reintroduction of Prpe 
(Flechsig et al. 2003). 
1.8.2 PrP: Overexpressor mice (PrpOexP) 
In order to assess the species specificity of scrapie infectivity, Scott et al. (1989) and 
Prusiner et al. (1990) constructed mice expressing Syrian Hamster prion protein 
(SHaPrpC), as weIl as endogenous mouse prion protein (Prpe). Eggs were obtained 
from superovulated (C57BL/6 X SJL)FlIJ hybrid females mated to (C57BL/6 X 
SJL)Fl/J hybrid males. DNA constructs were made by fusing sequences of the 
SHaPrP promoter, a fragment of a cDNA clone encoding the open reading frame 
(ORF) and a restriction fragment containing the SHaPrP polyadenylation signal (Scott 
et al. 1989, Prusiner et al. 1990). The DNA constructs were microinjected into the 
pronuclei of one-celled mouse eggs (Scott et al. 1989, Prusiner et al. 1990). 
Weanling animaIs were screened for the presence of the SHaPrnp gene using 
Southern transfer analysis (Scott et al. 1989, Prusiner et al. 1990). 
Mice expressing hamster Prpe, in addition to mou se Prpe, became susceptible to 
infection with Syrian Hamster prions, to which they are normally resistant (Scott et 
al. 1989), and the incubation time paralleled protein expression level (Prusiner et al. 
1990). When infected with mouse prions, they had a longer incubation time than 
non-transgenic littermates (Scott et al. 1989). The importance of the amount of Prpe 
in the cell to the development of the disease was illustrated by the observation that 
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transgenic mice overexpressing wild-type PrP, when infected with mouse prions, had 
a shorter incubation time (Telling 2000). 
These findings support a direct protein-protein interaction in the propagation of the 
disease. Unlike their PrpC knockout counterparts, mice expressing wild-type PrpC 
derived from either hamsters or sheep developed spontaneous disease, in proportion 
to the copy number of the transgene (Westaway et al. 1994). The pathological 
changes described ineIuded necrotizing myopathy, demyelinating neuropathy and 
focal spongiform degeneration in the central nervous system (eNS) (Westaway et al. 
1994). 
These data indicate that the host Prpc is qualitatively and quantitatively essential for 
the development of the disease. 
1.8.3 BeIxL knockout mice 
BeIx is a member of the BeI-2 gene family and its gene product BeIxL , inhibits certain 
forms of apoptosis (Motoyama et al. 1995). BeIxL in the mouse is widely expressed 
during development and in certain adult tissues, such as the brain (Motoyama et al. 
1995). In order to investigate the functional and developmental role of BeIx, 
Motoyama et al. (1995) isolated genomic DNA containing the BeIx locus and 
replaced most of the BeIx coding region with either a PGK-neo (neomycin) 
polyadenylate (poly A) cassette or PGK-hyg (hygromycin) poly (A) cassette and 
transfected mouse embryonic stem (ES) cells via homologous recombination to 
generate heterozygous mutant mice containing only one wild-type BeIx allele (BeIx+/-
). The heterozygous mutant mice had no observable phenotype, whereas, 
homozygous Bclx knockout mice died around day 13 of gestation (Motoyama et al. 
1995). These homozygous knockout mice had extensive apoptotic cell death of 
neurons in the developing brain, spinal cord and dorsal root ganglia, as weIl as in 
developing hematopoietic cells in the liver (Motoyama et al. 1995). This cell death is 
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due to the imbalance between proapoptotic (Bax) and antiapoptotic proteins 
(Motoyama et al. 1995). 
The neuronal cell death of the BclxL knockout is rescued by a further knockout of 
Bax, however, the embryolethal phenotype is unaltered due to continued cell death in 
the developing hematopoietic system (Shindler et al. 1997). We hope to demonstrate 
that homozygous Bclx knockout mice expressing Syrian hamster PrPc under a mouse 
Bclx promoter are protected from the embryolethal phenotype. If so, we will be able 
to conclude that Syrian Hamster PrpC is able to assume the function of endogenous 
mouse Bclx in vivo. 
1.8.4 Other transgenic mice 
Thus far, approximately 20 distinct mutations in the PRNP gene have been identified 
(Prusiner et al. 1998a). PartI y due to the "species barrier" (i.e. difficulty in 
transmission of a TSE agent to a new species with a different PrP primary structure 
on first passage) and partly due to few studies attempting transmission, which may be 
a reflection of the rarity of clinical cases and therefore infectious material, brain 
homogenate from few of these familial mutations have successfully transmitted 
disease to mice. Brain homogenate from familial mutations such as E200K, M232R, 
P102L and D178N have successfully induced disease in mice, with variable degrees 
of difficulty (Tateishi et al. 1996). 
In the case of the human mutation P102L, the equivalent mouse mutation (P101L) has 
been created in transgenic mice expressing approximately 8 fold normal amounts of 
PrP and these mice spontaneously developed neurological "symptoms" of ataxia, 
lethargy and rigidity (Hsiao et al. 1990). Histologically, spongiform degeneration 
was identified in most gray and white matter structures in the cerebral hemispheres 
and brainstem with mild to moderate reactive astrocytic gliosis (Hsiao et al. 1990). 
Using 10% brain homogenate, this disease was successfully transmitted to a 
transgenic line expressing the same mutation at an estimated 2 fold normal levels of 
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PrP (Hsiao et al. 1990), however, it was not transmissible to wild-type mice, even 
though brain extracts from human patients with the P102L mutation and human prion 
primary structure is transmissible to wild-type mice with the mouse primary prion 
structure (Tateishi et al. 1996). 
Similarly, in an attempt to reproduce the human familial A117V mutation, Hegde et 
al. (1998) created a transgenic mou se predominantly expressing a C transmembrane 
form of the prion protein, CtmprP, with Ala to Val substitutions at positions 113, 115, 
and 118 (PrP A V3). They were unable to demonstrate the presence of PrpSc in the 
mice, however, these mi ce still developed neurological disease characterized 
clinically by ataxia and paresis (Hegde et al. 1998). They described focal vacuolar 
degeneration in the neuropil of the gray matter, which was most pronounced in the 
hippocampus and piriform cortex (Hegde et al. 1998), however, lesions in these 
locations do not explain the clinical signs. Hegde et al. (1998) reported that increased 
CtmprP was noted in the single GSS brain with codon 117 mutation relative to the 
single control brain that they examined. However, patients with this mutation 
predominantly present with dementia and Parkinsonian signs, with ataxia described as 
a minor feature (Belay 1999). HistologicaIly, these GSS patients have numerous 
amyloid plaques, occasional neurofibrillary tangles with variable vacuolation, gliosis 
and neuronal loss (Belay 1999). These data suggest that the transgenic 
overexpression of CtmprP may be associated with neurological disease in mice, 
however, the evidence for a link between CtmprP and codon 117 mutation GSS is less 
convmcmg. 
Mutations within the Prnp gene, coding for a truncated amino terminal, were 
reintroduced into PrnpO/O mice, and resulted in granule cell loss in the cerebellum and 
subsequent ataxia, a phenotype that was rescued by the reintroduction of a single 
copy of the Prnp gene (Shmerling et al. 1998). Granule cell loss is not a feature of 
TSEs in mice, suggesting that this truncated amino terminal form of the protein is not 
significant in the development of the TSEs in mice. Shmerling et al. (1998) 
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speculated that these truncated PrPs may have competed with sorne other molecule 
for a ligand and disrupted the ligand's function. 
Ma et al. (2002) also created a transgenic mouse expressing a truncated (23-230AA) 
Prpc lacking both the N-terminal and C-terminal sequences. These mice were ataxie 
and had cerebellar atrophy due to massive granule cell loss. Apparently, the 
transgene lacked the necessary enhancer element to be expressed in Purkinje ceIls, 
and so no changes were detected in them. Ma et al. (2002) proposed a unifying 
model for the pathogenesis of the prion diseases, suggesting that mutations and 
presumably the infectious agents, increase misfolding of Prpc triggering the cell to 
transport these proteins to the cytosol, where they are metabolized by the proteasome. 
They proposed that impaired proteasomal function could provide a mechanism for the 
build-up of prion proteins in the cytoplasm. Similarly, Cohen and Taraboulos (2003) 
treated cells with cyclosporin A to inhibit peptidyl-propyl cis-trans isomerases 
(PPIases) and detected the accumulation of a protease-resistant "prion-like" PrP 
species, which was not degraded by the proteasome and accumulated in 
nonmembrane bound aggresomes. Cohen and Taraboulos (2003) however, did not 
report cell degeneration or death as a consequence of their treatment. Ma et al. 
(2002) found that "very small quantities of soluble PrP are toxic". Their construct, a 
truncated Prpc (23-230AA) induced cell death, presumably by apoptosis, as there was 
no inflammation described. However, neuronal loss has not been unequivocally 
described in scrapie, and may not be present in cases of OD and GSS (Jeffrey et al. 
1995a) and granule cell loss is not a feature of scrapie in mice, in fact, of the 
approximately 20 distinct scrapie strains recognized in mice inoculation tests, only 
22L, has significant cerebellar lesions, and these consist of vacuolation of the gray 
matter (Bruce and Fraser 1991). The only other mouse model of TSE that produces 
significant cerebellar lesions is BSE, where Purkinje ceIl loss, rather than granule ceIl 
loss has been described (Lasmézas et al. 1997). The unifying process in the 
spongiform encephalopathies is the loss of the ability of neurons to maintain their 
specialized function with cell death occurring sorne time later i.e. degeneration, and 
so a proposed process that kills neurons when very small quantities of PrP are in the 
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cytosol rather than simply impairing their function would not explain the observed 
sequence of lesions in the spongiform encephalopathies. For the cytoplasmic PrP 
theory of Ma et al. (2002) to be valid in the naturally occuring diseases, the 
accumulated PrP isoform would have to impair neuronal function rather than simply 
initiate the cell death pathway. In this respect, both the pathogenesis of the disease 
and the lesions described by Ma et al. (2002), appear to be unique, suggesting that it 
is a unique disease and not part of the TSE spectrum. Moreover, Drisaldi et al. 
(2003) in contrast to Ma et al. (2002) found that blocking the proteasome in cell 
cultures does not result in retrotranslocation and increased PrP in the cytoplasm. 
Drisaldi et al. (2003) suggested that the neurotoxicity noted by Ma et al. (2002) was 
the result of increased PrP synthesis due to a side effect of the prote as omal inhibitor 
on the CMV promoter used by Ma et al. (2002). Drisaldi et al. (2003) hypothesize 
that the mechanism of PrP accumulation may be due to stabilization of transcription 
or translation factors or to activation of signaling pathways that impinge on 
transcription of the promoter. In addition, Roucou et al. (2003) found that PrP 
accumulation and passage through the ERAD pathway was not toxic in human 
primary neurons. 
Another transgenic mouse was created that expressed additional octapeptide repeats, 
similar to a human inherited prion mutation (Chiesa et al. 1998). These mi ce express 
9 additional octapeptide repeats (PG 14) and develop neurological disease 
characterized c1inically by ataxia. HistologicaIly, there is massive cerebellar granule 
cell loss, PrP accumulation and astrogliosis (Chiesa et al. 1998). This disease is not 
transmissible to wild-type mice, and the lesion is n?t reported in any of the prion 
strains that have been typed in mice, indicating that this disease is not part of the TSE 
spectrum and is a disease of protein overexpression. 
Overall, these data suggest that the transgenic overexpression of a mutant prion 
protein in mice can result in a disease with neurological signs and pathological 
changes in the nervous system. However, none of these mutant forms of PrP have 
been shown to be transmissible to wild-type mice. These diseases cannot therefore be 
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considered "transmissible" spongiform encephalopathies and are therefore diseases of 
overexpression of a protein in neurons that result in neuronal dysfunction and 
degeneration. The overexpression of other proteins may also result in neurological 
disease e.g. Syrian Hamster PrP (Westaway et al. 1994), uB-adrenergic receptor 
(Zuscik et al. 2000), neurofilament proteins (NF-L, peripherin)(Robertson et al. 2002) 
and G-protein coupled, protease-activated receptor for thrombin (Festoff et al. 2000). 
Therefore, we should not be surprised that the expression of a protein above 
physiological levels may disrupt metabolic pathways and result in degeneration. A 
summary of the major transgenic mou se models is shown in Table 1.1. 
1.9 Specifie Methodologieal Approaehes 
1.9.1 Mouse Bax-mediated neuronal death model 
Ethanol triggers apoptotic neuronal cell death by blockade of N-methyl-D-aspartate 
(NMDA) glutamate receptors and excessive activation of GABAA receptors in post-
natal rats (Olney et al. 2000). This is a model of the human neurotoxic syndrome 
termed fetal alcohol effects (FAE) or fetal alcohol syndrome (FAS) (lkonomidou et 
al. 2000). This group has developed a model whereby a 20% solution of ethanol is 
administered to 7 day-old Sprague-Dawley rats (lkonomidou et al. 2000) or mice 
(Olney et al. 2002a), in two separate treatments, two hours apart at a dosage of 2.5 
g/kg subcutaneously (sc) with histological examination of the brain harvested 24 
hours after the first treatment (lkonomidou et al. 2000, Olney et al. 2002a). With this 
protocol, blood ethanol concentrations are maintained at or above 200 mg/dL for 4 
consecutive hours (Olney et al. 2000), whereas the corre nt legal blood alcohol content 
limit for driving is 0.08 g/dL (80 mg/dL), therefore, a level readily attainable with 
binge drinking (Heng et al. 2006). This model induces reduced brain mass, 
significantly higher rates of apoptosis in ethanol-treated versus saline-treated animaIs 
in various areas of the brain including, the CAl hippocampus, subiculum, caudate 
54 
Table 1.1: Summary of the major transgenic prion protein mou se models 
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Mouse Molecular Lesion Reference 
Effect 
PrpOlO knock out 4-187 of altered circadian Bueler et al. 1992 
ORF rhythm, +/-
seizures 
PrpOexp addition of SHPrP myopathy, Scott et al. 1989 
cDNA neuropathy, 
spongiform 
degeneration CNS 
Shmerling mou se N-terminal cerebellar granule Shmerling et al. 
truncation cellioss 1998 
Hegde Ctm mouse Valine to alanine vacuolation, Hegde et al. 1998 
substitutions 113, hippocampus, 
115,118 piriform cortex 
PG14 mouse 9 additional cerebellar granule Chiesa et al. 1998 
octapeptide repeats cellioss 
Ma cytosolic PrP N and C terminal cerebellar granule Ma et al. 2002 
mouse truncations cellioss 
Sakaguchi Prp-/- Entire coding exon cerebellar Purkinje Sakaguchi et al. 
knockout strategy cellioss 1996 
PrppI02L 8 fold cerebral and Hsiao et al. 1990 
overexpression of brainstem 
P102L spongiform 
degeneration 
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nucleus, thalamus, pallidum and in various areas of the cerebral cortex (lkonomidou 
et al. 2000), if administered during the period of synaptogenesis (the first 2 weeks 
after birth) (Olney et al. 2002b). This neuronal apoptosis was not seen in Bax 
knockout mice injected with ethanol, indicating that this apoptosis is mediated by Bax 
(Young et al. 2003). They also demonstrated an apoptotic response due to the 
administration of benzodiazepines and barbiturates that potentiate the effect of GABA 
at GABAA receptors, as weIl as with the administration of MK-801, a blocker of 
NMDA glutamate receptors (Ikonomidou et al. 2000). The effects of ethanol were 
more extensive than either of these other agents alone and corresponded to both 
patterns of apoptosis superimposed in the same brain (Ikonomidou et al. 2000). 
Ethanol was therefore a more robust apoptosis inducing agent. 
The specific link between ethanol injection, potentiation of GABAA receptors, 
blockade of NMDA receptors and Bax activation has not been extensively studied. 
However, recent work has determined that ethanol leads to reduced activity of 
survival kinases, such as Akt, Erk 1/2 and PKAu and increased activity of JNK 
kinase (Han et al. 2006). In this model, Han et al. (2006) propose that JNK activity 
resulted in phosphorylation of proapoptotic Bcl-2 family member Bad releasing it 
from 14-3-3 and allowing the dimerization of Bad with anti-apoptotic protein 
Bclx(L), thereby triggering the release of Bax from Bclx(L). Bax would then be free 
to translocate to the mitochondria, oligomerize and initiate the mitochondrial 
apoptotic pathway (Han et al. 2006). 
1.9.2 Neuronal quantification 
ln order to assess the effect of various treatments on neuronal death, quantification of 
neurons is an accepted technique (Hyman et al. 1998, West 1999, Benes and Lange 
2001, Yang et al. 1998, von Bartheld 2001). Two major methods are available, three-
dimensional stereological counting and two-dimensional counting. 
57 
Three-dimensional stereological counting involves the use of thick tissue sections, 
commonly up to 50 ]lm thick and selecting a random starting point, then every "Nth" 
section thereafter (Hyman et al. 1998). Once stained, the structure of interest is 
counted in a clearly defined area of the section and counting is continued in the Z-
axis through the depth of the section with the volume and counts used to calculate the 
number of structures in the entire slide (Hyman et al. 1998). The stereological 
approach has certain advantages, especially in cases where atrophy of the brain could 
"normalize" the density of neurons after a lesion (Hyman et al. 1998), and may be 
most appropriate where the total number of neurons in a structure ego entire brain, 
cerebellum or specific gyrus, are to be compared, as both the number and the volume 
could change with sorne insults making the results of two-dimensional counting 
uninterpretable (West 1999). Direct counting of objects in a defined volume is 
believed to eliminate potential biases (sources of error) inherent with assumption 
based two-dimensional methods (West 1999). 
However, three-dimensional counting methods require that the objects to be counted 
are distributed in a completely random fashion (Benes and Lange 2001) and it is 
almost impossible to select fields randomly without a microscope equipped with a 
stage encoder (Hyman et al. 1998). In addition, the collapse of the tissue in the Z-
axis due to processing does introduce bias into the counting procedure and this 
collapse is non-linear and so its effect will vary with the depth of the tissue section 
(Guilerry and Herrup 1997). Thick sections also limit antibody penetration and so 
may make quantification of immunohistochemically stained sections less reliable 
(Benes and Lange 2001). Due to the light scattering effect of the thick sections and 
mounting media, as weIl as the increased mental and physical fatigue involved in 3-D 
counting, the stereological method is more difficult, more expensive, and more time 
consuming than 2-D counting (Benes and Lange 2001). In addition, 3-D derived 
estimates are not in fact "unbiased", when compared to the gold-standard, 3-D 
reconstruction of seriaI sections (reviewed by von Bartheld 2001). 
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The other method available for quantification of objects is two-dimensional counting. 
This method involves examination of a stained paraffin embedded thin section and 
counting of the objects in a prescribed area (Clarke and Oppenheim 1995). The 
Abercrombie equation can be applied to 2-D counts to give an accurate assessment of 
numerical density of the object of interest (Benes and Lange 2001, Hedreen 1998). 
The Abercrombie equation is as follows: 
M 
P=Ax 
L+M 
Here P is an estimate of the true number of nuclei in the section; A is the crude count 
of nuclei in the section; M is the (mean) thickness of the section in !lm; L is the mean 
height (length) of the nuclei in !lm (Abercrombie 1946). 
This technique has the advantages that it is technically easier to prepare the si ides and 
count the objects (reviewed by von Bartheld 2001). As the sections are thinner 
(commonly less than 5 }lm), ail of the cells present in the Z-axis are visible and so the 
effect of tissue collapse, a disadvantage of examining thick sections in 3-D counting, 
is virtually eliminated (Clarke and Oppenheim 1995). Two-dimensional counting has 
also been compared directly to seriai section reconstruction and found to be within 
2% of the true "gold standard" value (Clarke and Oppenheim 1995). In addition, thin 
sections stain more consistently with immunohistochemical methods (Benes and 
Lange 2001). Correctly performed 2-D counting may have less biases than 3-D 
counting and the superior quality of optimally fixed and stained paraffin embedded 
sections may provide better recognition of the stained particles, and so be more 
advantageous than 3-D methods (reviewed by von Bartheld 2001). The major 
drawback however, is that counting neurons in a single section may lead to more 
interindividual variability than sampling the entire structure, due to differences in the 
exact are a examined, plane of section etc. (Hyman et al. 1998). 
In this study, we are not comparing the total number of neurons in the brain between 
groups but rather the proportion of neuronal death in specific areas or nuclei between 
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groups. Neurons are not distributed in a random fashion in the brain, but rather are 
specifically organized into non-random nuclei or layers. The particles that we will be 
counting are cells, which will be stained using immunohistochemical methods. Our 
objective is to stain apoptotic neurons containing active caspase 3, and obviously the 
amount of active caspase 3 present, will vary depending on how far the neuron is 
along the pathway of apoptosis. An unknown and variable number of ceUs will 
contain only trace amounts of active csp3 either early in the process or late in the 
process. Therefore, the ability of the anti-active caspase 3 antibody to penetrate the 
tissue section is critical and will undoubtedly add another major source of variation if 
it is applied to sections that are 50 I-tm thick. The technical difficulty of embedding 
and preparing sections of an entire mouse brain for 3-D counting is also a 
consideration. In the study proposed here, two-dimensional counting is the more 
appropriate method. 
2.0 Hypothesis and objectives 
Therefore, in the studies that we are proposing, we are testing the hypothesis that PrP 
protects against Bax-mediated cell death in vivo. The rationale for our hypothesis is 
that there is abundant evidence that PrP protects against Bax in in vitro systems, using 
primary neurons and differentiated neuronal cell lines. More specifically, the 
cytosolic form of PrP has been shown to be protective by preventing the 
conformational change in Bax. This is the same step that is inhibited by the natural 
antagonists of Bax, such as Bcl-2 and BclxL • The conformational change in Bax is a 
crucial early step in the conversion of the protein from a potential proapoptotic 
protein to a de facto proapoptotic one. To test the hypothesis we are using 2 
experimental paradigms. The first is using an exogenous stimulus, ethanol injection, 
to stimulate Bax-mediated neuronal death in post-natal mice. To measure the Bax-
mediated neuronal death induced, we use neuronal quantification by anti-active 
caspase 3 immunohistochemical staining as a downstream marker of Bax activation 
and compare the total number of anti-active caspase 3 positive cells among 3 groups 
of mice expressing 3 different levels of PrP i.e. no PrP (PrpO/O), wild-type levels of 
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PrP (Prp+/+) and mice overexpressing PrP that express both mouse and Syrian hamster 
prion protein (PrpüexP). The second experimental paradigm is using an endogenous 
stimulus, physiological Bax activation in pre-natal mice. During development Bax is 
the major pro-apoptotic protein responsible for inducing apoptosis in the nervous 
system and its most important antagonist is Bclx. We intend to create a transgenic 
mouse expressing PrP under the Bclx promoter and cross it with Bclx heterozygous 
mice to see if PrP expressed under these circumstances will be able to assume the 
function of Bclx in vivo and thereby pre vent the neuronal death that is seen in Bclx 
homozygous knockout mice. The end point will be measured by counting viable and 
apoptotic neurons in E12 embryos. This is the stage of maximum Bax-mediated cell 
death in the developing nervous system. Then we will compare the results to control 
mice. 
Using these two paradigms, we hope to definitively show that PrP is protective 
against Bax-mediated cell death in vivo and in so doing, demonstrate the first 
definitive function for PrP in vivo. 
Chapter 2 Ethanol-induced Bax-mediated ceII death in mice 
2.1 Introduction 
Despite the realization in 1985 that the agent believed to be responsible for the TSE's 
was in faet, derived from a host protein (Oesch et al. 1985), the physiologie function 
of this ho st protein, Prpc, has defied confirmation. The protein is widely expressed 
both in terms of tissue distribution (Bendheim et al. 1992, Brown et al. 2000) and in 
terms of species distribution (Wopfner et al. 1999). This degree of conservation of 
the protein suggests that it has an important function. Prpc is predominantly 
expressed on the cell surface, where it is attaehed by a GPI anchor (Borchelt et al. 
1990), but significant amounts are present within the cytoplasm of a subpopulation of 
neurons in adult mice (Mironov et al. 2003) and may also be found in the 
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endolysosomal compartment (Arnold et al. 1995) or in the cytosolic proteasome and 
endoplasmic reticulum associated degradative (ERAD) pathway (Yedidia et al. 2001). 
The proposed functions of PrpC are numerous. These inelude a role in copper 
metabolism and as an anti-oxidant (Brown et al. 1997b, 1998a). Prpe is reported to 
be involved in signal transduction (Spielhaupter et al. 2001) and growth (Graner et al. 
2000). It may be involved in calcium metabolism (Colling et al. 1996, Hermes et al. 
2001) and in regulating neuronal activity (Collinge et al. 1994, Tobler et al. 1996). 
PrpC binds to nueleic acids, which has suggested an anti-retroviral role (Derrington 
and Darlix 2002). It may be involved in the immune response (Mabbott et al. 1997, 
Bainbridge and Walker 2005). Prpe is also proposed to have a role in cell survival 
following ischemic (McLennon et al. 2004) or traumatic brain injury (Marciano et al. 
2004). More specificaIly, evidence suggests that Prpe binding at the cell surface 
increases anti-apoptotic Bel-2 levels and decreases proapoptotic Bax levels, 
suggesting that prpe may support neurite outgrowth via a Bel-2 family mediated 
mechanism (Chen et al. 2003). However, the nature of this relationship between 
Prpe, Bel-2 and Bax-mediated cell death has thus far, not been elucidated. 
The four N-terminal PrP octapeptide repeats share limited similarity with the Bel-2 
homology domain (BH2) of the Bel-2 proteins, which is crucial to the anti-apoptotic 
function of Bel-2 against Bax (LeBlanc 1998, Yin et al. 1994). This similarity 
suggested that Prpe may also have an anti-Bax function, and using microinjection of 
PrP and Bax into human primary neuronal cultures, Bounhar et al. (2001) found that 
Prpe protects as weIl as Bel-2, against Bax-mediated cell death in this model. 
Furthermore, microinjection of a construct expressing PrP cDNA lacking both the N-
terminal and C-terminal signal peptides (CyPrP) and therefore expressed in the 
cytosol, protects against Bax-mediated cell death in human primary neurons (Roucou 
et al. 2003). The mechanism of how PrP protects against Bax-mediated cell death is 
unknown, however, the first step in Bax activation involves a conformational change 
of the protein, which is inhibited by PrP (Roucou et al. 2005). This protection is 
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specifie to Bax, as PrP does not protect against other Bcl-2 family pro-apoptotic 
proteins, such as tBid or Bak (Roucou et al. 2005). 
There is also in vivo evidence that PrPc protects against neuronal death induced by the 
overexpression of the prion-like protein DpI (Moore et al. 2001) or induced by the 
expression of an N-terminally truncated form of PrP (Shmerling et al. 1998). In at 
least one model of inherited prion disease (PG 14), the crossing of mutant mice onto a 
homozygous Bax knockout background pre vents the neuronal death, indicating that 
the cell death is Bax-mediated (Chiesa et al. 2005). Therefore, we were interested in 
testing the hypothesis that PrPc protects against Bax-mediated cell death in vivo, 
which if true, would provide the first definitive evidence for a physiologie function 
for PrpC in vivo. 
In order to test our hypothesis, we need an experimental paradigm to induce Bax-
mediated cell death. In vitro experiments often use serum deprivation, which is 
obviously incompatible with life and therefore cannot be used in an in vivo system. 
Ethanol was selected as the external insult to induce cell death as it triggers neuronal 
cell death by blockade of N-methyl-D-aspartate (NMDA) glutamate receptors and 
excessive activation of GABAA receptors in post-natal rats (Olney et al. 2000). If 
administered during the period of synaptogenesis (the first two weeks after 
birth)(Olney et a1.2002b) massive amounts of apoptosis are induced in the CA 1 
hippocampus, subiculum, caudate nucleus, thalamus, pallidum and in various areas of 
the cerebral cortex (Ikonomidou et al. 2000). This apoptosis is not seen in Bax 
knockout mice, confirrning that it is Bax-mediated (Young et al. 2003). Other models 
that induce neuronal death are available, however, the amount of cell death and 
dependence on Bax are less weIl known. Ethanol is readily available, inexpensive, is 
not a restricted drug, the effects are consistent and restricted to neurons, is a robust 
apoptosis inducing agent that is mediated by Bax, and so it was selected as the agent 
to induce Bax-mediated neuronal death. 
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Therefore, we used the Olney ethanol injection model in 7 day old mouse pups and 
compared the amount of neuronal death induced in PrpOlO, PrP+1+ and Prpüexp mice to 
see if Prpc could prote ct against Bax. We found greater numbers of neurons 
undergoing apoptosis following ethanol insult in PrpO/O mice than Prp+/+ mice although 
the differences were not statistically significant. Our results suggest that Prpc may 
protect sorne, but not aIl neurons from Bax-mediated cell death in vivo. 
2.2 Objective and Rationale 
Several lines of evidence suggest a role for Prpc in neuronal survival. Prp+/+ 
hippocampal ceIllines survive serum deprivation better th an PrP-1- cells (Kuwahara et 
al. 1999). Prpc directly interacts with Bcl-2 (Kurschner and Morgan 1996). Prpc 
protects human neuronal cells in culture from Bax-mediated cell death (Bounhar et al. 
2001). Prpc increases antiapoptotic Bcl-2 levels and decreases proapoptotic Bax 
levels in cerebellar granule neuronal culture from C57BL/6J mice (Chen et al. 2003). 
These data indicate that in vitro, Prpc may promote neuronal survival by inhibiting 
Bax-mediated cell death. In this experiment, we assessed the in vivo function of PrpC 
against Bax-mediated cell death. We used an ethanol toxicity model, whereby, 
ethanol is injected into mice to induce massive neuronal cell apoptosis, during the 
period of synaptogenesis (Ikonomidou et al. 1999, Olney et al. 2000). Bax is required 
for neuronal cell death during development (Deckwerth et al. 1996) and the apoptosis 
induced by the ethanol model is mediated by Bax (Young et al. 2003). Therefore, we 
tested if wild-type Prpc expressing mi ce are less vulnerable to ethanol-induced 
neurotoxicity than are PrpO/O (nuIl) mice and if mice expressing endogenous murine 
Prpc in addition to Syrian Hamster PrpC (Prpc overexpressors) are less vulnerable 
than wild-type mice. 
2.3 Methods and Experimental Design 
2.3.1 Mice 
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Prp+JO (heterozygous Prnp knockout) mice were derived from the Zurich PrnpOJO strain, 
developed by Dr. Charles Weissmann. They were backcrossed onto a C57Bl6 
background, and were obtained from Dr. David Westaway, (University of Toronto, 
Centre for Research in Neurodegenerative Diseases, Tanz Neuroscience Building, 6 
Queen's Park Cre sent West, Toronto, Ontario, M5S 3H2, Canada). Heterozygous 
mice carrying Syrian Hamster Prnp, were derived from Tg(SHaPrP)7 mice (Scott et 
al. 1989), backcrossed onto a C57Bl6 background, and were also obtained from Dr. 
David Westaway. Wild-type mice were generated from crosses during the 
experiment and via wild-type C57Bl6 founder mice obtained from Charles River, St. 
Laurent, Québec, at the initiation of the breeding program. The genotype of the mice 
used in the study was confirmed using a polymerase chain reaction (PCR) to identify 
wild-type, knockout alleles (neomycin phosphotransferase "neo" gene, see 
Genotyping below) and single SHaPrnp alleles (see Genotyping). Suspected 
homozygous SHaPrP mice were backcrossed to wild-type mice to verify their 
homozygosity. DNA was extracted from samples of the tail, or a small sample of 
liver (see Genotyping section 2.3.4 below). However, during the course of the 
experiment after establishing a homozygous SHaPrP line, the homozygous animaIs 
began to manifest the clinical signs (hunched posture, paraparesis) and pathological 
changes (myopathy, neuropathy and spongiform degeneration within the central 
nervous system) previously reported (Westaway et al. 1994) and had serious breeding 
problems at around 200 days of age. Therefore, we decided to use heterozygous 
Syrian Hamster PrP mice, as these animaIs contain 60 copies of the transgene 
(Westaway et al. 1994) and are expressing large amounts of the protein (see Figure 
2.3). A total of 360 mice were used in the experiment. Mice were housed in the 
Animal Facility at the Lady Davis Institute, in accordance with the guidelines of the 
Canadian Council on Animal Care and a protocol approved by the McGiIl University 
Animal Care Committee. 
2.3.2 Induction of Bax-mediated cell death with ethanol 
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The protocol for the ethanol toxicity model was developed by Olney et al. (2000). 
Two subcutaneous injections of 20% ethanol at 2.5 g/kg, 2 hours apart were given, 
and animais are sacrificed at 8 hours and 24 hours post-first injection. The injections 
were administered on post-natal day 7, after the mice have been weighed. In order to 
stimulate extensive apoptotic neurodegeneration, these injections must be given 
during the period of synaptogenesis (first 2 weeks after birth)(Olney et al. 2000). 
This group, using the deOlmos cupric sil ver staining technique, reported that in sorne 
areas, ethanol treated brains had lost 30 to 50% of their neurons (Olney et al. 2000). 
They also found that in sorne areas, up to 1 % of the neuronal population may be 
undergoing apoptosis i.e. physiological cell death, and suggested that these may be 
neurons that have faited to establish appropriate connections (Olney et al. 2000). 
This model has been tested in Bax knockout mice to confirm that the cell death is 
Bax-mediated (Young et al. 2003). 
2.3.3 Histological preparation of the brain 
The mice were euthanized via decapitation, the calvarium was removed to expose the 
brain, the skull immersed in Bouin's fluid tissue fixative (Fisher Scientific, Ottawa, 
Ontario) for approximately 8 to 10 hours. The brains were then dissected free of the 
skull, rinsed thoroughly and immersed in 10% neutral phosphate buffered formai in 
for approximately 7 days, at which point the brain was trimmed and embedded in 
paraffin. Fixation by perfusion with various combinations of glutaraldehyde and 
paraformaldehyde are often used to prepare tissues from mature rodents, as this 
technique avoids much of the artifact induced by delayed fixation via immersion. 
However, the mice in our study were only 7 days old and so with a combination of 
Bouin's fluid and formalin, delayed penetration of the fixative was insignificant. 
However, the artifact induced by perfusing 7 day old mice is prohibitive. The quality 
of the fixation of the mouse brains was excellent. Sections were cut 5 !lm thick on a 
microtome and stained with hematoxylin and eosin, and sections cut 4 !lm thick on a 
66 
microtome were placed on poly-L-Iysine slides for immunohistochemical 
examination. Due to the variation in time of birth over the night (a possible 12 hour 
variation), pairs of mice, one treated with ethanol and one treated with saline were 
selected from litters used in the experiment. From each mouse 20 sections were cut 
per brain and immunostained for anti-active caspase 3 activity. Then 10 tissue 
sections per mou se were selected for counting. The 10 sections counted were 
selected on the basis of location, tissue damage, symmetry, background staining and 
counterstaining. A schematic diagram showing the location of the sections is shown 
in Figure 2.1 below. 
2.3.4 Genotyping 
At approximately 3 weeks of age for potential breeding animaIs, or following 
sacrifice for treated animaIs, and using a protocol supplied by the laboratory of Dr. 
David Westaway approximately 1 cm of the tail (or appropriately small tissue 
sample) was removed from the desired mouse and placed in an eppendorf tube, and 
500 ilL of Tail Buffer (50 mM Tris pH 8.0, 100 mM NaCl, 1 % SDS, 25 mM EDT A 
pH 8.0) plus 35 ilL of Proteinase K (20 Ilg/mL) was added. The sampi es were 
incubated overnight in a 55°C waterbath. Then 500 ilL of buffer-saturated phenol 
was added to each digested sample. The samples were centrifuged at 13,000 rpm for 
10 minutes. The upper layer was transferred to a new eppendorf and 1 mL of 95% 
ethanol was added. The tubes were tipped gently to mix. The samples were 
centrifuged at 1O,000g for 10 minutes. The supernatant was discarded and 1 mL of 
70% ethanol was added to the tube. The samples were centrifuged at 13,000 rpm for 
10 minutes. The supernatant was discarded and 1 mL of 100% ethanol was added. 
The sampI es were centrifuged at 1O,OOOg for 10 minutes. The supernatant was 
discarded and the tubes were dried by pressing the eppendorf onto paper towels. The 
DNA pellet remaining was resuspended in 50 ilL of TE (10 mM Tris pH 7.4, 1 mM 
EDT A pH8.0) and the tube placed in a 37°C waterbath for 10 minutes to aid 
resuspension. The genotype was then confirmed by the polymerase chain reaction 
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(PCR) using primer sequences and protocols kindly provided by the laboratory of Dr. 
David Westaway. For the Syrian Hamster Prnp (PrpOexP) transgenic mice, the primer 
sequences were, DW190: 5' GCCfTTGAATTGAGTCCATCACGGGCCA 3' and 
DW191: 5' GGCCGCGGAGAAATGAGAAACGCCAAGCGCCGTGACf 3'. The 
conditions were as follows; 94° C 3 min, 1 cycle; 94° C 20 s, 68 oC 20 s,72°C 45 s, 
42 cycles; 72°C 7 min, 1 cycle; 4°C soak. For the Prnp knockout mice (PrpO'°) and 
Prnp wild-type mice (Prptl+) , the pnmer sequences were, RKl: 5' 
TCAGCCfAAATACfGGGCAC 3', RK2: 5' GCCfAGACCACGAGAAATGC 3', 
RK3: 5' GCATCAGCCATGATGGATAC 3'. The conditions were as follows; 94°C 
3 min, 1 cycle; 94°C 15 s,62°C 15 s,72°C 2:30, 42 cycles; 72°C 7 min 1 cycle; 
4°C soak (see also Appendix 1). 
2.3.5 Protein expression 
Expression of Syrian Hamster or mouse pnon protein was confirmed using the 
following brain extraction protocol. Briefly, the brains were removed from the mice 
and immediately rinsed in PBS on ice to remove any blood, then homogenized on ice 
in an appropriate volume (approximately 1 mL for a 7 day old mou se brain) of 
CHAPS lysis buffer (50 mM TrisHCl pH 8.0, 150 mM NaCl, 1 % CHAPS, 5 mM 
EDTA). The samples (approximately 500 ~L volume) were then transferred to a 
DNA storage vial (Cryovial, Fisher Scientific, Ottawa, Ontario) and sonicated for 20 
seconds using a Branson Sonifier 450 (Branson Ultrasonics Corporation, Danbury, 
Cf) at a 20% setting, output control 6, then frozen at -20°C. The samples were then 
thawed and refrozen at -20°C and then centrifuged at 10,000 g for 15 minutes at 4°C 
and the supernatant collected. An aliquot of the supernatant was used for a 
bicinchoninic acid (BeA) protein assay (Pierce Biotechnology Inc., P.O. Box 117, 
Rockford, IL, 61105, USA) with the remainder being frozen. The samples were 
assayed using a BCA protein quantitation assay, using a bovine serum albumin (BSA) 
standards of 0 to 40 ~g/mL to make a standard curve. Test samples were diluted at 
1: 10 and 1 :50 and the samples were incubated as per the manufacturers protocol. 
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Approximately, 50 f.tg of protein was loaded in al: 1 ratio with loading dye (100 mM 
TrisHCI pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% glycerol then 100 mM 
dithiothreitol was added in a 1:4 ratio just before use) on a western blot. The western 
blots were prepared according to an established protocol, to make 15% acrylamide 
gels (SDS-PAGE). When the gels were ready for loading, the gel apparatus was then 
inserted into the running apparatus containing running buffer (14.4 g glycine, 3.1 g 
trizma base, 1 g SDS in 1 L of water). The protein samples were prepared for 
loading by adding an equal volume of loading dye (100 mM trisHCI ph 6.8, 2% SDS, 
0.1 % bromophenol blue, 10% glycerol with 1:4 ratio of 100 mM dithiothreitol added 
to the dye just before use), and then boiled in a heat block for 5 minutes immediately 
prior to loading. The samples were loaded and the gel was run at approximately 130 
volts for approximately 1 hour 20 minutes (until the blue dye ran off the end of the 
gel). PVDP membranes (lmmobilon P Transfer Membrane, Millipore Corporation, 
Bedford, MA) were prepared by soaking in 100% methanol for several minutes and 
then rinsed in transfer buffer (lOX transfer buffer contains 144.1 g glycine, 30.3 g 
trizma base). To make the working solution of transfer buffer, 100 mL of the lOX 
solution was added to 200 mL of 100% methanol and 700 mL of double distilled 
water. The gels were removed from the running apparatus and transferred to the 
transfer apparatus. The transfer was effected at 230 mAmp for approximately 2 hours 
and 30 minutes for a thick gel or at 40 mAmp overnight. After the transfer was 
complete, the PVDP membrane was removed and placed in a plastic container and 
rinsed in TBS tween buffer (8.78 g sodium chloride, 10 mL 1 M trisHCI pH 8 with 
989 mL of water and 1 mL of Tween 20 (SigmaAldrich Inc. St. Louis, MO)) for 5 
minutes at room temperature on a rotating platform. At this point, the TBS tween 
was poured out and replaced with 25 mL of a blocking solution (2.5 g powdered low 
fat skim milk in 50 mL TBS tween) and incubated on the rotating platform at room 
temperature for 1 hour. The primary antibody was prepared using an appropriate 
dilution of antibody in 1.25 g powdered low fat skim milk in 50 mL of phospate 
buffered saline pH 7.4 (Irwin and Janssen 2001). Approximately 1 mL of the diluted 
antibody was prepared and placed on a glass plate in a humid chamber at 4°C. The 
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PVDF membrane was placed protein side down on the antibody and incubated on the 
plate in the chamber overnight. In the morning, the membrane was placed in a plastic 
container and rinsed three times in approximately 20 mL of TBS tween for 10 
minutes each on the rotating platform at room temperature. An appropriate dilution 
of the secondary antibody (see Appendix 3) was prepared in 15 mL of the antibody 
dilution solution and after the TBS tween was poured out, the antibody was poured in 
and incubated for 1 hour at room tempe rature on the rotating platform. The 
membrane was then rinsed three times in TBS tween as above. The membrane was 
then developed in an appropriate western developing solution (either ECL Western 
blotting reagents, Amersham Biosciences RPN2106 or Immobilon Western 
Chemiluminescent HSP substrate, Millipore Corporation, WBKLS0100) and 
exposed to X-ray film in the dark room for an appropriate period of time. 
2.3.6 Detection of cell death with TUNEL 
Terminal deoxytransferase-mediated deoxyuridine triphosphate nick end-Iabeling 
(TUNEL), using an In Situ Cell Death detection kit (Roche Diagnostics, Laval, 
Québec) is a widely used method of immunohistochemical examination to visualize 
cells undergoing cell death. The technique is amenable to visualizing apoptotic 
neurons following ethanol-induced Bax-mediated apoptosis in rodents (Olney et al. 
2000, Ikonomidou et al. 2000). This technique uses terminal deoxynucleodidyl 
transferase (TdT) to catalyze polymerization of fluorescein labeled nucleotides to free 
3' -OH ends in DNA strand breaks. The fluorescein labeled nucleotides are detected 
by the incorporation of fluorescein using anti-fluorescein antibodies conjugated with 
alkaline phosphatase. The reaction is developed using nitrobluetetrazolium/5-bromo-
4-chloro-3-indolyl phosphate (NBTIBCIP 1 tablet in 10 mL of water) 
diaminobenzidine tetrahydrochloride (DAB). This technique recognizes strand breaks 
and is therefore not specific for apoptosis as DNA strand breaks obviously occur in 
necrosis as weIl. 
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Large numbers of poly-L-Iysine coated slides were prepared for 
immunohistochemical staining with TUNEL and stained using the manufacturers 
protocol (In situ Cell Death detection kit, Roche Diagnostics, Laval, Québec). 
Subsequently, various techniques recommended by the manufacturer were used in an 
attempt to increase the sensitivity of staining. These methods included treatment with 
0.1% Triton-X, proteinase K (10-20 ~g/mL in 10 mM TrisHCL, pH 7.4-7.8) and 
microwaves (370 W for 5 min in 200 mL 0.1 M citrate buffer pH 6.0). Triton-X and 
proteinase K methods did not produce positive staining. Abundant background 
staining was present in slides from both the saline and ethanol treated animaIs, 
necessitating dilution of the reaction mixture to 1:3 with TUNEL dilution buffer, as 
per the manufacturers protocol. At this dilution, a positive control slide prepared by 
incubating a deparaffinized tissue section in DNase 1, grade 1, (3000 U/mL) in 50 
mM Tris-HCl, 10 mM MgCl2 and 1 mg/mL of (bovine serum albumin) BSA for 10 
minutes at room temperature, demonstrated positive staining. 
2.3.7 Detection of cell death using anti-activated caspase 3 antibody staining 
Caspase 3 is one of the effector caspases (reviewed by Degterev et al. 2003), and has 
been shown to be activated in the ethanol model, providing a good indication of the 
cell death thereby induced (Olney et al. 2002). 
The protocol for anti-activated caspase 3 staining was as follows: 4 ~m thick tissue 
sections on poly-L-Iysine slides were incubated at 56°C overnight. The sections were 
deparaffinized and rehydrated using standard methods. Antigen retrieval was 
effected by immersing the slides in a Coplin jar containing Dako target retrieval 
solution high pH (Dako Corporation, Carpinteria, CA, USA) at 95°C to 99°C in a 
water bath and incubated for 20 minutes followed by 20 minutes at room temperature. 
Following rehydration, endogenous peroxides were quenched using 3% hydrogen 
pero xi de in PBS for 5 minutes. The slides were incubated in a blocking buffer 
solution of PBS-BB (PBS with 1% bovine serum albumin, 0.3% triton X-lOO and 
0.2% powdered skim milk) for 5 minutes. The primary antibody, anti-active caspase 
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3 (specific for the large fragment p17/19)(Cell Signaling Technology Inc. New 
England Biolabs Ltd. Pickering, Ont. Canada ASPI75) was diluted 1:1000 with PBS-
BB. The slides were incubated overnight at 4°C in a humid chamber then rinsed 3 
times in PBS. The secondary antibody (AffiniPure Donkey-Anti-rabbit conjugated 
with horseraddish peroxidase, Jackson Immunoresearch Laboratories Inc., PA, USA) 
was diluted to a 1:2000 solution with the PBS-BB and incubated at room tempe rature 
for 1 hour. The slides were rinsed in 3 times in PBS for 5 minutes each. During the 
final incubataion step, TSA biotin-tyramide reagent (Nen Life Science Products, 
Perkin Elmer Life Sciences, Woodbridge, Ont, Canada) was prepared in a 1: 100 
solution, with the amplification buffer as per the manufacturers protocol and 
incubated in a humid chamber at room temperature for 5 minutes. The si ides were 
rinsed 3 times in PBS for 5 minutes each. The slides were then incubated with a 
Strepavidin-HRP (JacksonImmuno Research Laboratories Ltd) in a 1:500 dilution 
with PBS-BB and incubated for 30 minutes at room temperature. The slides were 
rinsed in PBS for 5 minutes and distilled water for 5 minutes then a 1: 10 dilution of 
DAB (diaminobenzidine) metal development solution, which had been prepared 
according to the manufacturers directions (Pierce Biotechnology Inc, Rockford Il. 
USA) was added for 5 minutes. A drop of hematoxylin (Hematoxylin QS, Vector 
Laboratories Inc., Burlingame, USA) was and washed off after 15 seconds to provide 
a counterstain. The slides were mounted with a drop of Permount (Fisher Scientific, 
Nepean, Ont., Canada) added with a coverslip. 
2.3.8 Quantification of anti-active caspase 3 positive cells in tissue sections 
Apoptotic neurons were quantified using 2-D counting of aIl anti-active Caspase 3 
positive cells in 10 tissue sections per animal, and so it was not necessary to use the 
Abercrombie equation to estimate total numbers to compare among animaIs (Benes 
and Lange 2001, vonBartheld 2001). For each mouse, 20 tissue sections each 4 !-lm 
thick were stained with anti-active Csp3 antibody, as described above, and then the 
10 best sections selected for counting. These sections were selected on the basis of 
location, tissue damage, symmetry, background staining and counterstairiing. The ten 
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sections included the hypothalamus, thalamus, hippocampus, striatum and overlying 
cerebral cortex, extending rostrally from the medial posterior arcuate nucleus of the 
hypothalamus to the most rostral extent of the arcuate nucleus (see Figure 2.1). The 
sections were examined blindly and active-caspase 3 positive cells counted 3 times. 
These sections correspond to the area from Figure 53 to Figure 41 depicted in The 
Mouse Brain in Stereotaxic coordinates, 2nd edition, 2001, G Paxinos and K Franklin, 
Academic Press, San Diego, Ca. USA. The cell counting data had tremendous 
variability in aIl 3 groups of mice and did not have a normal distribution. As a result, 
in order to analyze the data statistically, we were obliged to use non-parametric tests. 
The statistician that we consulted (Dr. lan Shrier, Jewish General Hospital) suggested 
that the Kruskal-Wallis statistical test would be appropriate with significance set at p 
< 0.05. The data were analyzed using StatView (Statview, SAS lnstitute, Cary, NC). 
2.3.9 lmmunofluorescent multi-Iabeling to confirm anti-active Caspase 3 staining in 
neurons 
In order to confirm that the overwhelming majority of the active Caspase 3 positive 
cells counted were neurons, immunofluorescent multi-Iabeling was performed as 
described below. Active caspase 3 positive cells were identified using ASP175 
antibody and then sections co-immunostained with either anti-NeuN antibody as a 
marker for neuronal nudei or anti-Glial Fibrillary Acidic Protein (GFAP) as a marker 
for astrocytes. Tissue sections were cut 4 ~m thick, as above, and mounted on pol y-
L-Iysine coated microscope slides. The slides were deparaffinized and rehydrated as 
above, (in section 2.3.7 Detection of cell death using anti-activated caspase 3 
antibody staining). Antigen retrieval was using the Dako target retrieval solution, as 
above, with similar washes in tap water, PBS and blocking in 3% H20 2 in PBS, 
followed by distilled water and incubation in the PBS-BB blocking buffer for 30 
minutes at room temperature. The anti-active Csp 3 antibody was applied as above 
and the slides incubated overnight at 4°C overnight. Following 3 washes in PBS and 
incubation with the secondary antibody (Donkey anti-Rabbit HRP) for 1 hour at room 
temperature, the slides were rinsed 3 times in PBS. At this point, a 1 :500 dilution of 
73 
CY -3Plus, as directed in PLUS diluent (NEN TSA-Plus kit NEL-744b, PerkinElmer 
Life Sciences, Boston, MA) was added to the tissues sections for 5 to 10 minutes at 
room temperature in a humid chamber. Following 3 more washes in PBS and 
incubation in 3% H20 2 as above, the slides were rinsed in distilled water twice and 
PBS once (5 minutes each, as above). The same blockingPBS-BB buffer was used 
under the same conditions and incubated at room temperature for 30 minutes. A 
second primary antibody was then used, sorne slides incubated with anti-GFAP 
(astrocyte marker MAB3402, Chemicon International) 1:2000 in PBS-BB and for 
mouse anti-NeuN (neuronal marker MAB377, Chemicon International) 1:5000 in 
PBS-BB, and also incubated overnight at 4°C as above. The slides were rinsed three 
times in PBS as above, and incubated for 1 hour at room temperature with Donkey 
anti-mouse HRP (IgG, 715-035-151 Affinipure Antibodies, Jackson Immunoresearch 
Laboratories, West Grove, PA) at a 1:2000 dilution in PBS-BB. The slides were then 
rinsed three times in PBS as above. Then a 1 :500 dilution in PLUS diluent of FITC-
Plus (NEN TSA-Plus kit NEL-741B, PerkinElmer Life Sciences, Boston, MA) was 
added to the tissue section and they were incubated in a humid chamber for 5 to 10 
minutes at room temperature. The slides were then rinsed in PBS for 5 minutes, 
followed by PBS containing bis benzimide counterstain (3 /-lL of stock bis benzimide 
(2 mg/mL) in 30 mL of PBS in the Coplin jar, B2261 SigmaAldrich Inc, St. Louis, 
MS) added for 5 minutes. The slides were then rinsed in PBS for 5 minutes and a 
drop of 50% PBS:Glycerol added followed by a coverslip. The Cyanine 3 excites at 
550 nm and emits at 570 nm and so the caspase 3 positive cells appear red, whereas, 
the fluorescein excites at 494 nm and emits at 517 nm and appears green. 
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Legend Figure 2.1 Schematic diagram of a mouse brain demonstrating the 
location of the sections counted for Csp3 immunopositive ceUs in the brain. C 
cerebral cortex, Lv lateral ventricle, 3v third ventricle, T thalamus, Hi hippocampus, 
Hy hypothalamus, mpan medial posterior arcuate nucleus, an arcuate nucleus. 
(Adapted from Paxinos and Franklin 2001). 
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2.4 Results 
2.4.1 Establishment of Homozygous Lines of Mice of genotypes PrpOlO, PrP+/+, and 
PrpOexp 
In order to test our hypothesis that Prpc protects against Bax-mediated cell death, we 
initially decided to use homozygous mice of each genetic background to maximize 
the difference in Prpc expression among groups. The generation of mice with these 
genotypes is described below. 
2.4.1.1 Genetic screens 
2.4.1.1.1 PrP'/o Homozygous PrP knockout mice 
Heterozygous mice carrying one Prnp wild-type allele and one neomycin 
phosphotransferase "neo" gene (Le. one Prnp allele knocked out) were obtained from 
Dr. David Westaway as described. Heterozygous males were crossed to 
heterozygous females to produce an expected FI generation containing 1 homozygous 
knockout, 2 heterozygous knockout and 1 wild-type mouse. The genotype of the FI 
generation was determined by PCR (see section 2.3.4 Genotyping above). Using the 
PCR protocol from Dr. Westaway, homozygous knockout animais produce a single 
PCR product at 730 bp visualized on an agarose gel. Heterozygous animais yield a 
product at 730 bp corresponding to the aminoglycoside phosphotransferase gene and 
a second product at 880 bp corresponding to the wild-type allele. Homozygous wild-
type animais produce a single product at 880 bp. The results for sorne of these 
animais are shown in Figure 2.2 below. In panel A, PrP+/+ male 4804 and PrP+/+ 
female 4837 were crossed and their first litter produced 5 pups, Al to A5. Similarly, 
PrP+/+ male 4904 and PrP+/+ 4939 female were crossed and their first litter produced 5 
pups, Al to A5. PCR amplification of their genomic DNA yields only a single 
product on an agarose gel at 880 bp, corresponding to the PrP+/+ allele, indicating that 
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these pups are PrP+1+. The positive control genomic DNA yields a product at 880 bp 
corresponding to the wild-type allele and another product at 730 bp that corresponds 
to the knockout allele, indicating that this mouse is Prp+lO. The water control lane 
does not contain a PCR product and suggests that the PCR reagents were not 
contaminated with genomic DNA. In panel B, PrpOlO male 4103 and PrpOlO female 
4101 were crossed and their first litter produced 9 pups, Al to A9. PCR 
amplification of their genomic DNA yields only a single product on an agarose gel at 
730 bp, corresponding to the knockout allele, indicating that these pups are PrpO/O. 
The positive control genomic DNA yields a product at 880 bp and a product at 730 bp 
indicating that this mouse is Prp+lO. The water control lane does not contain a PCR 
product and suggests that the PCR reagents were not contaminated with genomic 
DNA. The results were similar for aIl of the tested suspected Prp+/+ and PrpO/O mice 
and confirmed the genotype of these mice used in the experiment. 
2.4.1.1.2 PrpOexp (Syrian Hamster PrP expressing mice) 
Heterozygous mice carrying one Syrian Hamster PrP cDNA transgene were obtained 
from Dr. David Westaway as described. Heterozygous males were crossed to wild-
type females, and wild-type males crossed to heterozygous females to produce an 
expected FI generation containing 1 heterozygous SHaPrP expressor, and 1 animal 
not expressing the transgene i.e.wild-type. Using the PCR protocol from Dr. 
Westaway (see section 2.3.4 Genotyping above), heterozygous transgene expressors 
produce a single PCR product on an agarose gel at 530 bp, whereas, those FI 
generation animaIs lacking the SHaPrP transgene do not produce a product of this 
size. The results for sorne for these animaIs are shown in Figures 2.2 C above. 
Offspring that contain the transgene (SHaPrnp cDNA) produce a 530 bp product with 
PCR amplification of genomic DNA and PrP+/+ mice do not produce a PCR product. 
In panel C, Prpüexp male 30082 was crossed to Prp+/+ female 5133 and their second 
litter produced Il pups, BI to B Il. PCR amplification of their genomic DNA yields 
a product at 530 bp, corresponding to the ShaPrnp cDNA, for offspring BI, B3, B4, 
B6, B8, and BlO, indicating that these mice are PrpOexp whereas, B2, B5, B7, B9 and 
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B Il do not produce this product and they therefore do not contain this cDNA and are 
Prp+/+. The results were similar for other mice tested and confirmed the genotype of 
all of the PrpOexp mice used in the experiment. 
2.4.1.1.2.1 Backcrosses to generate homozygous SHaPrP overexpressing 
mice 
Heterozygous SHaPrP transgenic male mice were crossed with heterozygous SHaPrP 
female mice to produce an expected FI generation of; 1 homozygous ShaPrnp : 2 
heterozygous ShaPrnp and: 1 wild-type mouse. Mice were confirmed as containing 
the ShaPrnp transgene by PCR. Male mice expressing the SHaPrP transgene were 
backcrossed to wild-type female mice and the genotype of this F2 generation 
determined by PCR (see above). If the male FI generation mou se was heterozygous 
for the transgene, then 50% of the F2 generation would be expected to not contain the 
transgene and so be wild-type. If the male FI generation mou se was homozygous for 
the transgene, then aIl of the F2 generation would be expected to contain the 
transgene. The genotype of the F2 generation would therefore indicate the genotype 
of the FI generation male. Similarly, female mice expressing the SHaPrP transgene 
were backcrossed to wild-type male mice and the genotype of the F2 generation 
determined using the same PCR protocol to confirm the genotype of the FI generation 
female mouse. A homozygous SHaPrP transgene-expressing male (3156) and a 
homozygous SHaPrP transgene expressing female mouse (3159) were then used as 
founders of a line of homozygous SHaPrP transgene expressing mice. 
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Legend Figure 2.2; PCR amplification from genomic DNA to confirm mouse 
genotypes. The peR products were stained with ethidium bromide and ron on 
agarose gels. The peR product from the morine Prnp allele is 880 bp. The peR 
product for the Prnp knockout allele is 730 bp. The peR product for the ShaPrnp 
allele is 530 bp. A; 4804/4847 and 4904/4939 PrP+1+ mice crossed to produce two 
litters Al to A5 and Al to A5 respectively. All test offspring contain a single peR 
product at 880 bp. The +ve control contains a product at 880 bp and a product at 730 
bp. The water lane has no peR product. B; 4103/4101 PrpOlO mice crossed to 
produce a litter Al to A9. All test offspring contain a single peR product at 730 bp. 
The +ve control contains a product at 880 bp and a product at 730 bp. The water lane 
has no peR product. C; 30082/5133 a PrpOexp male crossed to a Prp+/+ female. Test 
offspring BI, B3, B4, B6, B8 and BlO contain a single product at 530 bp. Test 
offspring B2, B5, B7, B9 and B Il do not contain a peR product. The +ve control 
contains a single peR product at 530 bp. The water controllane has no peR product. 
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The pair of homozygous founder mice 3156 (male) and 3159 (female) were crossed 
and produced a litter of seemingly healthy pups. However, this pair did not produce a 
second litter and in fact, the male was soon observed to have a hunched posture and 
exhibited less and slower spontaneous movement than control mice. The female also 
began to show similar clinical signs. The clinical signs worsened and it was evident 
that this pair would not breed successfully again. The Tg(SHaPrP)7 mice, from 
which these mice were derived are reported to demonstrate postural changes (i.e. 
hunched posture) and motility deficits (paraparesis) with histological changes 
including a necrotizing myopathy, demyelinating neuropathy and focal spongiform 
degeneration in the CNS (Westaway et al. 1994). The lumbar musculature is 
reportedly severely affected in these mice (Westaway et al. 1994). These muscles are 
particularly important in the male to successfully mount and breed the female mouse. 
Therefore, these mice have very poor breeding success. In fact, the pups produced 
from the litter of this pairing did not successfully breed. As a result, we elected to 
continue the experiment with heterozygous PrpOexp mice, as described in section 2.3.1. 
2.4.1.2 Protein expression 
As described in the Methods section 2.3.5 above, protein was extracted from the brain 
of representative mice from each genotype and aliquots run on a 15% SDS-PAGE 
gel, blotted onto a PVDF membrane, and probed with 3F4 antibody (to detect 
SHaPrP) and R155 antisera (to detect SHaPrP and mouse PrP) to confirm the 
appropriate protein expression in the mice. The results of sorne of the protein 
expression experiments are shown in Figure 2.3 below. In panel A, the presence of 3 
protein signaIs of variable intensity below the 36 kDa marker correspond to Syrian 
Hamster PrP. These protein signaIs are present in the Prpüexp mouse brain extract but 
not in either the PrpO/O or PrP+1+ brain extract, indicating that the PrpOexp mice are 
expressing the Syrian Hamster prion protein and the PrpO/O and PrP+1+ mice are not. In 
panel C, the signaIs correspond to mouse prion protein. This protein band is present 
in the Prp+/+ and PrpOexp mouse brain extracts, but not in the PrpOlO brain extract, 
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indicating that the PrpO/o mice do not express mouse prion protein and both the PrP+/+ 
and Prpüexp mice express the protein. Panels Band D correspond to mou se beta-actin, 
which is present in all of the mou se brain protein extracts and demonstrates that 
protein loading was equal. These results confirm that the mice in each group 
expressed or did not express the appropriate prion proteins. 
2.4.2 Treatment of animaIs and confirmation of ethanol-induced Bax-mediated 
neuronal death 
2.4.2.1 Mice treated and brains collected 
The total number of mice treated with either ethanol or saline was 360. Initially, one 
group of mice was harvested at 24 hours after the first treatment and another at 8 
hours post first treatment. However, due to the poor results with the TUNEL 
staining, which reaches its maximum at 24 hours post-treatment (Olney et al. 2002a) 
and the better success with anti-active caspase 3 staining, which reaches its maximum 
at 8 hours post-treatment, we decided to discontinue using animaIs at 24 hours and 
only use a group at 8 hours post-treatment. Due to the possible variation in time of 
birth during the 12 hour dark period, paired ethanol and saline treated animaIs were 
taken from litters used in the experiment. 
2.4.2.2 Evidence for Apoptosis 
2.4.2.2.1 TUNEL 
Large numbers of slides and a great deal of time were used in attempts to optimize the 
TUNEL staining technique, particularly three different well established antigen 
retrieval techniques i.e. triton-X, proteinase K and microwaves. Unfortunately, none 
of these techniques were successful in labeling cells with DNA strand breaks in 
ethanol or saline treated animaIs. As a result, several unstained slides were sent to 
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Dr. Kevin Roth (Department of Pathology, University of Alabama), who was part of 
the original group that developed the ethanol-induced Bax-mediated apoptosis model, 
for his analysis. Dr. Roth was also unable to obtain positive staining. We agreed that 
the most likely cause was the fixation protocol. Dr. Roth felt that tissues collected 
using this protocol, although producing excellent histology, and reasonable for 
immunohistochemistry, would not be suitable for TUNEL staining. Dr. Roth was 
able to obtain positive staining using an antibody against the active form of caspase 3, 
an effector caspase and therefore downstream marker of Bax activation. Therefore, 
TUNEL staining was abandoned in favor of anti-activated caspase 3 staining, 
discussed below. 
2.4.2.2 Anti-active caspase 3 staining 
The anti-active Caspase 3 staining protocol in this model was developed by Olney et 
al. (2002a), and confirmed in our laboratory. A photomicrograph of brain sections 
from saline or ethanol-treated mice stained with anti-active caspase 3 antibody is 
shown in Figure 2.4. During the examination of the anti-active Csp3 stained sections, 
it became apparent that there was a spectrum of anti-active Csp3 staining, which was 
directly related to the histological appearance of the cell (see Figure 2.5 below). In 
the earliest stage of apoptosis (panel 1) the earliest morphological feature of 
apoptosis at the light microscopic level is a slight shrinkage of the cell with slight 
condensation of the cytoplasm, indicated by subtle darker staining cytoplasm. At this 
stage, there may also be early condensation of the chromatin. There is however, no 
active-Csp3 staining and so these cells are not counted. As apoptosis proceeds, 
active-Csp3 becomes apparent in the cytoplasm, where it is initially confined, but 
progressively occupies the entire shrunken cell (panels 2 to 5). Cells in these stages 
are therefore counted. In the terminal stages of apoptosis (panel 6) the cell remains 
as a shrunken cell outline with markedly condensed cytoplasm and a single course 
clump of condensed chromatin that no longer contains positive active Csp3 staining, 
and is therefore not counted. 
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Legend Figure 2.3; Western blot of brain protein extracts from PrPO/O, Prp+l+ and 
PrPOexp mice to demonstrate prion protein expression. The extracts were run on 
polyacrylamide gels, with 50 ~g of protein loaded per lane. A; Brain protein extracts 
probed with anti-Syrian Hamster PrP 3F4 antibody. Positive protein signaIs are 
present only in the extract from the PrpOexp mouse. B; Brain protein extracts probed 
with anti-mouse beta-actin antibody. A signal corresponding to mou se beta-actin is 
present in brain extracts of mice from aIl 3 genetic backgrounds PrpO/O, Prp+/+ and 
PrpOexp in equal amounts. C; Brain protein extracts probed with RISS anti-mouse PrP 
antiserum. The signal present in the Prp+/+ lanes corresponds to mouse prion protein. 
This protein signal is not present in the PrpOlO mouse brain extract. D; Brain protein 
extracts probed with anti-mouse beta-actin antibody. A signal corresponding to 
mouse beta-actin is present in brain extracts of mice from aIl 3 genetic backgrounds 
PrpOlO, Prp+/+ and PrP°exp in equal amounts. 
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Anti-active caspase 3 immunopositive cells in the required are a were counted and the 
results for the PrpO/O mice shown in Table 2.1; for the Prp+/+ mice in Table 2.2; and for 
the Prpüexp mice shown in Table 2.3. In each of these Tables, the individual animal 
total active caspase 3 positive cell counts for the ethanol-treated group is on the left 
and the saline-treated group on the right. In aIl cases, the total individual counts for 
the ethanol-treated mice are markedly greater than the paired saline-treated mice. 
These data also illustrate tremendous variability from the highest to the lowest counts 
for aIl of the groups and the lack of a normal distribution. Using. the Kruskal-Wallis 
test at p < 0.05, the differences between the ethanol and saline-treated groups was 
statistically significant on aU 3 genetic backgrounds of mice (i.e. PrpO/O, Prp+/+ and 
PrpüexP). However, due to the variability, the differences among genetic backgrounds 
were not statistically significant. These data, although not statistically significant, 
show that the ethanol-treated PrpOlO mice had greater numbers of anti-active caspase 3 
immunopositive cells than did the ethanol-treated Prp+/+ mice (742.2 vs. 577.9). 
Similarly, the ethanol-treated PrpOexp mice had greater numbers of anti-active caspase 
3 immunopositive cells than did the ethanol-treated Prp+/+ mice (673.8 vs. 577.9). 
The ethanol-treated PrpO/O mice also had greater numbers of anti-active caspase 3 
immunopositive cells than did the Prpüexp mice. The differences among saline-treated 
mice were doser together and were also not statistically significantly different. The 
same data is shown in chart form, see Figure 2.6, with the standard error of the mean 
(SEM). The statistically significantly higher ethanol vs. saline counts are evident, as 
is the trend in the ethanol-treated mice for the highest counts in the PrpO/O mice and 
the lowest counts in the Prp+/+ mice. 
Additional counting of apoptotic cells lacking active Csp 3 staining (see Figure 2.5 
panel 6) or regional counting of 3 mice per group showed the same trend, however 
these differences were also not statistically different (data not shown). The raw 
individual mou se active Csp 3 immunopositive cell counting data is shown in 
Appendix 2. 
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2.4.2.2.3 Confirmation that anti-active caspase 3 cells are neurons 
Olney et al. (2000, 2002a, 2002b) and Ikonomidou et al. (2000) developed the ethanol 
injection model and have demonstrated that the apoptosis is Bax-mediated (Young et 
al. 2003). They have also shown in their work that their model induces apoptosis 
only in neurons in PrP+1+ rodents. Ethanol is known to inhibit astrocyte proliferation 
but does not induce apoptosis (Guizzetti et al. 1997). However, in order to be 
absolutely certain that the anti-active Csp3 positive cells counted are in fact neurons, 
we decided to use immunofluorescent multi-Iabeling (see Section 2.3.8) to label 
active-Csp3 positive cells with cyanine 3 and GFAP positive cells (astrocytes) or 
NeuN positive cells (neurons) with fluorescein. The results are shown in Figure 2.8 
below. These results confirmed that the overwhelming majority of active-Csp3 
positive cells were also anti-NeuN positive and anti-GFAP negative and are therefore, 
neurons. 
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Legend Figure 2.4; Mouse brain sections from saline or ethanol treated mice 
stained with anti-active caspase 3 antibody. Ami-active caspase 3 immunopositive 
cells (arrows) that were counted (hematoxylin counterstain) (lOOX magnification). 
The section shown in the left panel was from a mou se treated with saline and the 
section shown in the right panel was from a mouse treated with ethanol. 
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Legend Figure 2.5; Spectrum of anti-active caspase 3 staining visible 8 hours 
after ethanol treatment. Anti-active Csp3 immunostaining is absent at the earliest 
stage of apoptosis, depicted by a slight shrinkage of the neuron and early 
condensation of the cytoplasm and sometimes chromatin (panel 1). Active Csp3 is 
initially confined to the cytoplasm, but progressively occupies the entire shrunken cell 
(panels 2 to 5). EventuaIly, the neuron remains as a shrunken cell outline with a 
single coarse clump of condensed chromatin that no longer contains positive active 
Csp3 staining (panel 6). Cells in stages depicted in panels 2 to 5 are counted. 
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Table 2.1: Total anti-active caspase 3 immunopositive cens counted in an brain 
sections for individual PrpO'o mice treated with ethanol (left) or saline (right). 
Individual mice in each treatment group are paired with a mouse from the same litter. 
The number in brackets is the standard error of the mean (SEM). The differences 
between the ethanol and saline treated mice were significantly different p < 0.05. 
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Prpll/O Ethanol PrplllO Saline 
3197/3196B6 1794.3 3197/3196/B5 478.6 
3197/3196B1 1283.9 3197/3196B4 356.6 
3197/3196B2 950.9 3197/3196B3 444.3 
3175/3168B4 681.6 3175/3168B2 302.6 
3175/3168A1 675.3 3175/3168A2 177.6 
3197/3196B9 586.3 3197/3196B8 118.3 
4103/4101A4 401.9 4103/4101A3 105.9 
4104/4102A5 357.9 4104/4102A1 132.6 
4103/4101A2 338.6 4103/4101A8 165.9 
41 04/41 02A2 350.6 4104/4102A4 138.3 
Mean (SEM) 742.2 (151) Mean (SEM) 242.1(45) 
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Table 2.2: Total anti-active caspase 3 immunopositive cells counted in aIl brain 
sections for individual PrP+/+ mice treated with ethanol (Ieft) or saline (right). 
Individual mice in each treatment group are paired with a mou se from the same litter. 
The number in brackets is the standard error of the me an (SEM). The differences 
between the ethanol and saline treated mice were significantly different p < 0.05. 
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PrP+1+ Ethanol Prp+/+ Saline 
3220/3187B2 1238.9 3 220/3187B 1 284.6 
3186/3180B4 947.6 3186/3180B3 281.9 
3220/3187B6 710.9 3220/3187B5 92.6 
3186/3180Bl 639.6 3186/3180B2 302 
3220/3187C2 527.6 3220/3187C5 212.9 
3145/3135Al 478.6 3145/3135A3 198.3 
3208/3199A5 369.6 3208/3199A4 159.3 
5134/5130Al 300.6 5134/5130A4 96.6 
3208/3199Al 285.6 3208/3199A3 150.6 
5134/5130A2 279.3 5134/5130A6 130.3 
Mean (SEM) 577.9(100) Mean (SEM) 190.9(25) 
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Table 2.3: Total anti-active caspase 3 immunopositive cells counted in all brain 
sections for individual PrPOexp mice treated with ethanol (left) or saline (right). 
lndividual mice in each treatment group are paired with a mou se from the same litter. 
The number in brackets is the standard error of the me an (SEM). The differences 
between the ethanol and saline treated mice were significantly different p < 0.05. 
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PrpOexp Ethanol PrpOexp Saline 
3149/3157A1 1030.9 3149/3157A4 356.6 
3149/3157 A8 831.6 3149/3157A5 264.3 
3156/3102A8 557.6 3156/3102A5 154.9 
3155/3104A7 794.3 3155/3104AlO 151.6 
3156/3102A3 754.3 3156/3102A6 144.3 
3128/3104A9 681.3 3128/3104A3 481.3 
30083/4830A 12 527.4 30083/4830A9 213.2 
30082/5133A3 487.9 30082/5133A1 295.4 
30082/5133A8 723.2 30082/5133A4 383.3 
4832/4186A5 349.7 4832/4186 158.7 
Mean (SEM) 673.8(62) Mean (SEM) 260.4(37) 
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Legend Figure 2.6; Quantitative measures of active caspase 3 in the brain of 
saline and ethanol injected PrPOIO, Prp+I+ and PrPOexp mice. Data represent the 
mean and standard error of the mean (SEM) of 10 mice per group. 10 sections were 
counted per mouse and each section was counted blindly 3 times. *p < 0.05 ethanol 
versus saline groups. 
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Legend Figure 2.7; Coimmunofluorescence with anti-active caspase 3 and anti-
GFAP or anti-NeuN antibodies. Left panels; anti-active Csp3 positive cells are 
red. Top middle panel; GFAP positive cells are green. Other middle panels; 
increasing magnification as the panels descend to the bottom panel, NeuN positive 
cells are green. Top right panel; merge of positive anti-active Csp 3 positive cells 
are still red and positive GFAP positive cells are still green i.e. no colocalization. 
Other right panels; increasing magnification as the panels descend to the bottom 
panel, anti-active Csp 3 positive and anti-NeuN positive cells are yellow l.e. 
colocalize. The magnification of the images are shown to the left of the figure. 
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2.5 Discussion 
Our results show a trend that PrP may protect sorne neurons against ethanol-induced 
Bax activation in post-natal mice, although the differences were not statistically 
significant. Bax conformational change is thought to be the first step in the 
transformation of a cytosolic Bax protein that is inoffensive to one that becomes pro-
apoptotic. After the conformational change, Bax translocates to the mitochondria, 
forms oligomers and integrates into the mitochondria resulting in the release of 
cytochrome c from the mitochondria to the cytosol and subsequently, caspase-3-
dependent cell death. We suggest here that ethanol-induced Csp3 activation resulting 
from Bax activation in mice brains may be more prominent in the absence of PrP than 
in the PrP expressing tissues. While the null mice brains had more Csp3 positive cell 
death th an the wild type and over-expressing mice brain after the ethanol injection, 
the results did not reach statistical significance. A number of features of this model 
lead us to believe that the effect is however biologically significant. First, in the 
presence of a strong insult like ethanol, there cannot be complete protection unless the 
protective protein, in this case, PrP, is up regulated. Therefore, the presence of PrP is 
enough to suppress but not completely prevent ethanol-induced neuronal cell death. 
With a less acute insult, it is possible that endogenous PrP would protect against Bax-
mediated cell death. In fact, we have observed that PrP can prevent serum deprivation 
or Bax overexpression induced apoptosis but not staurosporin or tunicamycin-induced 
cell death despite Bax activation being inhibited (Roucou et al. 2005). This appeared 
to be due to the fact that PrP could not prevent cell death in the presence of other 
proapoptotic Bcl-2 family members Bak and tBid-mediated activation, which are 
activated by staurosporin or tunicamycin (Roucou et al. 2005). These results indicate 
that the anti-apoptotic effect of PrP is specific against Bax. 
The trend that our results demonstrate supports numerous in vitro studies showing 
that PrP protects against Bax-mediated cell death (Bounhar et al. 2001, Diarra-
Mehrpour et al. 2004, Roucou et al. 2003, Roucou et al. 2005), however, our in vivo 
experimental model uses ethanol to induce Bax-activation. In retrospect, we suspect 
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that our model may not be ideal to test our hypothesis. Ethanol, although selected on 
the basis of it being a robust activator of apoptosis, may in fact be too robust an 
insult. Perhaps future experiments using the ethanol model would benefit from a pilot 
study with small numbers of mice in which 2 or more dose levels of ethanol could be 
used. Perhaps there is a dose of ethanol that will successfully induce Bax-mediated 
apoptosis in PrpD/o mice but will leave PrP+/+ mice unaffected. In addition, although 
we now know that PrP protects against only Bax and not Bak or tBid (Roucou et al. 
2005), we do not know if the ethanol injection model also induces Bak or tBid-
mediated cell death. The Bax-mediated apoptosis in our experimental model was 
verified using Bax knockout mice (Young et al. 2003). However, the cell death 
induced in the ethanol treated wild-type mice was not compared to ethanol treated 
Bax knockout mice, nor were the ethanol treated Bax knockout mice compared to the 
saline treated knockouts or the saline treated wild-type mice, which have the true 
physiological background level of cell death. Therefore, we do not know if the 
ethanol injection model is also inducing sorne cell death via another pathway as weIl 
as Bax. 
Secondly, the steady state level and the localization of PrP are different in neuronal 
subtypes. For example, cytosolic PrP is present in specific neuronal subpopulations in 
the hippocampus, neocortex, and thalamus but not in the cerebellum (Mironov et al. 
2003). We have shown that cytosolic PrP protects human neurons against Bax-
mediated cell death when Bax is activated via over-expression (Roucou et al. 2003). 
Possibly, only neurons that can accumulate enough PrP may be protected and if this 
number is small, it may not be possible to detect a significant difference when 
counting total neurons. Therefore, sorne neurons that undergo ethanol-induced Bax-
mediated cell death may not contain enough PrP in a specific sub-cellular localization 
to prevent Bax activation. CyPrP protects neurons against Bax-mediated cell death 
(Roucou et al. 2003) and we now know that at least in adult mice, the number of 
neurons with significant CyPrP accumulation is very smaIl, perhaps only 1 to 2% of 
neurons in certain areas of the brain (Mironov et al. 2003). It may be useful to 
examine 7 day old mice using similar immunoelectronmicroscopic methods to see if a 
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particular area of the developing brain contains large numbers of CyPrP expressing 
neurons and may therefore be better to examine for its protection against Bax. 
Third, at this time, we believe that PrP does not protect neurons through a direct 
interaction with Bax (unpublished observations) and that PrP likely protects through a 
signal transduction pathway. The signal transduction pathway has not yet been 
identified. It is thus also possible that signal transduction pathways are not yet 
present at 7 days of development to allow PrP's anti-Bax function. When this 
pathway has been identified, it may be useful to examine specific neuronal 
populations that have more activity in this pathway and concentrate on examining 
them in an effort to obtain more definitive results. 
Our results are consistent with other in vivo studies that indicate that PrP has a 
neuroprotective role. The reintroduction of a single copy of PrP cDNA protects 
neurons in vivo from cell death resulting from the transgenic overexpression of an N-
terminally truncated form of PrP (Schmerling et al. 1998) and the transgenic 
overexpression of PrP cDNA protects neurons in vivo from Doppel associated cell 
death (Moore et al. 2001; Nishida et al. 1999). In these studies, the mechanism of 
induction of cell death is currently unknown. Speculatively, our results may also 
suggest a possible mechanism whereby PrP may provide in vivo protection against 
Bax in the N-truncated PrP- or Doppel-induced cell death in mice. Recent evidence 
suggests that PrP may protect hematopoietic stem cells from apoptosis or sustain their 
long-term self-renewal, which supports a potential anti-apoptotic role for PrP (Zhang 
et al. 2006). 
We have also shown a trend that the overexpression of PrP does not provide increased 
protection against Bax-mediated cell death, but rather, that the overexpression of PrP 
may sensitize neurons to Bax-mediated cell death. Our results are consistent with 
numerous in vivo studies. The overexpression of both wild-type Syrian hamster and 
Sheep PrP cDNA (Westaway et al. 1994) and numerous mutated forms of PrP in mice 
(Chiesa et al. 1998; Hegde et al. 1998; Hsiao et al. 1991; Schmerling et al. 1998: Ma 
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et al. 2002; Telling et al. 1996) result in neurodegeneration culminating in ceIl death. 
The toxicity of PrP in these overexpression models is also seen in stably transfected 
HEK293 cells and in murine TSM1 cells (Paitel et al. 2002; Paitel et al. 2003). Bax 
deletion provides neuroprotection against the neuronal ceIl death resulting from at 
least one transgenic model of overexpression of a mutant prion protein (Chiesa et al. 
2005) suggesting that cell death resulting from the overexpression of sorne forms of 
PrP may involve Bax. However, the neurological signs were unchanged indicating 
that the neurons were alive but dysfunctional. Numerous other proteins, if 
overexpressed in neurons, lead to neurodegeneration and death, for example; u lB-
adrenergic receptor (Zuscik et al. 2000), neurofilament proteins (NF-L, peripherin) 
(Robertson et al. 2002), G-protein-coupled, protease-activated receptor for thrombin 
(Festoff et al. 2000). The apparent neuroprotective versus neurodegenerative 
properties of PrP are also not unprecedented as, for example, amyloid ~ protein may 
be toxic in vitro, at high concentrations but neurotrophic at low concentrations 
(Yankner et al. 1990). Therefore, we should not be surprised that the expression of a 
protein above physiological levels may disrupt metabolic pathways and have 
deleterious results. 
There are also various technical reasons why our model may not be ideal. For 
example, we were concerned that there may be considerable variation in IHC staining 
for active Csp3 positive ceIls in less experienced hands and as a result, sent the slides 
actually counted in this study, to the laboratory of our collaborator Dr. Kevin Roth at 
the University of Alabama for staining. Dr. Roth's technician, Ms. Cecelia Latham, 
who was involved in the initial development of the model, has many years of 
experience with anti-active Csp3 staining. The tissue sections were sent to Ms. 
Latham in batches. There is variation in the staining even with experienced hands, 
and so in an effort to minimize this, Ms. Latham selects small numbers of slides from 
each animal in each batch rather than doing aIl of one animal at one time. There was 
still however, considerable variation in the staining. The model was developed as a 
model of fetal alcohol syndrome and the goal of the anti-active Csp3 staining was 
simply to see a difference between ethanol injected mice and controls and these 
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differences were significant ln their laboratory and indeed in our experiment. 
However, we are trying to see differences between mi ce on different genetic 
backgrounds treated with ethanol and so the methods need to be more sensitive than 
those trying to see a difference between ethanol and saline treated mice. In my 
opinion, the degree of variation in the staining between batches contributed to the 
variability in our cell counting data. Perhaps the best way of reducing this variability 
in staining between batches would be to do aIl of the si ides at the same time via an 
automatic stainer. This is obviously not necessary to see the difference between 
ethanol and saline treated, which was what the model was intended for, but may be 
necessary to see the more subtle difference among mice treated with ethanol on 
different genetic backgrounds. 
Recently, it has been shown that the effect of ethanol on the developing rodent brain 
is not quite as uniform and as simple as had originally been described by Olney et al. 
(2000). For example, the developing cerebellum is exquisitely sensitive to ethanol on 
post-natal days 4 to 6 but the effects are minimal on post-natal day 7 or later (Siler-
Marsiglio et al. 2005). This group used an inhalation model and did not examine the 
cerebral cortex, hippocampus or thalamus, as we, and the group of Olney et al. have 
examined. However, these results do illustrate the complex nature of the developing 
brains' temporal and spacial response to an ethanol insult. A brief examination of the 
cerebellae of sorne of our mice stained with hematoxylin and eosin did not reveal 
significant neuronal cell death (data not shown). Although the peak for apoptosis in 
the Olney model in the cerebral cortex, hippocampus, thalamus and hypothalamus is 
8 ho urs following the first treatment on the 7th day, it is possible that the peak may be 
at a slightly different time in mice derived from C57Bl6 mice from Charles River 
Canada than mice derived from C57Bl6 mice from Washington University, St. Louis 
or the University of Alabama. Furthermore, at 7 days there is variation in the 
development of the mice arising from differences in the time of birth (+/- 12 hours) 
and the differences in milk production in each mammary gland. Therefore, sorne of 
our mice may have been functionally less or more mature than others at 7 days and 
therefore be more or less sensitive to an ethanol insult. If this is indeed the case, it 
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would also contribute to the variability that we observed. We inadvertedly attempted 
to correct for this when trying to select 20 sections per mou se in the correct area for 
staining and 10 sections per mouse for counting, as very small brains i.e. less mature 
mice, did not produce enough good sections. However, this remains a possible source 
of variability. 
Another possible source of variability may be the sacrifice of the mice. The time of 
day was constant for the initiation of the necropsies (i.e. 2:30 PM), however, there 
could be variation among mice with regard to time of feeding, and during the time 
required to sacrifice and remove the brain from the mice in a given litter. It is also 
possible that the stress of removing littermates could have a direct effect on the pups, 
or an indirect effect due to the stress on the dam, as the litter is gradually diminished 
in size. 
1 believe that aIl of these factors could weIl have contributed to the wide variation in 
the results that we observed. The variability did not effect the trend that we saw, 
which supports the now extensive in vitro data demonstrating that Prpc protects 
against Bax-mediated cell death, however, it was responsible for removing the 
opportunity for statistical significance among groups. 
2.5.1 Variability of in vivo experiments 
The tremendous variability that we observed in our in vivo experiment using 
transgenic mice is far from unique. In a neurobehavioral study, Crabbe et al. (1999) 
went to extraordinary lengths to standardize the environment, the mice and the tests 
evaluated at 3 different centres and still reported radically different results depending 
on the test centre location. They suggested that interactions with the laboratory 
environment to explain these differences. In another study examining the variability 
in mou se gene expression via microarrays, Pritchard et al. (2001) found significant 
variation in gene expression in mice that were genetically identical, the same age and 
housed under the same conditions. They hypothesized that many genes may be 
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regulated by cytokines or hormones, which may vary depending on stress levels, 
inflammatory processes, injury or infection. They also suggested that variability in 
the process of killing the mice may be another factor, differences in circadian rhythm 
and the effect of removing liUermates. Similar interanimal variation is weIl 
recognized in the metabolism of various toxins. There is marked variation in the peak 
of plasma acetaminophen-induced glutamic-pyruvic transaminase (GPT) activity in 
mice of the same strain and environmental conditions, such that single blood samples, 
regardless of time of sampling, are considered unreliable (Wells and To 1986). 
2.6 Conclusions 
Taken together, many in vivo and in vitro results suggest that PrP plays an important 
neuroprotective role against Bax activation and cell death. This aspect of PrP 
function merits further study. Therefore, caution should be exercised in advocating 
the ablation of or inhibition of PrP as possible preventative therapies in domestic 
animaIs or in human patients with transmissible spongiform encephalopathies. 
Chapter 3 Demonstration of Bax activation in ex-vivo mouse brains 
3.1 Introduction 
The previous section discussed the Olney model of ethanol-injection of neonatal 
rodents to stimulate Bax-activation and neuronal apoptosis (Young et al. 2003). With 
this model, the Olney group uses active Csp3 immunostaining with cell counting as a 
downstream marker of Bax-activation. Using this paradigm, we found that although 
we induced neuronal apoptosis, and the PrpO/O mice had more neuronal apoptosis than 
the PrP+1+ mice, we were unable to demonstrate a statistically significant difference 
among mice on different genetic backgrounds i.e. PrpOexp, Prp+/+, PrpO/O. Therefore, 
we sought another method, which may provide a more sensitive measure of Bax-
mediated cell death. Activation of Bax proceeds in a series of steps. In non-apoptotic 
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conditions, Bax is present in the cytosol and is tightly associated with the DNA repair 
factor Ku70 (Cohen et al. 2004), but has also been reported to have weak affiliation 
with the mitochondrial outer membrane (Jemmerson et al. 2005). Following an 
apoptotic stimulus, Ku70 becomes acetylated resulting in the dissociation of Ku70 
and Bax (Cohen et al. 2004). Cytosolic monomeric Bax then undergoes a 
conformational change (Khaled et al. 1999) and translocates from the cytosol to the 
outer mitochondrial membrane (Eskes et al. 2000), where it oligomerizes (Antonsson 
et al. 2001) and induces the release of, most significantly, cytochrome c, which 
combined with apoptosis activating factor 1 (Apafl) activates caspase 9 and 
subsequently caspase 3 (Reviewed by Wang 2001). 
In order to further test our hypothesis that Prpc protects against Bax-mediated cell 
death, we decided to examine Bax-activation more directly. The conversion of Bax 
to its active form only requires a conformational change and so its translocation to the 
mitochondria is used in vitro as an indication of Bax activation. The most reliable 
antibody available to detect active Bax (6A 7 BDPharmingen) has been used in vitro 
to demonstrate active Bax, and is recommended for immunoprecipitation, where it 
specifically binds to the active form of Bax, and for western blotting, where it binds 
to aIl Bax, as the active form is denatured under western blotting conditions. 
However, methods have not been described to specifically examine active Bax or Bax 
translocation to the mitochondria in routinely fixed, paraffin embedded tissue 
sections. Therefore, we decided to use an ex vivo model to examine Bax activation 
and compare among PrPOexp, PrP+1+ and PrpO/O mice treated with ethanol to stimulate 
Bax activation. 
It has been reported that PrpO/O mice are more susceptible to oxidative stress (Walz et 
al. 1999, Brown et al. 2002) and so we were interested to see if PrpO/O mice were more 
susceptible to Bax activation with the stress of handling and saline-injection or if 
these mice had a higher background level of Bax present at the mitochondria when 
untreated compared to Prp+/+ mice. We were also considering the possibility that our 
ethanol-injection model may be inducing too much neuronal apoptosis (see discussion 
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Chapter 2) and so we felt that it may be more advantageous to examine untreated 
PrpOlO and PrP+1+ mice for differences. In addition to investigating Bax activation 
using this model, we decided to also look at the next downstream step in Bax 
activation i.e. Bax insertion into the mitochondrial membrane. 
We hoped that by using the most readily available techniques we would determine if 
there is a relationship between prion protein expression and Bax activation following 
ethanol-injection, saline-injection or background levels without an exogenous insult. 
Under normal circumstances, Bax is present in the cytosol, although a small amount 
is also present in the mitochondrial fraction following subcellular fractionation 
(Roucou et al. 2005). We expected that following an apoptotic in suIt, Bax would 
translocate from the cytosol to the mitochondrial fraction. We expected to be able to 
detect this active Bax via immunoprecipitation in the mitochondrial fractions and 
visualize a shi ft of total Bax from the èytosolic fraction to the mitochondrial fraction 
via western blot and expected that PrpO/O mice would have greater amounts of Bax in 
the mitochondrial fractions than Prp+/+ mice. Since PrpO/O mice are known to be more 
susceptible to oxidative stress (Walz et al. 1999, Brown et al. 2002), than Prp+/+ mice, 
we suspected that they would be more susceptible to the stress of handIing and would 
have more Bax inserted into the mitochondria th an PrP+1+ mice. We expected to 
detect this Bax insertion using western blotting of subcellular fractions and that there 
would be more Bax inserted into the mitochondrial membrane in PrpO/O mice. Within 
the central nervous system, Bax is the dominant proapoptotic protein involved in 
cytochrome c release (White et al. 1998) and so we expected that we would be able to 
demonstrate a decrease in mitochondrial cytochrome c following the apoptotic 
stimulus and this would be more marked in the PrpO/O mice, as they have no Prpc to 
protect against Bax. 
We were unable to demonstrate a difference among treatment groups or among 
genetic backgrounds using subcellular fractionation of brain proteins due to the wide 
variability among mice. We conclude that subcellular fractionation of brain proteins 
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from 7 day old mouse pups is not a sensitive enough technique to evaluate Bax 
activation or cytochrome c release using our experimental paradigm. 
3.2 Experimental Design 
Seven day old mice were treated twice with either ethanol or saline via subcutaneous 
injection (as described in section 1.5.1 Mouse Bax-mediated neuronal death model) 
or untreated. Eight hours following the first treatment each mouse was sacrificed and 
immediately, the· brain was removed for subcellular fractionation and the 
immunoprecipitation of active Bax. We also examined the levels of total Bax present 
in the subcellular fractions, as weIl as cytochrome c release from the mitochondria. 
In addition, mitochondrial heat shock protein (mitoHSP70) and cytosolic heat shock 
protein (cytoHSP70) were examined to confirm the purity of the subcellular fractions. 
3.3 Methods and experimental protocol 
3.3.1 Subcellular fractionation and immunoprecipitation of active Bax 
The brains were removed from the skull of the mice and placed in a glass 
homogenizer on ice, that had previously been rinsed in isolation buffer (225 mM 
mannitol, 75 mM sucrose, 1 mM EGTA, 10 mM HEPES in 100 mL water pH 7.4) 
with one Complete Mini-EDTA free protein inhibitor cocktail tablet (Roche 
Diagnostics, Indianapolis, IN) in 10 mL of isolation buffer to make the working 
buffer. The brains were homogenized in 1000 ~L of working isolation buffer on ice. 
The samples were centrifuged at 1000 g for 10 minutes at 4°C to make P1000, which 
contains unbroken cells and nuclei and was discarded and SlOOO, which was then 
centrifuged at 10,000 g for 10 minutes at 4°C, to make PlO,OOO and S 10,000. The 
SlO,OOO is cytoplasm and was then transferred to a polyallomer tube and centrifuged 
at 100,000 g for 30 minutes at 4°C to yield P100,000, which is the microsomal 
fraction and S100,000, which is cytosol in isolation buffer. The PlO,OOO was 
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resuspended in approximately 1000 !-tL of isolation buffer and recentrifuged at 1000 g 
to yield a second P1000, which is more unbroken cells and was discarded and a 
second S 1000, which was then recentrifuged at 10,000 g for 10 minutes at 4° C. The 
second SlO,OOO thus generated was discarded and the second PlO,OOO, which is the 
crude mitochondrial fraction or heavy membrane fraction, was then resuspended in a 
volume of CHAPS buffer (50 mM tris pH 8.0, 150 mM NaCl, 1 % CHAPS, 5 mM 
EDT A pH 8.0) equal to the volume of cytosol obtained for that animal. Aliquots of 
the cytosolic and mitochondrial fractions were then used for a BCA protein assay so 
that an estimate of the volume of the fractions that would be needed to contain 
approximately 30 !-tg of protein for a western blot or an appropriate volume 
(containing 500 !-tg) of protein for immunoprecipitation. 
The immunoprecipitations (lP)s were prepared using the following protocol; an 
appropriate volume of protein was prepared for immunoprecipitation (IP). The early 
IP experiments were prepared using 500 !-tg of protein, but subsequently, an equal 
volume of cytosol and mitochondrial proteins were prepared corresponding to 
approximately 500 !-tg of protein. For each sample 60 !-tL of Prot-A-Sepharose beads 
(Protein-A-Sepharose, P3391-1G Sigma-Aldrich, OakvilIe, Ontario) were prepared as 
follows; the beads were withdrawn from the buffer and centrifuged at 3000 rpm in a 
bench centrifuge for 2 minutes at 4°C, the buffer removed and replaced with CHAPS 
buffer with added anti-protease tablets (as described above). This was repeated three 
times to thoroughly wash the beads. Each protein sample corresponding to 
approximately 500 !-tg of protein was then diluted up to 500 !-tL in CHAPS and 30 !-tL 
of beads added per sample. The tubes were then put on an inverting rack at 4°C and 
incubated for at least 1 hour to remove non-specific binding to the beads. The 
samples are then centrifuged at 3000 rpm for 2 minutes at 4°C and the supernatant 
removed to new labeled tubes. Then 4 !-tL of 6A 7 anti-active Bax antibody (BD 
Pharmingen, BD Biosciences 556467 1: 125 dilution) was added and the tubes 
incubated on an inverting rack at 4°C overnight. Then the tubes were centrifuged at 
3000 rpm for 2 minutes at 4°C and an equal volume of CHAPS buffer with anti-
protease tablets was added. The samples were vortexed and recentrifuged at 3000 
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rpm. This washing procedure was repeated 3 times. The buffer was removed and the 
beads were then suspended in loading dye. The IP protein extracts bound to Prot-A-
sepharose beads or protein extracts were then run on 15% SDS-PAGE gels and 
blotted onto PVDF membranes via the western blotting technique. The membranes 
were then probed with the appropriate antibody and developed on X-ray film. The 
films from the IP experiments were subsequently quantified using densitometry 
(Molecular Dynamics version 3.5.1, VMD-Visual Molecular Dynamics, University of 
Illinois at Urbana-Champaign). 
3.3.2 Subcellular fractionation and Bax insertion into the mitochondria 
The brains were removed and placed in a homogenizer that had been prerinsed with 
isolation buffer containing a protease inhibitor as in section 3.3.1 Subcellular 
fractionation and immunoprecipitation of active Bax above. The brains were 
homogenized and centrifuged as above to yield the crude mitochondrial (heavy 
membrane pellet) and the cytoplasm. As above, the cytoplasm was centrifuged at 
100,000 g in polyallomer tubes to separate the cytosol. The crude mitochondrial 
fraction (heavy membrane pellet) was resuspended in the working isolation buffer to 
an equal volume to the volume of cytosol obtained for that animal. Then an aliquot 
of the crude mitochondrial fraction and the cytosol fraction was diluted 1: 1 in a 
CHAPS buffer (50 mM tris pH 8.0, 150 mM NaCl, 1 % CHAPS, 5 mM EDTA pH 
8.0 in 100 mL of water) and a BCA Protein Assay performed to estimate the protein 
concentration of the samples. The remainder of the crude mitochondrial fraction was 
then centrifuged at 10,000 g for 10 minutes at 4°C to repellet the mitochondria. The 
mitochondria were then resuspended in freshly prepared 0.1 M Na2C03 pH Il.5 and 
incubated on ice for 20 minutes. The sampi es were then transferred to polyallomer 
tubes and centrifuged at 68,000 g for 20 minutes at 4°C. The volume of the 
mitochondrial supernatant (Mito-sup) was noted and was approximately equal to the 
cytosol fraction (Cyto). The mitochondrial pellet (Mito-pellet) was resuspended in an 
equal volume of CHAPS to the volume of the Cyto and Mito-sup fractions. The 
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cytosolic fraction represents the cytosolic proteins, the mitochondrial supernatant 
represents the soluble mitochondrial proteins and the mitochondrial pellet represents 
the membrane bound proteins in the mitochondria and inc1udes the Bax inserted into 
the mitochondrial membrane. 
3.3.3 Sodium Dodecyl Sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
western blotting procedure 
The procedure for the SDS-PAGE and western blots was as previously described in 
section 2.3.5 Protein expression. Briefly, 15% acrylamide gels were prepared, the 
wells rinsed with tap water and the gel apparatus placed in the running apparatus 
containing running buffer. The protein sampi es were prepared for loading by adding 
an equal volume of loading dye to the protein sample and incubating in a heating 
block at 100°C for 5 minutes immediately prior to loading. The samples were loaded 
. in the sample wells and run at 130 volts for approximately 1 hour 20 minutes (until 
the blue dye ran off the end of the gel). The proteins in the gel were transferred onto 
a PVDF membrane (Immobilon P Transfer Membrane, Millipore Corporation, 
Bedford, MA) in the transfer apparatus immersed in working transfer buffer at 230 
mAmp for approximately 2 hours and 30 minutes or at 40 mAmp overnight. 
Following the transfer, the membranes were rinsed in TBS tween for 5 minutes then 
blocked for 1 hour at room temperature in blocking solution. The primary antibody 
was prepared at an appropriate dilution in 1.25 g powdered low fat skim milk in 50 
mL phosphate buffered saline. The primary antibodies and dilutions used were as 
follows; anti-cytosolic HSP70 (Stressgen SPA-81O, 1:5000); anti-mitochondrial 
HSP70 (Affinity BioReagents MA3-028, 1:500); anti-total Bax (N20 Santa-Cruz 
Biotechnology sc-493, 1: 1000); anti-beta-actin (Sigma-Aldrich AC-15, 1:5000); anti-
cytochrome c (BD Pharmingen 556433, 1:500). Approximately 1 mL of the diluted 
antibody was prepared and placed on a glass plate in a humid chamber. The 
membrane was placed protein side down on the diluted antibody and incubated 
overnight at 4°C. Following incubation the membranes were rinsed 3 times in TBS 
tween for 5 minutes each, then the diluted secondary antibody (in 1.25 g milk in PBS 
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solution) incubated in a plastic tray with the membrane for 1 hour at room 
temperature. The secondary antibodies and dilutions used were as follows; Donkey 
anti-mouse (AffiniPure, Jackson Immunoresearch 715-035-151, 1:5000); and Donkey 
anti-rabbit (AffiniPure Jackson Immunoresearch 715-035-152, 1:3000). The 
membranes were then rinsed 3 times in TBS tween and developed with an appropriate 
western developing solution. The developing solutions were either ECL Western 
Blotting Detection Reagents (Amersham Biosciences RPN2106) or Immobilon 
Western Chemiluminescent HRP Substrate (Millipore Corporation WBKLSOlOO). 
The membranes were then exposed to X-ray film in the dark room for an appropriate 
period of time. The bands were also quantified using densitometry (Molecular 
dynamics version 3.51, VMD-Visual Molecular Dynamics, University of Illinois at 
Urbana-Champaign). The data were analyzed using the non-parametric Kruskal-
Wallis test with significance set at < 0.05 using Statview software (Statview, SAS 
Institute, Cary, NC). 
3.4 Results 
3.4.1 Subcellular fractionation of proapoptotic proteins and immunoprecipitation of 
active Bax 
ln order to demonstrate the efficiency of the subcellular fractionation procedure, 
samples of the subcellular fractions were examined via western blotting and probed 
with anti-cytosolic HSP70 and anti-mitochondrial HSP70 antibodies. Sorne of these 
results are shown in Figure 3.1. In panel A; PrpDlO mice 4636/5455Al ethanol-treated, 
A2 saline-treated and A4 untreated and in panel B; PrpDlO mice, 5453/5449Al 
ethanol-treated, A3 saline-treated and A5 untreated, aIl have a protein signal present 
in the cytosolic fraction lane and no signal present in the crude mitochondrial fraction 
lanes. This signal corresponds to cytosolic HSP70. In panel C; PrpDlO mice, 
5453/5449Al ethanol-treated, A3 saline-treated and A5 untreated and in panel D; 
Prp+/+ mice, 7079/7038Bl ethanol-treated, B3 saline-treated, and B5 untreated mice 
aIl have a protein signal present in the crude mitochondrial fraction lanes and no 
signal present in the cytosolic fraction lanes. This signal corresponds to 
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mitochondrial HSP70. These results demonstrate that the fractions are relatively 
pure. 
Western blots of brain subcellular fractions were also probed with an anti-Bax 
antibody, which does not discriminate between active Bax and inactive Bax, and is 
therefore a marker of total Bax in the fraction. Sorne of these results are shown in 
Figure 3.2; corresponding to the same animaIs shown in Figure 3.1. Bax is present in 
aIl of the subcellular fractions. In panel A; PrpO/o ethanol-treated mou se 4636/5455Al 
has more Bax present in the cytosolic fraction than is present in the mitochondrial 
fraction, whereas in panel B; the PrpOlO ethanol-treated mouse 5453/5449Al has more 
Bax in the mitochondrial fraction. In panel A; the saline-treated and untreated mice 
have slightly more Bax in the cytosolic fraction than is present in the mitochondrial 
fraction, whereas in panel B; the saline-treated and untreated mice have slightly more 
Bax in the mitochondrial fraction. In panel C; the Prp+/+ mice, there is more Bax in 
the cytosolic fraction than the mitochondrial fraction, with the smallest quantity of 
mitochondrial Bax being present in the ethanol-treated mouse. As these results show, 
and other blots that are not shown demonstrate, there is no pattern with regard to the 
total Bax present among treatment groups or among genetic background of the mice. 
In Figure 3.3; the western blot of the immunoprecipitation of active Bax is shown in 
the upper panels and the corresponding western blot of samples from the same 
subcellular fractions are shown in the middle panels and beta-actin in the lower 
panels, as a western blot loading control. In the ethanol-treated mice i.e. PrpOexp 
4832/4186B4, PrP+/+ 4832/4186Bl and PrpOlO 4109/4108Bl, aIl of them have large 
amounts of active Bax present in the crude mitochondrial fraction and very little in 
the cytosolic fraction. Small amounts of active Bax are present in the cytosolic and 
crude mitochondrial fractions of the PrpOexp and Prp+/+ saline-treated mice 
4832/4186B8 and B6 respectively. The PrpO/o saline-treated mouse in panel B; upper 
panel, has large amounts active Bax in the crude mitochondrial fraction and very little 
in the cytosolic fraction. Unfortunately, these results were not reproducible. In panel 
A; middle, the total Bax is consistent in the Prpüexp and PrP+/+ mice regardless of 
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ethanol or saline treatment and shows moderate amounts of Bax in aU fractions with 
more being present in the mitochondrial fractions. For the PrpOlO mice in panel B; 
given that there may be slightly less protein loaded in the mitochondrial fraction 
compared to the cytosolic fraction of the ethanol-treated mou se than the saline-treated 
mouse, the same trend seems to be present, i.e. slightly more total Bax present in the 
mitochondrial fractions. However, these results are in contrast to the PrpO/o mice in 
Figure 3.2 panel A and the PrP+/+ mice in panel C; where there is more total Bax in 
the cytosolic fraction. These results were also inconsistent (data not shown) in 
numerous other experiments. 
The results of the immunoprecipitation of active Bax experiments for PrpOexp, PrP+/+ 
and Prp% mice were quantified using densitometry and are shown in Table 3.1. The 
ratio of the active Bax in the crude mitochondrial fraction .over the active Bax in the 
cytosolic fraction, in order to compare among blots, was calculated and is shown in 
the far right column of the table. In each case, the SEM is nearly as large as the mean 
value for the group. Due to the wide variability among mice, the differences among 
treatment groups and among genetic backgrounds were not statisticaUy significant. 
Table 3.2 shows more data from immunoprecipitation of active Bax experiments for 
PrpOlO and PrP+/+ mice, also quantified using densitometry in PrpO/o. The ratio of the 
active Bax in the crude mitochondrial fraction over the active Bax in the cytosolic 
fraction is shown in the right column. There is no trend with respect to the mean 
values among treatment groups or among mice of the same genotype and the SEM is 
very large relative to the mean. Again, due to the wide variability among mice, the 
differences among treatment groups and among genetic backgrounds were not 
statisticaUy significant. 
In Table 3.3; the results of a series of experiments calculating the ratio of active Bax 
(via immunoprecipitation) to total Bax (via western blot) are shown. In order to 
compare among different blots where the amount of protein loaded and exposure time 
may be different, the amount of active Bax in the mitochondrial fraction of the saline-
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treated mou se was assigned an arbitrary value of l and the ethanol and untreated 
values on the same blot related to it. Similarly for total Bax in the western blots, the 
amount of total Bax in the mitochondrial fraction of the saline-treated mouse was 
assigned a value of l and the ethanol and untreated values on the same blot related to 
it. These ratios of active Bax to total Bax in the cytosol and mitochondrial fractions 
are shown in the two columns on the far right respectively, of Table 3.3. Again, there 
is no trend with respect to the treatment groups even among the same genotype and 
the SEM is very large relative to the mean. Due to the wide variability among mice, 
the differences among treatment groups and among genetic backgrounds were not 
statistically significantly different, nor was any trend apparent. 
The release of cytochrome c from the mitochondria was also examined via western 
blots of the subcellular fractions. Sorne of these results are shown in Figure 3.4. In 
panel A; there is a roughly equal amount of cytochrome c in the mitochondrial 
fraction of the ethanol-treated mouse (Al) and the untreated mou se (A5), which is 
more th an is present in the mitochondrial fraction of the saline-treated mouse. In 
panel B; also in PrP+/+ mice, there is approximately equal cytochrome c in the 
mitochondrial fraction ofthe ethanol-treated mouse (BI) and the saline-treated mouse 
(B3) and there is slightly more in the mitochondrial fraction of the untreated mou se 
(B5). In contrast, in panel C and panel D; both in PrpD/o mice, there is approximately 
equal cytochrome c in the mitochondrial fractions of the ethanol and saline-treated 
mice (B2, Al and B4, A3 respectively) and less in the mitochondrial fractions of the 
untreated mice (B6 and A5). The protein signaIs visible on western blots were 
quantified using densitometry. The ratio of cytosolic cytochrome c over the total 
cytochrome c in both the cytosolic and crude mitochondrial fractions was calculated 
for a series of experiments and the se results are presented in Table 3.4. The wide 
variability among mice present on visual inspection of the western blots is also 
evident when the data is presented in tabular form, with no trend present in the mean 
values and a very large SEM relative to the average values in aIl groups. Due to the 
wide variability among mice, there are no statistically significant differences or 
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patterns among treatment groups or among genetic backgrounds with respect to 
cytochrome c release from the mitochondria. 
Another series of experiments involved subcellular fractionation of the brain from 
untreated mice to examine the insertion of Bax into the mitochondrial membrane, a 
later step in the pathway of Bax activation than the change in conformation of Bax to 
its active form, as examined above. These fractions were examined via western blots 
and are shown in Figures 3.5 and 3.6. Visual inspection of the western blots revealed 
that there is less Bax in the mitochondrial pellet fraction (inserted into the 
mitochondria) than is present in either the cytosolic fraction or the mitochondrial 
supernatant fraction. In addition, there appears to be slightly more Bax in the 
cytosolic fraction th an is present in the mitochondrial supernatant fraction in most of 
the mice. The exceptions are in Figure 3.5 panel C; PrP* mouse 7079/7167A3 and 
Figure 3.6 panel B; PrP+1+ mouse 7079/7167A5, where the amount of Bax in these 
two fractions is approximately equal. The protein bands visible on the western blots 
were quantified VIa densitometry and various ratios including total 
mitochondrialltotal cytosol, mitochondrial-pellet/mitochondrial-pellet + 
mitochondrial-supernatant + cytosol, and mitochondrial-pelletlmitochondrial-
supernatant + cytosol, calculated. These ratios are shown in Table 3.5. There are no 
differences between the PrpO/O and PrP+1+ mice. Other ratios examined (data not 
shown) include; mito-sup/mito-pellet + cytosol; mito-pelletlmito-pellet + mito-sup; 
mito-pelletlmito-sup; mito-pellet/cytosol. There is also no pattern with regard to the 
quantification of these data. 
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Legend Figure 3.1; Western blot of cytosolic HSP70 and mitochondrial HSP70 
in brain subcellular fractions from Prp+l+ and PrPO/O mice treated with either 
ethanol or saline, or untreated. C cytosolic fraction, M crude mitochondrial 
fraction. Panel A; PrpOlO mice 4636/5455Al ethanol-treated, A2 saline-treated, A4 
untreated. The protein signal in the C fraction corresponds to cytosolic HSP70. 
Panel B; PrpOlO mice 5453/5449Al ethanol-treated, A3 saline-treated, A5 untreated. 
The protein signal in the C fraction corresponds to cytosolic HSP70. Panel C; PrpO/O 
mice 5453/5449Al ethanol-treated, A3 saline-treated, A5 untreated. Panel D; PrP+1+ 
mice 7079/7038B 1 ethanol treated, B3 saline treated and B5 untreated. The protein 
signal in the M fraction corresponds to mitochondrial HSP70. Approximately 30 ~g 
of protein loaded per lane with equal volumes of cytosol and crude mitochondrial 
fractions. 
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Legend Figure 3.2; Western blot of total Bax (active + inactive forms) in brain 
subcellular fractions from Prp+l+ and Prpo/O mice treated with either ethanol or 
saline, or untreated. C cytosolic fraction, M mitochondrial fraction. The same mice 
as in Figure 3.1. Panel A; PrpO/O mice 4636/5455Al ethanol-treated, A2 saline-
treated. The protein signal present in both C and M fractions corresponds to total 
Bax. Panel B; PrpOlO mice 5453/5449Al ethanol-treated, A3 saline-treated, A5 
untreated. The protein signal present in both C and M fractions corresponds to total 
Bax. Panel C; PrP+1+ mice 707917038Bl ethanol-treated, B3 saline-treated, B5 
untreated. The protein signal present in both C and M fractions corresponds to total 
Bax. Approximately 30 Ilg of protein was loaded per lane with equal volumes of 
cytosolic and crude mitochondrial fractions. 
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Legend Figure 3.3; Western blot of immunoprecipitation of active Bax and 
western blot of total Bax (active + inactive forms) in brain subcellular fractions 
from Prpoexp, Prp+l+ and Prpo/O mice treated with either ethanol or saline. C 
cytosolic fraction, M crude mitochondrial fraction. Panel A; PrpOexp mice 
4832/4186B4 ethanol-treated, B8 saline-treated. Prp+/+ mice 4832/4186Bl ethanol-
treated, B6 saline-treated. Upper; the visible signal correspond to the active form of 
Bax immunoprecipitated from 500 fA-g of protein. Middle; the visible signaIs 
correspond to total Bax with 30 fA-g of protein loaded per lane. Lower; the visible 
protein signaIs correspond to beta-actin with 30 fA-g of protein loaded per lane. Panel 
B; PrpOlO mice 4109/4108Bl ethanol-treated, B3 saline-treated. Upper; the visible 
protein signaIs correspond to the active form of Bax. Middle; the visible signaIs 
correspond to total Bax with 30 fA-g of protein loaded per lane. Lower; the visible 
protein signaIs correspond to beta-actin with 30 fA-g of protein loaded per lane. 
125 
A 
26kDa -
26kDa _ 
47kDa -
B 
PrPOexp PrP+/+ 
4832/4186 4832/4186 
B4 B8 BI B6 
Ethanol Saline Ethanol Saline 
C M C M C M C 
.. 
--e-
PrPO/O 
4109/4108 
BI 
Ethanol 
C M 
B3 
Saline 
C M 
M 
", 
26kDa - _ activeBax 
47 kDa -1.' ......., Il • . ,1 beta-actin 
126 
active Bax 
total Bax 
beta-actin 
Table 3.1: Quantification of immunoprecipitation of subcellular fractionation of brain 
proteins from PrpOexP, PrP+/+ and PrpO/o mice, with 6A 7 anti-active Bax antibody. The 
extracts were run on a 15% polyacrylamide gel and visualized with N20 anti-Bax 
antibody, then quantified using densitometry (Molecular Dynamics version 3.51, 
VMD-Visual Molecular Dynamics, University of Illinois at Urbana-Champaign). 
SEM standard error of the mean. The differences were not statistically different p < 
0.05. 
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Genotype Treatment Mitochondria Cytosol Mito/Cyto 
PrpOexp Ethanol 2728.92 80.28 34 
Saline 286.31 561.25 0.51 
PrpOexp Ethanol 69.95 137.4 0.50 
Saline 150.31 150.34 1.0 
PrpOexp Ethanol 547.02 1642.25 0.33 
Saline 1035.37 919.53 1.13 
Ethanol Mean (SEM) 11.6 (9.1) 
Saline Mean (SEM) 0.88 (0.32) 
Prp+l+ Ethanol 2759.97 250.71 11.0 
Saline 113.46 256.38 0.44 
Prp+l+ Ethanol 1202.4 14.05 85.6 
Saline 1943.59 763.81 2.54 
Prp+I+ Ethanol 313.57 591.13 0.53 
Saline 92.52 252.58 0.15 
Ethanol Mean (SEM) 32.3 (26.7) 
Saline Mean (SEM) 1.0 (0.75) 
PrpO/O Ethanol 5361.65 617.18 8.7 
Saline 2686.65 344.92 7.8 
PrpOlO Ethanol 1129.86 316 3.6 
Saline 1248.88 292.4 4.3 
PrpOlO Ethanol 1037.23 473.35 2.2 
Saline 414.61 468.36 0.89 
Ethanol Mean (SEM) 4.83 (1.9) 
Saline Mean (SEM) 4.3 (2.0) 
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Table 3.2: Quantification of immunoprecipitation of subcellular fractionation of brain 
proteins from PrpD/o and Prp+/+ mice, with 6A 7 anti-active Bax antibody. The extracts 
were run on a 15% polyacrylamide gel and visualized with N20 anti-Bax antibody, 
then quantified using densitometry (Molecular Dynamics version 3.51, VMD-Visual 
Molecular Dynamics, University of Illinois at Urbana-Champaign). SEM standard 
error of the mean. The differences were not statistically different p < 0.05. 
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Genotype Treatment Mitochondria Cytosol Mito/Cyto 
PrpD/O Ethanol 3063.43 396.8 7.7 
Saline 330.44 1130.95 0.30 
Untreated 355.84 453.91 0.78 
PrpD/O Ethanol 803.24 59.94 13.4 
Saline 1383.16 121.72 11.4 
Untreated 1073.05 143.54 7.5 
PrpD/O Ethanol 157.96 820.87 0.20 
Saline 2033.84 2446.36 0.83 
Untreated 968.68 123.75 7.8 
PrpD/O Ethanol 136.19 835.73 0.16 
Saline 347.32 535.66 0.65 
Untreated 13.89 14.86 0.93 
PrpD/O Ethanol 248.14 28.49 8.7 
Saline 389.88 266.44 1.5 
Untreated 1139.38 79.75 14.3 
Ethanol Mean (SEM) 6 (2.6) 
Saline Mean (SEM) 2.9(2.1) 
Untreated Mean (SEM) 6.2 (2.5) 
Prp+/+ Ethanol 899.74 168.81 5.3 
Saline 1003.41 54.51 18.4 
Untreated 783.54 360.59 2.17 
Prp+/+ Ethanol 5796.58 3516.43 1.7 
Saline 4361.17 3443.74 1.3 
Untreated 4816.31 1191.57 4.0 
Prp+/+ Ethanol 590.74 3741.25 0.16 
Saline 1753.53 1800.72 0.97 
Untreated 3372.79 1896.39 1.78 
Prp+/+ Ethanol 1329.73 497.35 2.7 
Saline 473.74 1152.54 0.41 
Untreated 994.12 413.29 2.4 
Prp+/+ Ethanol 644.52 348.94 1.8 
Saline 1429.26 798.43 1.8 
Untreated 313.01 401.58 0.78 
Prp+/+ Ethanol 2077.96 3325.65 0.63 
Saline 764.54 2651.34 0.29 
Untreated 1648.24 782.42 2.1 
Prp+/+ Ethanol 15.92 0 0 
Saline 784.59 30.45 25.8 
Untreated 1944.02 994.31 2.0 
Ethanol Mean (SEM) 4 (2) 
Saline Mean (SEM) 7 (4) 
Untreated Mean (SEM) 2.2 (0.4) 
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Table 3.3: Quantification of immunoprecipitation of subcellular fractionation of brain 
proteins from PrpO/O and PrP+1+ mice, with 6A 7 anti-active Bax antibody expressed as 
a ratio of active Bax to total Bax, which was detected with N20 anti-total Bax 
antibody from the same subcellular fraction, run on 15% polyacrylamide gels, then 
quantified using densitometry (Molecular Dynamics version 3.51, VMD-Visual 
Molecular Dynamics, University of Illinois at Urbana-Champaign). The saline 
mitochondrial samples were assigned a value of 1 to calculate ratios for the ethanol 
and untreated samples on the same blot. SEM standard error of the mean. The 
differences were not statistically different p < 0.05. 
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Genotype Treatment Cytosol Mitochondria Cytosol Mitochondria 
( active/total) (active/total) (AIT) (AIT) 
PrpO/O Ethanol 1.2 / 0.95 9.3 / 2.3 1.26 4.0 
Saline 3.4 / 1.2 1/1 2.8 1 
Untreated 1.4 / 0.83 1.0 1.3 1.7 0.76 
PrpOlO Ethanol 2.4 / 1.0 0.39 / 0.40 2.4 0.97 
Saline 1.54 / 0.88 1/1 1.7 1 
Untreated 0.04 / 0.57 0.04 / 0.09 0.07 0.4 
PrpOlO Ethanol 0.04 / 0.14 0.58 / 0.31 0.3 1.9 
Saline 0.09 / 0.24 1/1 0.38 1 
Untreated 0.1 / 0.19 0.78 / 1.2 0.5 0.65 
PrpOlO Ethanol 0.07 / 0.95 0.64 / 1.2 0.07 0.53 
Saline 0.68 / 1.2 1/1 0.56 1 
Untreated 0.2 / 1.1 2.9 / 1.2 0.18 2.4 
Ethanol Mean (SEM) 1.0 (0.53) 1.85 (0.77) 
Saline Mean (SEM) 1.56 (0.49) 1 (0.5) 
Untreated Mean (SEM) 0.61 (0.37) 1.0 (0.45) 
Prp+/+ Ethanol 4.35 / 1.89 2.7 / 2.4 2.3 1.1 
Saline 3.46 / 1.8 1/1 1.5 1 
Untreated 1.0 / 1.68 2.2 / 1.22 0.6 1.6 
Prp+/+ Ethanol 2.1 / 0.4 0.34 / 0.83 5.25 0.4 
Saline 1.0 / 0.41 1/1 2.4 1 
Untreated 1.0 / 0.6 1.9 /0.25 1.6 7.6 
Prp+/+ Ethanol 0.24 / 1.7 0.45 / 0.38 0.14 1.2 
Saline 0.56 / 1.3 1/1 0.43 1 
Untreated 0.28 / 1.8 0.22 / 1.0 0.15 0.22 
Prp+/+ Ethanol 0.8 / 0.16 1.3 / 0.6 5 2.1 
Saline 0.79 / 2.1 1/1 0.4 1 
Untreated 0.27 / 2.3 1.1 / 0.85 0.12 1.3 
Ethanol Mean (SEM) 3.1 (1.2) 0.97 (0.19) 
Saline Mean (SEM) 1.28 (0.5) 1 (0.5) 
Untreated Mean (SEM) 0.61 (0.34) 2.7 (1.6) 
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Legend Figure 3.4; Western blot of cytochrome c in brain subcellular fractions 
from Prp+l+ and PrPO/O mice treated with either ethanol or saline, or untreated. C 
cytosolic fraction, M crude mitochondrial fraction. Panel A; PrP+1+ mice 
7040/7042Al ethanol-treated, A3 saline-treated, A5 untreated. The signal present in 
the M fractions corresponds to cytochrome c. Panel B; PrP+1+ mice 7079/7038B 1 
ethanol-treated, B3 saline-treated, B5 untreated. The signal present in the M fractions 
corresponds to cytochrome c. Panel C; PrpO/O mice 4946/4958B2 ethanol-treated, B4 
saline-treated, B6 untreated. The protein signal present in the M fractions 
corresponds to cytochrome c. Panel D; PrpOlO mice 4946/4957Al ethanol-treated, A3 
saline-treated, A5 untreated. The signal present in the M fractions corresponds to 
cytochrome c. Approximately 30 !-tg of protein with equal volumes of cytosolic and 
crude mitochondrial fractions was loaded per lane. 
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Table 3.4: Quantification of cytochrome c release in subcellular fractions from brain 
proteins from PrpO/O and Prpt/+ mice detected with anti-cytochrome c antibody. The 
extracts were run on 15% polyacrylamide gels and quantified using densitometry 
(Molecular Dynamics version 3.51, VMD-Visual Molecular Dynamics, University of 
Illinois at Urbana-Champaign). Various cytosol to mitochondrial ratios were 
calculated and compared among blots. SEM standard error of the mean. 
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PrpO/O CytosoIlMito CytosoIlMito + Cytosol/Mito + 
+ Cyto Cyto Cyto 
Ethanol 0.086 Saline 0.25 Untreated 0.03 
0.014 0.0095 0.007 
0.0065 0.016 0.065 
0.0003 0.0004 0.0009 
0.0003 0.005 0.002 
0.0028 0.0043 0.012 
Mean 0.168 0.0475 0.019 
SEM 0.14 0.044 0.01 
PrP+1+ 
Ethanol 0.018 Saline 0.015 Untreated 0.014 
0.057 0.0081 0.006 
0.037 0.089 0.085 
0.0038 0.0036 0.0042 
0.024 0.019 0.015 
Mean 0.028 0.027 0.025 
SEM 0.009 0.0157 0.015 
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Legend Figure 3.5; Western blot of subcellular fractions of untreated Prpo/O and 
Prp+l+ mouse brains to verify Bax insertion into the mitochondrial membrane. 
For each mouse 50 ~g of crude mitochondrial extract with equal volumes of 
subcellular fractions were loaded per lane. Membranes were probed with anti-Bax 
(N20) antibody. The signais present correspond to Bax. Cytosol: cytosolic fraction, 
Mito-pellet: proteins inserted into the mitochondrial membrane, Mito-sup: soluble 
mitochondrial proteins. For each mouse, equal volumes of each fraction, 
corresponding to 50 ~g of crude mitochondrial extract was loaded per lane. 
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Legend Figure 3.6; Western blot of subcellular fractions of untreated PrPOIO and 
PrP+/+ m~use brains to verify Bax insertion into the mitochondrial membrane. 
For each mouse, 50 Ilg of crude mitochondrial extract with equal volumes of 
subcellular fractions were loaded per lane. Membranes were probed with anti-Bax 
(N20) antibody. The signal present corresponds to Bax. Cytosol: cytosolic fraction, 
Mito-pellet: proteins inserted into the mitochondrial membrane, Mita-sup: soluble 
mitochondrial proteins. For each mouse, equal volumes of each fraction, 
corresponding to 50 Ilg of crude mitochondrial extract was loaded per lane. 
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Table 3.5: Quantification of Bax insertion into the mitochondrial membrane in 
subcellular fractions from brain proteins from untreated PrpO/o and PrP-t-i+ mice, 
detected with anti-total Bax N20 antibody run on 15% polyacrylamide gels and 
quantified using densitometry (Molecular Dynamics version 3.51, VMD-Visual 
Molecular Dynamics, University of Illinois at Urbana-Champaign). Various 
mitochondrial and cytosolic ratios were calculated and compared among blots. SEM 
standard error of the mean. 
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PrpOlO Total M/Total C M-p/M-p + M-s + M-p/M-s + C 
C 
0.967496 0.170952 0.206203 
0.658452 0.059199 0.062924 
0.462705 0.040519 0.04223 
0.945698 0.184844 0.226759 
0.952742 0.159162 0.189289 
2.086374 0.263906 0.358522 
Mean 1.01224337 0.14643033 0.27537383 
SEM 0.2303279 0.0340978 0.0819799 
Prp+/+ 
0.866067 0.195619 0.243192 
0.372364 0.33142 0.034278 
1.169199 0.173028 0.147506 
0.757877 0.144184 0.168475 
1.414555 0.19322 0.239495 
1.04033 0.21464 0.273301 
Mean 0.936732 0.20868517 0.1843745 
SEM 0.1470647 0.08521 0.035825 
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3.5 Discussion 
After several months of repeated experiments involving subcellular fractionation, 
followed by immunoprecipitation of active Bax, then loading the IP's on western 
blots and probing them with another anti-Bax antibody, we were very disappointed to 
not find a consistent pattern. The results were equally disappointing for total Bax (i.e. 
without IP) cytochrome c and active caspase 3 (data not shown). Initially, we used an 
anti-beta tubulin antibody to try and confirm that our cytosolic fraction contained 
cytosol and our mitochondrial fraction did not, however, we found that this antibody 
was less useful as sorne beta-tubulin was also present in the crude mitochondrial 
fractions. Instead we used cytosolic heat shock protein (cytoHSP)70 and 
mitochondrial heat shock protein (mitoHSP)70 and these antibodies confirmed that 
our cytosol and crude mitochondrial fractions were relatively pure, indicating that the 
subcellular fractionation protocol and technique were adequate. 
One of the early IP results, see Figure 3.3, had a distinct active Bax signal in the 
mitochondrial fraction of a saline-treated PrpO/o mouse. A small amount of Bax is 
detectable in the mitochondrial fraction, relative to the amount in the cytosol, as a 
result of the subcellular fractionation procedure (Roucou et al. 2005). This is 
believed to be artifact, as it is not visible in neuronal cultures by immunofluorescence 
(Roucou et al. 2005). However, in Figure 3.3 panel B, mouse B3, the amount of 
active Bax in the mitochondrial fraction far exceeds that in the cytosolic fraction for 
this mouse, suggesting that perhaps PrpO/o mice are either more sensitive to the stress 
of handling and saline injection than Prp+/+ mice, or have greater amounts of Bax 
associated with the mitochondria than Prp+/+ mice. Due to the great significance of 
this finding, we decided to concentrate our efforts on PrpD/o and PrP+/+ mice. 
Unfortunately, we were unable to consistently demonstrate a difference among PrpD/o 
and PrP+/+ mice treated with ethanol or saline, or untreated. The next logical step was 
to see if there was a difference between Bax actually inserted into the mitochondrial 
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membrane of PrpO/O and Prpt/+ mice. Since the previous experiments had not shown a 
difference between ethanol and saline treatments in mice of the same genetic 
background, we decided to see if Bax insertion into the mitochondria may be a more 
sensitive measure of the difference between PrpOlO and Prpt/+ mice without the added 
insult of ethanol or saline injection i.e. untreated mice. These results were also 
inconsistent and inconclusive. 
In summary, despite usmg established protocols and producing relatively pure 
subcellular fractions, these methods were not able to show a difference among mice 
treated with ethanol and mi ce treated with saline or mice that were untreated. The 
difference between ethanol and saline treatments is clearly evident and statistically 
significant when examining active Csp3 positive cells (see Figure 2.6) indicating that 
the IRC methods are more sensitive than the molecular biology techniques employed 
in our experimental paradigm. 
There are several potential reasons for this. First, in the molecular biology methods, 
we were looking directly at Bax-activation either by IP or insertion into the 
mitochondria. In our experiment, the end point was 8 hours following the first 
ethanol or saline injection on post-natal day 7, which is, according to Olney et al. 
(2000), the peak time for active Csp3 visibility in neurons in section. The activation 
of caspase 3, followed by the morphologic changes in the neurons undergoing 
apoptosis (i.e. the majority of neurons counted were morphologically in panel 4 see 
Figure 2.5) are downstream of and therefore occur later th an the activation of Bax. 
Therefore, it is possible that we are examining the brain after the peak of Bax 
activation has already passed and sorne of it may be broken down. Mitochondria may 
not still be intact in neurons in panel 4 (see Figure 2.5) and so our subcellular 
fractions may contain less mitochondria and thus active Bax th an may have been 
present earlier in apoptosis. In fact, in the st~dy of Siler-Marsiglio et al. (2005), they 
examined Bcl-2 and Bax immediately following a 2 hr 45 min ethanol inhalation 
treatment period, as they believed that the molecular events induced by ethanol occur 
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very rapidly following exposure and therefore their time point was optimal. Their 
time point was approximately 5 hr 15 minutes prior to our model. 
Second, the number of neurons undergoing apoptosis, although significantly different 
between ethanol and saline treated mice of the same genotype, may be too small 
relative to the total number of cells used in the subcellular fractionation. For the 
subcellular fractionation experiments, the entire brain was harvested rather than the 
more restricted area examined histologically for active Csp3 positive cells. The 
number of positive cells in the ethanol treated group averaged between 577 and 742 
cells, whereas the total number of neurons present in the equivalent area of the brain 
must be at the very least, in the tens of thousands. The saline-treated mean values 
ranged from approximately 190 to 260 positive cells. Therefore, the difference 
between approximately 190 and 742 positive cells in a background of tens of 
thousands of cells not undergoing apoptosis, may dilute out any real differences and 
make them more difficult to see. 
Third, the activation of Bax does not involve a proteolytic cleavage, but rather only a 
conformational change. One would expect that the process of euthanizing a mouse, 
removing the brain, homogenizing it and performing the subcellular fractionation 
may induce this conformational change in sorne of the fraction. This may be 
especially true in young 7 day old mice, where the brains are more delicate than adult 
brains and may be more sensitive to insults. Indeed, Roucou et al. (2005) noted a 
small amount of Bax in the mi tochondri al fraction of subcellular fractions from 
human neuronal cultures, which was not visible when the cells were examined by 
immunofluorescence and they interpreted this as artifact induced by damage to the 
cells during the subcellular fractionation. We may expect more such damage when 
the subcellular fractions are derived from mouse brains. In addition, the tissue 
homogenizer used in these experiments was not of the Dounce type, which may 
therefore have augmented tissue damage and contributed to the artifact induced, 
despite the apparent purity of the fractions noted with cytosolic HSP70 and 
mitochondrial HSP70 immunoblots. Therefore, it may be reasonable to expect sorne 
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background artifactual rate of Bax activation as a result of experimental procedures, 
which would obviously vary among experiments. This could induce more Bax 
activation than our ethanol or saline injection and so be responsible for inconsistent 
results, as we observed. 
Fourth, the activation of Bax does not invariably result in cytochrome c release and 
effector caspase activation (Ott et al. 2002). Bax could lead to activation of apoptosis 
inducing factor (AIF) and endonuclease G (endo G), which may translocate to the 
nucleus initiating cell death and chromatin condensation without caspase 3 activation. 
We would therefore be less likely to detect cytochrome c release in the ex-vivo mouse 
brain experiments. 
Fifth, as has been discussed in Chapter 2, there is considerable variability between 
mice at 7 days of age. This would also contribute to the inconsistency that was noted 
in these subcellular fractionation experiments. 
3.6 Conclusions 
The ethanol injection experiment (Chapter 2) demonstrated that an ethanol in suIt 
induces significant apoptotic neuronal death compared to saline injected control s, as 
measured by active Csp3 staining of neurons. This apoptosis is Bax-mediated 
(Young et al. 2003) and Bax activation is upstream of the activation of caspase 3 
(reviewed by Wang 2001). Therefore, Bax was activated in the mou se brains that we 
examined. However, we were not able to consistently detect differences between 
ethanol and saline injected mice, nor untreated and treated mice on various genetic 
backgrounds. We can conclude that the methods available were not sensitive and 
accurate enough to detect these differences, perhaps due to the time of Bax activation 
relative to harvesting the brains, perhaps due to the small number of positive neurons 
relative to the total number of neurons harvested, or perhaps due to artifact induced 
by the experimental procedures and the variability among 7 day old mice. Most 
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likely, the failure to detect the se differences was due to a combination of these 
factors. 
Chapter 4 Transgenic expression of SHaPrP under the Beix 
promoter in mice 
4.1 Introduction 
In order to further investigate the in vivo function of PrP against Bax-mediated cell 
death, rather th an an external insult to stimulate cell death (i.e. ethanol) we propose to 
use the physiological insult of Bax activation during embryonic development. The 
natural antagonists for Bax are BeI-2 family members (reviewed by Wang 2001) with 
BeIxL being particularly important in embryonic development of the nervous system 
(Motoyama et al. 1995). Immunohistochemistry has been used in mi ce to confirm 
that BeIxL is diffusely expressed in preplate neurons (i.e. immature post-mitotic 
neurons) but not in proliferating ventricular zone neurons at embryo day 12.5 (Roth et 
al. 1999). In fact, BeIxL knockout mice undergo massive cell death of immature 
hematopoietic cells and neurons and die around embryonic day 12 to 13 (Motoyama 
et al. 1995). The neuronal cell death is rescued by concurrent Bax knockout (Shindler 
et al. 1997) indicating that this neuronal death is Bax-mediated. In mice, BeIxL 
mRNA has been detected in developing neurons and in the adult nervous system 
(Gonzales-Garcia et al. 1994, Grillot et al. 1997). Therefore, to investigate a possible 
role for PrP against Bax-mediated neuronal death, we propose to replace the lack of 
expression of BeIxL with Syrian hamster prion protein (SHaPrP) under the control of 
the BeIx promoter to see if SHaPrP under these conditions can also rescue the 
neuronal death mediated by physiologically expressed Bax during embryonic 
development. If SHaPrP expressed under the control of the mouse BeIx promoter in 
BeIx knockout mice is able to rescue the neuronal cell death, similar to Bax knockout 
in BeIx knockout mice, it will demonstrate eIearly that PrP can inhibit Bax in vivo. 
4.2 Objective and Rationale 
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In this experiment, we will further assess the in vivo function of Prpc against Bax-
mediated cell death. BeIxL is an antiapoptotic member of the BeI-2 family, 
particularly important during the development of the nervous system (Motoyama et 
al. 1995). Mice that do not express BeIxL during development die in utero by day 13, 
due to extensive Bax-mediated apoptosis of the brain, spinal cord, dorsal root ganglia 
and hematopoietic cells (Motoyama et al. 1995). Bounhar et al. (2001) demonstrated 
that Prpc protects against Bax-mediated cell death in cell culture in primary human 
neurons. Syrian hamster Prpc also protects primary human neurons in culture from 
Bax-mediated cell death (Bounhar and LeBlanc, unpublished observations). In this 
experiment, we will generate a construct of the murine BeIx promoter expressing 
SHaPrnp and create a homozygous transgenic mouse expressing the construct. We 
chose to use Syrian Hamster PrP in our construct for two reasons; one is that we need 
to be able to tell the difference between the prion protein that we are expressing with 
our BeIx promoter and the endogenously expressed murine PrP expressed under the 
murine PrP promoter and two; there was sorne concern expressed that we may be 
creating a transgenic mouse that could potentially be "infectious" for humans 
working with the mice or the transgene constructs. We therefore decided to use 
Syrian Hamster PrP, which is antigenically distinct from mouse PrP and due to the 
species barrier between humans and hamster, would be highly unlikely to cause 
disease in those humans exposed to the mice. These transgenic mice will be crossed 
to BeIx heterozygous knockout mice, which are phenotypically normal, to obtain 
BeIx homozygous knockout mice to test the hypothesis that expression of the Syrian 
hamster Prnp cDNA under the BeIx promoter will rescue the embryolethal phenotype 
of the BeIx homozygous knockout mice by inhibiting Bax-mediated cell death. 
4.3 Methods and Experimental Protocol 
4.3.1 The Transgenic Construct 
4.3 .1.1 BeIx Promoter 
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The murine Bclx promoter was amplified from mouse genomic DNA using PCR 
primers; forward, NheI/Bclx/-1207to-1179: S' AAAGCTAGCGCCGC 
CTTGGGCTCGGCCTC 3' and reverse, BglII/Bclx/-19 to -46: S' 
AAAAGATCTCTCAACCAGTCCATTGTCC 3'. The conditions were as follows: 
94°C 3 minutes 1 cycle; 94°C 1 minute, 62°C 1 minute, 72°C 2 minutes 42 cycles; 
72°C 7 minutes 1 cycle; 4°C soak (see also Appendix 1). The PCR reaction 
generated a PCR product of 1200 bp. The purified peR product and pGL3 basic 
modifed vector (Promega Corporation, 2800 Woods Hollow Road, Madison, WI., 
53711-5399. USA) were digested with Nhel and BglII restriction enzymes, purified 
and ligated together. 
4.3.1.1.1 Transfection of N2a and HEK293 cells to assess promoter efficiency 
The efficiency of the promoter was assessed by cloning the Murine Bclx promoter 
into a pGL3 basic modified vector (Promega Corporation, 2800 Woods Hollow Road, 
Madison, WI. 53711-5399, USA) and using the Dual Luciferase Reporter Assay 
(Promega Corporation). N2a and 293 cell lines were then transfected with the vector 
containing the promoter. The transfection protocol was as follows; 
N2a and 293 cells were grown in T75 flasks with DMEM media containing 10% 
serum up to approximately 70% confluence. The medium was removed and the cells 
were rinsed with 12 ml of phosphate buffered saline (PBS) pH 7.4. The PBS was 
aspirated and 2 ml of diluted trypsin solution (0.5 ml of trypsin with 9.5 ml PBS) and 
rocked gently in the flasks for 2 to 3 minutes. Once in solution, 10 ml of medium 
. with serum was added to neutralize the trypsin. Approximately 1 ml of medium and 
trypsin solution containing the cells was added to each weIl in a 6 weIl plate, then 1 
ml of medium is added to each weIl. The cells were incubated at 37 oC in 0.5% COz 
for 24 hours until approximately 70% confluence was obtained. For each cell line, 2 
wells in a 6 weIl plate were transfected with the Mix 1 (pRLTK 0.175 pg DNA + 
pGL3 3.93 pg DNA), Mix 2 (pRLTK 0.175 pg DNA + pGL3+Bclx 4.0 J1g DNA) and 
1 weIl in a 6 weIl plate transfected with Mix 3 (peGFP 4 pg DNA). For each weIl, 
tube A contained 250 f-tL of optimem minus serum and 10 f-tL of lipofectamine 2000. 
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Tube B contained 250 !-lL of optimem minus serum and the DNA mix. Tube A and 
tube B were incubated separately at room temperature for 5 minutes, then mixed 
together and incubated for 20 minutes at room temperature. During the incubation, 
the cells in the 6 weIl plate were washed with 2 ml of PBS per weIl, the PBS was 
aspirated and 500 !-lL of optimem minus serum was added per weIl. After the 20 
minute incubation period, the 500 !-lL mixture of A and B was added to each weIl and 
the wells were incubated at 37°C in 0.5% CO2 for 3 hours. After 3 hours, 2 ml of 
DMEM plus 10% serum was added to each weIl. The wells containing the peGFP 
DNA were examined periodically to assess the transfection efficiency. After 24 
hours of incubation at 37°C the transfection efficiency was estimated and the cells in 
the pRLTK-pGL3 and pRLTK-pGL3+BclxL wells were harvested in the following 
manner. The medium was removed and the cells were washed with PBS (pH 7.4), 
then 500 !-lL of IX Passive Lysis Buffer was added to each weIl. The plates were 
placed on a rocking platform at room temperature for 15 minutes. When the cells 
were lysed, the lysate was collected and placed in an eppendorf tube and centrifuged 
at 13,000 rpm for 10 minutes at room temperature. The supernatant was collected 
and used for the BCA Protein Assay and the Dual-Luciferase Reporter Assay. 
The BCA protein assay was performed as described in section 2.3.5 Protein 
expression. Briefly, standards were prepared using 0 to 40 !-lg of BSA diluted in 
passive lysis buffer and 1: 10 and 1 :50 dilutions of the cell lysates were similarly 
prepared. After adding the appropriate amounts of reagent A and Band incubating 
for 30 minutes at 37°C and 5 minutes at room temperature, the absorbance of the 
sampI es was measured at 562 nm and a standard curve prepared. The standard curve 
was used to estimate the protein concentration of the ceIllysates in !-lg/!-lL. This value 
was used in the luciferase assay calculation (see below). 
For the luciferase assay, 20 !-lL of cell lysate was put into a glass tube and 100 !-lL of 
LARII as say buffer added and a value for "firefly" luciferase recorded and repeated 
for a second tube. Then 100 !-lL of Stop and GIo buffer was added and a reading for 
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the "renilla" luciferase recorded for each tube. The result was expressed in arbitrary 
units, "luciferase activity units" using the following formula. 
[(firefly luciferase/renilla luciferase) x 10,000] + protein (!-lghtL) 
4.3.1.2 Syrian Hamster PrP cDNA (SHaPrP) 
The Syrian Hamster Prnp cDNA was amplified from genomic DNA obtained from 
Tg(ShaPrnp)7 mice using PCR primers; forward, BglII/HaPrP/-22to +10: 5' 
AAAAGATCTGGGCTTTGTGGCT ATGTGGACTG 3' and reverse, 
XhoIlHaPrP+ 791to+ 755: 5' AAACTCGAGCCACAAGAACGA 
GGAAGTACAAGCAGGG 3'. The conditions were as follows: 94°C 6 minutes 1 
cycle; 94°C 1 minute, 55°C 1 minute, 72°C 40 seconds 42 cycles; 72°C 10 minutes 1 
cycle; 4°C soak (see also Appendix 1). This PCR reaction generates a product of 790 
bp. The SHaPrP PCR product was ligated to the vector pCR2.1-TOPO (lnvitrogen 
Canada Include, 2270 Industrial Street, Burlington, Ontario, L7P lAI, Canada). The 
construct pCR2.1-TOPO/SHaPrP was digested with EcoRV and Spel restriction 
enzymes, to produce a SHaPrP cDNA in sert. The vector pBluescriptIIKS+/-
(Strategene Corporation, 11011 North Torrey Pines Road, La Jolla, CA, 92037, USA) 
was digested with EcoRV and Spel and then the purified SHaPrP cDNA ligated into 
the vector. The construct was sent to a private company (The Institute for Molecular 
Biology and Medicine, McMaster University Life Sciences Building, Room 123, 
1280 Main Street West, Hamilton, Ontario, L8S 4Kl, Canada) for sequencing. 
4.3.1.3 Bclx promoter/SHaPrP cDNA construct 
A pGL3 basic vector (Promega Corporation) was digested with NcoI and Xbal 
restriction enzymes to remove the luciferase cDNA from the vector, then Klenow 
DNA polymerase 1 (United States Biochemical, Amersham Canada Ltd., 1166 South 
Service Road West, Oakville, Ontario, L6L 5T7, Canada) used to create blunt ends. 
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The vector was then religated to produce pGL3 basic vector without the luciferase 
(pGL3~luciferase). The Bclx promoter (see above) was digested from the pGL3 
basic modified vector using Nhel and BglII restriction enzymes and the product 
purified. The SHaPrP cDNA was digested from the pBluescript IIKS+/- vector (see 
above) using BglII and Xhol restriction enzymes and the product purified. The Bclx 
promoter and the SHaPrP cDNA were then ligated together at the BglII digestion site. 
The Bclxpromoter/SHaPrP product was then purified and a forward primer 
AAAGAGCfCGCCGCCfTGGGCfCGGCCfC used to add a Sac! restriction site, 
and a reverse primer, AAAGCf AGCCCACAAGAACGAGG 
AAGTACAAGCAGGG used to add an Nhel restriction site, using the PCR protocol 
"Por amplifying: 1200 bp portion of Murine Bclx promoter from mouse genomic 
DNA" as listed in section 4.3.1.1 above (see also Appendix 1). The PCR product was 
then digested with Sac! and Nhel restriction enzymes and the product purified. The 
vector pGL3~luciferase was also digested with Sac! and Nhel restriction enzymes 
and the Bclxpromoter/SHaPrP ligated to the vector. The pGL3~luciferase­
Bclxpromoter/SHaPrP construct was then sent to a private company (McGill 
University/Sheldon Biotechnology Centre, 3773 University Street, Montreal, Quebec, 
H3A 2B4, Canada) for sequencing. Due to problems with the sequencing, the 
pGL3~luciferase-Bclxpromoter/ShaPrP construct was digested with Sac! and Xhol 
restriction enzymes, as was pBluescriptlIKS+/- vector (Strategene Corporation) and 
the insert ligated to the pBluescriptlIKS+/- vector. The new construct was sent to 
another private company (The Institute for Molecular Biology and Biotechnology, 
McMaster University) for sequencing. 
The murine Bclx promoter was fused with the SHaPrP cDNA, using the A TG start 
site of the SHaPrnp at a BglII restriction enzyme site. A linear fragment of the Bclx 
promoter and the SHaPrnp gene was digested using Sac! and Ec047III restriction 
enzymes and then sent to Dr. Michel Tremblay (Director, McGill Cancer Centre, 
McGill University) for generation of the transgenic mouse. 
4.3.1.4 Expression of SHaPrP under the Bclx promoter in N2a celIs 
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Murine neuroblastoma (N2a) cells were transfected, as described above. The DNA 
used was pGL3i1luciferase (the vector without the transgene), pGL3i1luciferaseBeIx-
SHaPrP (the vector with the transgene) and pEGFP (to visualize transfected cells). 
The cells were grown at 37°C to approaching 100% confluence, at which point the 
media was aspirated and replaced with methionine free DMEM. The cells were 
grown in methionine free media for 1 hour. The methionine free media was aspirated 
and replaced with methionine free media supplemented with radiolabeled e5S) 
methionine at 100 f.lCi/mL and incubated at 37°C for 3 hours, with gentle shaking 
every 30 minutes. The media and cells were collected and transferred to eppendorf 
tubes and centrifuged at 10,000 g for 10 minutes at 4°C. The supernatant was 
aspirated and 250 f.lL of NP40 lysis buffer (50 mM TrisHCI pH8, 150 mM NaCI, 1 % 
NP40, 5 mM EDT A pH 8) added to the pellet and incubated on ice for 10 minutes. 
The tubes were centrifuged at 10,000 g for 10 minutes at 4°C and the supernatant 
collected. A volume of 5X RIPA (750 mM NaCl, 5% NP40, 2.5% Nadeoxycholate, 
0.5% SDS, 500 mM TrisHCI pH 8.0, 0.05% PMSF, 0.1 f.lg/mL pepstatin A, 1 f.lg/mL 
TLCK, 0.5 f.lg/mL leupeptin) was added to make a final concentration of IX RIPA. 
Exactly 500 f.lg of protein in a volume of 500 f.lL of NP40 buffer was used for 
immunoprecipitation (as described above) with RISS antiserum, 5 f.lL of antiserum 
(1: 100) with 30 f.lL of prot-A-sepharose beads. Following the immunoprecipitation, 
the beads were loaded on a 15% polyacrylamide gel, as described above. The gel was 
exposed to X-ray film for 48 hours. 
4.3.2 Mice 
4.3.2.1 Transgenic mice TgBeIx/SHaPrP(TgBSH) Genotyping 
The linear cDNA containing the murine BeIx promoter and the Syrian Hamster prion 
protein cDNA is injected into appropriate 2 pronueIei stage embryos. At 
approximately 3 weeks after birth, these offspring have their tails cut and the tissue is 
used for DNA extraction (as described above in section 2.3.4 Genotyping) and 
153 
screening for the presence of the transgene by PCR. The mice were genotyped by 
PCR amplification using the following primer sequences; forward, TgBclx/SHaPrP-
F: 5' CCCATACCTCCGTGAGAGTTCTCCTGACTCCCAG 3' and reverse, 
TgHclx/SHaPrP-R: 5' GCCCCCATGTGCCGCCACCTGAG 3'. The conditions 
were as follows; 94°C 3 minutes 1 cycle; 94°C 30 seconds, 60°C 30 seconds, 72°C 1 
minute 42 cycles; 72°C 7 minutes 1 cycle; 4°C soak, (see also in Appendix l). The 
PCR reaction yields an 891 bp product. The PCR reaction to genotype the mice was 
run concurrently with a reaction to amplify a housekeeping gene (Mouse Ring Finger 
Mrfl), which produces a 565 bp PCR product. The presence of this product when the 
reaction was run at 42 cycles for genotyping, confirmed that the quality of the DNA 
was adequate and means that the absence of the Tg product (891 bp product) 
indicated that the mouse did not contain the transgene. This reaction when run for 33 
cycles allowed quantitation of the two PCR products to compare the ratio of the 
products to identify likely Homozygous Tg mice (see quantitative PCR section 
below). The PCR reactions were run on a 1 % agarose gel in 0.5X tris-borate-EDTA 
electrophoresis buffer (TBE) and stained with ethidium bromide. 
4.3.2.1.1 Protein expression 
At approximately 20 weeks of age (time of maximum Bclx mRNA) (Grillot et al. 
1997), selected mice from the first two transgenic lines, TgBSHl and TgBSH2 were 
sacrificed. The brains were removed from the rnice and immediately rinsed in PHS 
on ice to remove any blood, then homogenized on ice in an appropriate volume 
(approximately 1000 !-lL for 1/4 brain) of CHAPS lysis buffer (50 mM TrisHCI pH 
8.0, 150 mM NaCl, 1 % CHAPS, 5 mM EDT A). The samples (approximately 500 !-lL 
volume) were then transferred to a DNA storage vials (Cryovial, Fisher Scientific, 
Ottawa Ontario) and sonicated for 20 seconds using a Branson Sonifier 450 (Branson 
Ultrasonics Corporation, Danbury, CT) at a 20% setting, output control 6, then frozen 
at -20°C. The sampI es were then thawed and refrozen at -20°C and then centrifuged 
at 10,000 g for 15 minutes at 4°C and the supernatant collected. An aliquot of the 
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supernatant was used for a BCA protein assay (as described in section 2.3.5 Protein 
expression), with the remainder being frozen. 
Samples were prepared for immunoprecipitation (lP) using the following protocol. 
The IP experiments were prepared using 1000 !-tg of protein, with a positive control 
containing 980 !-tg of protein from a PrpO/O mouse added to 20 !-tg of protein from a 
PrpOexp mouse. Then 60 !-tL of Prot-A-Sepharose beads were prepared per sample as 
follows; The beads were withdrawn from the buffer and centrifuged at 3000 rpm in a 
bench centrifuge for 2 minutes at 4°C, the buffer removed and replaced with CHAPS 
buffer with added anti-protease tablets (as described above). This was repeated three 
times to thoroughly wash the beads. Each protein sample corresponding to 1000 !-tg 
of protein was then diluted up to 500 !-tL in CHAPS and 30 !-tL of beads added per 
sample. The tubes were then put on an inverting rack at 4°C and incubated for at 
least 1 hour to remove non-specifie binding to the beads. The sampi es were then 
centrifuged at 3000 rpm for 2 minutes at 4°C and the supernatant removed to new 
labeled tubes. Then 4 !-tL of 3F4 antibody (anti-SHaPrP) was added and the tubes 
incubated on an inverting rack at 4°C overnight. Then the tubes were centrifuged at 
3000 rpm for 2 minutes at 4°C and an equal volume of CHAPS buffer with anti-
protease tablets was added. The samples were vortexed and recentrifuged at 3000 
rpm. This washing procedure was repeated 3 times. The buffer was removed and the 
beads were then suspended in loading dye. The IP protein extracts bound to Prot-A-
sepharose beads or protein extracts were then run on SDS-PAGE gels, as described 
below and blotted onto PVDF membranes via the western blotting technique. The 
membranes were then probed with RISS anti-PrP antiserum and developed using 
Immobilon Western Chemiluminescent HRP Substrate (Millipore Corporation 
WBKLSOI00) western blot detection system and exposed on X-ray film. 
Brain protein extracts from the mice used for immunoprecipitation above, and 
selected mice from all 3 transgenic lines, TgBSHl, TgBSH2 and TgBSH3 were also 
prepared for western blotting. The procedure for the SDS-PAGE and western blots 
was as previously described in section 2.3.5 Protein expression. Briefly, 15% 
155 
acrylamide gels were prepared and the wells rinsed with tap water. Then the gel 
apparatus was placed in the running apparatus and running buffer added to fill the 
tank. The protein sampi es were prepared for loading by adding an equal volume of 
loading dye to the protein sample and incubating in a heating block at 100°C for 5 
minutes immediately prior to loading. The sampi es were loaded in the sample wells 
and run at 130 volts for approximately 1 hour 20 minutes (until the blue dye ran off 
the end of the gel). The proteins in the gel were transferred onto a PVDF membrane 
(Immobilon P Transfer Membrane, Millipore Corporation, Bedford, MA) in the 
transfer apparatus immersed in working transfer buffer at 230 mAmp for 
approximately 2 hours and 30 minutes or at 40 mAmp overnight. Following the 
transfer, the membranes were rinsed in TBS tween for 5 minutes then blocked for 1 
hour at room temperature in blocking solution. The primary antibody was prepared at 
an appropriate dilution in 1.25 g powdered low fat skim milk in 50 mL phosphate 
buffered saline. Approximately 1 mL of the diluted 3F4 or 13A5 (kindly provided by 
Dr. Lingappa) anti-SHaPrP antibodies were prepared and placed on a glass plate in a 
humid chamber. The membranes were placed protein side down on the diluted 
antibody and incubated overnight at 4°C. Following incubation the membranes were 
rinsed 3 times in TBS tween for 5 minutes each, then the diluted secondary antibody 
(in 1.25 g milk in PBS solution) incubated in a plastic tray with the membrane for 1 
hour at room temperature. The membrane was then rinsed 3 times in TBS tween and 
developed with Immobilon Western Chemiluminescent HRP Substrate (Millipore 
Corporation WBKLS0100) developing solution and exposed to X-ray film in the dark 
room for an appropriate period of time. 
For each of the western blots, 100 !-tg of protein was loaded for each of the transgenic 
mice, as weIl as PrP+/+ and PrpOlO controls. For the positive control, 98 !-tg of PrpOlO 
brain protein extract and 2 !-tg of brain protein extract from a SHaPrP expressing 
mouse (PrpOexP) was used. 
4.3.2.1.2 Messenger RNA extraction 
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Brains were removed from an adult transgenic mou se (approximately 20 weeks of 
age, which is the period of maximum Bclx mRNA expression) (Grillot et al. 1997), 
from each tine and immediately frozen in dry ice and subsequently, cut into 100 mg 
sections and stored at -80°C for analysis. For analysis, the brain samples were 
homogenized in 1 mL of TRIzol reagent (lnvitrogen life technologies cat. no. 15596-
026). Homogenized samples were incubated at room tempe rature for 5 minutes. 
Then 0.2 mL of chloroform was added, the tubes were shaken vigorously for 15 
seconds, then incubated at room temperature for 2 to 3 minutes. The samples were 
then centrifuged at 12,000 g for 15 minutes at 4°C. The upper aqueous phase 
contains the RNA and was retained and placed in another tube. Then 0.5 mL of 
isopropyl alcohol was added and the samples were incubated at room temperature for 
10 minutes, then centrifuged at 12,000 g for 10 minutes at 4°C. The RNA precipitate 
formed a gel-like pellet on the bottom of the tube. The RNA was washed once in 1 
mL of 70% ethanol and centrifuged at 7,500 g for 5 minutes at 4°C. The RNA pellet 
was then air-dried for 5 to 10 minutes at room temperature. The RNA was then 
dissolved in water and incubated at 55°C for 10 minutes. The RNA produced was 
then reverse transcribed to DNA using the manufacturers protocol (Roche 
Diagnostics Cat No. Il 495 062001, Indianapolis, IN, USA). The reaction mix was 
incubated at 42 oC for 1 hour followed by 10 minutes at 70°C and was then stored at 
4°C. 
The mRNA extraction and reverse transcription was performed by a colleague in the 
laboratory (Dr. Laure Duplan). The cDNA thus produced was then used as a template 
for a PCR reaction amplifying the 790 bp product from SHaPrP cDNA from 
Tg(SHaPrnp)7 genomic DNA, see section 2.3.4 Genotyping above (see also 
Appendix 1). The PCR reactions from the cDNA template were performed by a 
colleague in the laboratory (Ms. TRA Truong). 
4.3.2.2 Bclx+/- Mice 
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Heterozygous Bclx+l- mice were obtained from Dr. Kevin A Roth (Department of 
Pathology, University of Alabama, Birmingham, Alabama). The genotype of these 
mice was verified by PCR. The Bclx knockout allele was amplified using the 
following primer sequences; forward, KO-l: 5' 
GCCTACCCGCTTCCATTGCTCAGC 3' and reverse, KO-4: 5' 
GAAACGCGGGGAGAACTTGCTGCTCTC 3' and produces a 600 bp product. The 
Bclx wild-type allele was amplified using the following primer sequences; forward, 
NM4: 5' GTGCCATCAATGGCAACCCAT 3' and reverse, NM5: 
CCGCCGTTCTCCTGGATCCAA 3' and produces a 400 bp product. The conditions 
were as follows: 94°C 5 minutes 1 cycle; 94°C 1 minute, 68°C 1 minute 30 seconds, 
72°C 1 minute 42 cycles; 72°C 5 minutesl cycle; 4°C soak; (see also Appendix 1). 
The PCR products were run on a 1 % agarose gel and stained with ethidium bromide. 
4.3.2.3 Tg(BSH)-Bclx+l- mice 
Heterozygous Tg(BSHtl- mlce were crossed with heterozygous Bclx+l- mlce to 
generate the required Tg(BSHtl+Bclx+l- mice that will be crossed to generate the 
required Tg(BSHtl+Bclx-l- mice to test the hypothesis that the expression of Syrian 
Hamster PrP under the mouse Bclx promoter will protect against Bax-mediated cell 
death in mice that are lacking the natural antagonist for Bax during development. 
4.4 Results 
4.4.1 Bclx Promoter 
The murine Bclx promoter was amplified from mouse genomic DNA, using PCR 
conditions and primers as described in section 4.3.1.1 Bclx promoter (see also 
Appendix 1) and cloned into a pGL3 basic modified vector (Promega Corporation, 
2800 Woods Hollow Road, Madison, WI. 53711-5399, USA). The map for this 
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construct is shown in Figure 4.1 below. Two cell lines, HEK293 (human embryonic 
kidney ceIls) and N2a (mou se neuroblastoma ceIls) have been transfected using 
Lipofectamine 2000 (Gibco-Invitrogen Canada Inc. 2270 Industrial Street, 
Burlington, ON, L7P lAI) with the vector and construct (see protocol above). The 
transfection efficiency was estimated at 40%. The efficiency of the promoter has 
been assessed by using the expression of the Firefly Luciferase gene downstream of 
the promoter, via the Dual Luciferase Reporter Assay (Promega Corporation). The 
results are shown in Table 4.1 below. Briefly, the promoter demonstrated good 
efficiency with the assay, as the vector containing the BeIx promoter had significantly 
higher luciferase activity in both N2a and 293 cell lines (range 45,256 to 127,960 
luciferase activity units) than the vector lacking the promoter (range 810 to 875 
luciferase activity units). In a recent study, Ou et al. (2006) used a luciferase reporter 
assay to assess the increase in monoamine oxidase A activity as a result of 
dexamethasone treatment, since the promoter contains 3 consensus glucocorticoid 
response elements. They reported an up to 6 fold increase in activity as a result of 
dexamethasone binding. These data would suggest that the increase that we noted 
over controls not containing the promoter, indicates that the BeIx promoter has good 
activity in HEK293 and N2a cells. 
4.4.2 Syrian Hamster PrP cDNA 
The Syrian Hamster Prnp cDNA was amplified from the genomic DNA obtained 
from Tg(SHaPrnp)7 mice, using PCR conditions and primers as described in section 
4.3.1.2 Syrian Hamster PrP cDNA (see also Appendix 1) and eIoned into a 
pBluescriptlIKS+/- vector (Strategene Corporation) The map for this construct is 
shown in Figure 4.2 below. The construct was sent to a private company for 
sequencing (The Institute for Molecular Biology and Medicine, McMaster 
University) for sequencing. The sequence results confirmed that there had been no 
mutations introduced into the construct. 
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Figure 4.1: Map of pGL3 Basic-modified with Murine Beix promoter 
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SV40late 
pofy(A) signal 
(for lue+ reporter) 
Hpa11902 
pGL3 Basic modified 
with Bclx promoter 
5979bp 
Plasmid Name: pGL3 Basic-modified/Murine BeIx promoter 
Plasmid Size: 5979 bp 
Constructed By: Malcolm Gains 
Construction Date: August 2002 
clx 
romoter 
Vector pGL3 Basic-modified: 4788 bp (HindIII-NcoI removed by Dr. Lin lab, LDI) 
Insert Murine BeIx promoter Size: 1191 bp 
Site of Cloning: NheI, BglII 
Antibiotic Resistance: Ampicillin 
Gene Bank Accession #: Murine BeIx promoter 
In case of any questions, contact Dr. Andrea LeBlanc. Tel. (514) 340-8222 ext. 4976 
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Table 4.1: BeIx promoter aetivity measured by the Dual-Luciferase Reporter 
Assay System 
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Cell Line 
N2a 
HEK293 
PRLTK-pGL3 
875 LAU 
810 LAU 
pRLTK-pGL3 control transfection, with no Bclx promoter 
pRLTK-pGL3-Bclx test transfection, with Bclx promoter 
units are in "luciferase activity units" (LAU). 
PRLTK-pGL3-Bclx 
45,256LAU 
127960LAU 
N2a and 293 cells were simultaneously transfected with pEGFP to assess transfection 
efficiency. N2a results represent an average of 2 experiments. In each case, the 
transfection efficiency was estimated at approximately 40% by cell counting 
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4.4.3 BeIx Promoter/SHaPrP cDNA construct 
4.4.3.1 Generation of the transgene construct 
A pGL3 basic vector (Promega Corporation) was prepared for ligation with the insert 
and the luciferase cDNA was removed as described above. The vector was then 
religated to produce pGL3 basic vector without the luciferase (pGL3Aluciferase). 
The BeIx promoter and the SHaPrP cDNA were digested from their respective 
vectors, as described above, and inserted into pGL3Aluciferase vector. The map for 
this construct is shown in Figure 4.3 below. The sequence results indicated that there 
were enormous numbers of mutations introduced into the construct since the original 
sequencing of the SHaPrP cDNA alone. We suspected that there was a problem with 
the sequencing procedure. The sequencing for the SHaPrPcDNA in pGL3Aluciferase 
vector was performed using the primers that were used for eIoning the cDNA, which 
although theoretically adequate, were not optimum. The optimum for sequencing is 
to use universal primers specific for the vector. Therefore, the pGL3Aluciferase-
BeIxpromoter-SHaPrP construct, and pBluescript IIKS+/- vector (Strategene 
Corporation) were digested with Sad and XhoI enzymes and the BeIxpromoter-
SHaPrP insert ligated to the pBluescript IIKS+/- vector. The map for this construct is 
shown in Figure 4.4 below. This construct was sent to a different private company 
(The Institute for Molecular Biology and Biotechnology, McMaster University) for 
sequencing. The company was therefore able to use universal primers to do the 
sequencing with the construct in pBluescriptIIKS+/- vector. The results indicated that 
there were no mutations in either the BeIx promoter or the SHaPrP cDNA. 
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Figure 4.2: Map of pBKSII+ with Syrian Hamster PrP 
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ompicillin 
pBIIKS(+) with 
SHaPrP 3.8kb 
Plasmid Name: pBSKII( +/-)/SHaPrP 
Plasmid Size: 3.8 kb 
Constructed By: Qi Guo and Malcolm Gains 
Construction Date: April 2003 
BstXI 
EcoRI 
EcoRV 
Notl 
EcoRI 
Comments/References: Hamster PrP was transferred from pCR2.1-TOPO to pBKS 
(EcoRV, SpeI) 
Vector pBKSII Size: 3.0 kb 
Insert: Syrian Hamster PrP Size 800 bp 
Site of Cloning: EcoRV, SpeI 
Antibiotic Resistance: Ampicillin 
In case of any questions, contact Dr. Andrea LeBlanc. Tel: (514) 340-8222 ext 4976 
166 
--
4.4.3.2 Expression of SHaPrP under the Bclx promoter in N2a cells 
Mouse neuroblastoma (N2a) cells were transfected with the transgene to verify 
expression of SHaPrP. The results of this experiment are shown in Figure 4.5. In the 
left pGL38luciferase lane, a background signal of very low intensity is present 
between the 24 kDa and 31 kDa markers. In the right pEGFP lane, a signal of 
stightly greater intensity is present between the 24 kDa and 31 kDa markers. In the 
middle pGL38luciferaseBeIx-SHaPrP lane, a more intense signal is present between 
the 24 kDa and 31 kDa markers confirming the presence of SHaPrP expressed under 
the mouse BeIx promoter 
4.4.4 Mice 
4.4.4.1 Transgenic mice BeIxpromoter/SHaPrP (TgBSH) 
A linear construct of the transgene was removed from the vector and sent to the 
laboratory of Dr. Michel Tremblay (Director, Mc Gill Cancer Centre, Mc Gill 
University). Several hundred 2 pronueIei stage embryos were injected and over 30 
mi ce were identified by PCR as containing the transgene in their genomic DNA. 
Following breeding to wild-type mice, only two of these mice were found to be 
carrying the transgene in their germ cells and so passed the transgene on to their 
offspring as expected. Each of these two founder mice was the founder of a distinct 
transgenic tine carrying the TgBSH. 04-153-2 was a male mou se and estabtished 
TgBSH1, and 04-155-4 was a female mouse and estabtished TgBSH2. Another male 
mou se 04-151-6 was mated to 3 wild-type females and appeared to produce a single 
offspring with the transgene. This mouse was subsequently rebred to more wild-type 
mice and produced occasional mouse pups containing the transgene. When one of 
these pups had reached breeding age, it was crossed with a wild-type mouse and 
produced the expected number of offspring containing the transgene. This mouse 
was then used to establish another transgenic line TgBSH3. 
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Figure 4.3: Map of pGL3 ALuciferase with Beix promoterlSHaPrP 
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Construct N ame: BeIx -promoter -SHaPr P-pG L3~Luciferase 
Construct size: 5109 bp 
Constructed By: Paresa Giannopoulos, Heather Ternan, Qi Guo (SHaPrP), and 
Bclx-SHaPrP 
Bclx-promoter-
SHaPrP-
pGL3L\Luciferase 
5109 bp 
6\140 I .. ~t€ :=', 
poIy(A) ii9'la l ! 'AfA (for 1[!C+ reporter) :; 
Hik'i 1 190'2 ~ 
GGTACCGAGCTCTTACGCGTGCTAGCCCGGGCTCGAGATCTGCG~AAGT~TTGG 
1 ~~n.1 Il ~~c! 1 1 l't.'fJol 'l N!#f01 l 'xuJ... ... Il X"~I log/ll' 'H,nr.:J1I1 1 
.... \c.-c.6f:, 1 Srna 1 
fuç·#· CadlnQ Rog/Of:,oq 
~tA .. t ... 
SV40 l 
E..~~.!l~ 
BglII 
CATTCCGO""""ACTGTTGGTAAAGCCACCATGG.AAGACGCCAAAAACATAAAG _ (18a2bp) . GGATCCGTCGAC 
( ! l " 1 BR/oH 1 SalI 
RVprirnoc4 
Malcolm Gains 
Constructed Date: October 2003 (Final) 
Comments/references: Vector does not contain Luciferase . Unique RE sites: Nhel 
(position 1965), Sad (position 13), and Xhol (position 1976) 
VectorSize: pGL3DeitaLuciferase 3131 bp 
Insert Size: BeIx-promoter-SHaPrP 1978 bp 
Site of Cloning: Between bases Sad at position 13 and Nhel at position 1965 
Cloning Procedure: 
I-Digestion of pGL3-bm-Bclx-promoter (Nhel + BglII), releasing Bclx-promoter 
(1200 bp) 
2-Digestion of PBKS-SHaPrP (BglII + Xhol), releasingSHaPrP (800 bp) 
3-Ligation of BeIx-promoter-SHaPrP and PCR amplification 
4-Digestion of PCR product (Nhel + Sad) and pGL3DeitaLuciferase (derived from 
pGL3-basic; Luciferase removed using Ncol + Xbal) , ligation. 
Antibiotic Resistance: Ampicillin 
Gene Bank Accession# 
In case of any question, contact Dr. Andrea LeBlanc. Tel.: (514)340-8222 ext.4976 
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Figure 4.4: Map of pBKS-Bclxpromoter/SHaPrP 
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M1:3~ ...... b ...... 1111 T1p1_........... liCpI ... ,b ........ .. 
!l!P 11'l61 ':::,1 ~109' ri ' ...... 0 ri ~'I r"1 r"V ~ltdlll,.1 t" t"1 ~.I t,,1 
...... IeTAGTGlGATyCCŒoGCTœ-*GG.U.n~TATCAAGCTTAT~TAC(lQ~lllGMN~TACC ..... 
"c3C pl.............. ii'S p .... ,IM ....... 
Construct Name: PBKS-Bclx-promoter-SHaPrP 
Construct size: 4836 bp 
Constructed by :Paresa Giannopoulos, Malcolm Gains 
Constructed date: November 2003 
Comments/references: Bclx-promoter-SHaPrP inserted between XhoI and Sad 
Vector size: 2864 bp (pBKS) 
Insert size : 1972 bp (Bclx-promoter-SHaPrP) 
Antibiotic resistance: Ampicillin " 
Gene Bank Accession # 
Cloning Procedure: Both pBKS and Bclx-promoter-SHaPrP-pGL3DeltaLuciferase 
vectors were digested using Sad and XhoI. Bclx-promoter-SHaPrP insert was then 
ligated into pBKS. 
In case of any question, contact Dr. Andrea Leblanc. Tel. (514) 340-8222 ext.4976 
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Sad 
Bclx-
promoter 
SHaPrP 
XhoI 
Legend Figure 4.5; Autoradiogram of immunoprecipitation with R1SS antibody 
from N2a celllysate to verify PrP expression under the murine Beix promoter. 
Immunoprecipitates were run on a 15% polyacrylamide gel. N2a cells were 
transfected with the empty vector (pGL3Ôluciferase), the vector plus the transgene 
(pGL3ÔluciferaseBclx-SHaPrP), or a vector containing GFP respectively (pEGFP). 
The signais present in aIl 3 lanes correspond to PrP. 
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Heterozygous Tg(BSHt
'
- mice were crossed with heterozygous Bclx+'- mice to 
generate the required Tg(BSHt'+Bclx+'- mice that will be crossed to generate the 
required Tg(BSHr'+Bclx-'- mice to test the hypothesis that the expression of Syrian 
Hamster PrP under the mouse Bclx promoter will prote ct against Bax-mediated cell 
death in mice that are lacking the natural antagonist for Bax during development. 
The 8 breedings required to generate the mice with the appropriate background are 
tisted in Figure 4.6 below. 
These breedings are repeated for each of 3 lines with a great deal of attention paid to 
make certain that the tines do not have any possibility of becoming mixed. Breeding 
1 (see Figure 4.6 below) is to cross the founder mice, which are on an FVB Hybrid 
background onto a C57BI6 background, and also generate adequate numbers of 
heterozygous Tg(BSHt'- mice and confirm that the founder mice are carrying the 
transgene in their germ cell tines and are not chimeric mice. Breeding 2 (see Figure 
4.6 below)is to cross heterozygous mice to generate homozygous Tg(BSHr'+ mice. 
These mice are screened with quantitative PCR to identify possible homozgyous 
animais that are subsequently crossed with Wild-type mice to confirm their 
homozygous status in Breeding 3. In breeding 4, confirmed homozygous Tg(BSHt
'
+ 
mice are crossed to generate adequate numbers of homozygous mice carrying the 
transgene. Breeding 5, heterozygous Tg(BSHt
'
- that also contain the Bclx+
'
-
knockout allele (progeny of Breeding 3) are then crossed to homozygous 
Tg(BSHt'+Bclx+
'
+ mice (progeny of Breeding 4) in order to generate homozygous 
Tg(BSHt'+ that also contain the Bclx+'- knockout allele. These animais are screened 
with quantitative PCR to identify likely Tg(BSH)+I+ mice and conventional PCR to 
identify those that also contain the Bclx+'- and the mice thought to be of the correct 
genotype are then crossed to Wild-type mice i.e. Tg(BSHr/-Bclx+'+ mice to confirm 
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Legend Figure 4.6; Breeding strategy to generate TgBSH+'+Bclx°'o mice. 
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1. Tg(BSHt'- X Wild-type Tg(BSHr/-
2. Tg(BSHt'- X Tg(BSHt/-
3. Tg(BSHt/+ or Tg(BSHt'- X Tg(BSHr/-Bclx+'-
4. Tg(BSHt'+ X Tg(BSHt'+ 
5. Tg(BSHt'-Bclx+'- X Tg(BSHt'+Bclx+'+ 
6. Tg(BSHt'+Bclx+'- X Tg(BSHr/-Bclx+'+ 
7. Tg(BSHt'+Bclx+'- X Tg(BSHt'+Bclx+'+ 
8. Tg(BSHt'+Bclx+'- X Tg(BSHt'+Bclx+'-
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the Tg(BSHt/+ homozygous status of the parent. Confirmed homozygous 
Tg(BSHt/+BeIx+/- mice are then crossed to homozygous Tg(BSHt/+BeIx+/+ mice in 
order to generate adequate numbers of Tg(BSHt/+BeIx+/- mice to cross with each 
other for the experiment (Breeding 8). In breeding 7, Tg(BSHt/+BeIx+/- male mice to 
be used in the cross are preferred as their fertility is less affected than the same 
genotype of female mice (BeIx+/- mice have reduced fertility, especially the females 
(Dr. Kevin Roth, personal communication) and so they are bred to wild-type mice to 
generate the number of BeIx+/- mice that are required for crossing with the TgBSH 
mice above). Therefore, the Tg(BSHt/+BeIx+/+ mice used in breeding 7 should be the 
females. Breeding 8 will generate the anticipated Tg(BSHt/+BeIx-/- genotype, which 
is required to test our hypothesis. 
A figure containing PCR results at various stages of the breeding program are shown 
below (see Figure 4.7). In Figure 4.7 panel A, two heterozygous TgBSH+/- mi ce were 
crossed to yield offspring that are either homozygous for the transgene (TgBSH+/+), 
heterozygous (TgBSH+/-) or wild-type (TgBSR/) in a 1:2: 1 ratio. AlI mice contain a 
single copy (in each strand of DNA) of the mouse ring finger housekeeping gene 
(Mrf-1). The ratio of the TgBSH product (890 bp) to the Mrf-l product (565 bp) 
allows us to identify mice with the highest ratio, which are considered to be suspected 
homozygous for the transgene (TgBSH+/+). In panel A, A2, A3 and A5 aIl contain the 
transgene. In Figure 4.7 panel B, a suspected homozygous male TgBSH+1+? (5369) 
was backcrossed to a female mouse T gBSR/- (7031) and aIl of the offspring Alto A 7 
contain the transgene. This confirms that 5369 is TgBSH+/+. In Figure 4.7 panel C, 
the homozygous BeIx+/+ male mouse (5669) was crossed to female BeIx+/- mouse 
(7031) and the offspring Alto A 7 checked for the presence of a 600 bp PCR product, 
which corresponds to the BeIx knockout alleie. Therefore, A3, A5, A6 and A 7 aIl 
contain the knockout allele and so are Bclx+/-. The other products shown in Figure 4.7 
panel C are non-specific products that appear whenever the target DNA sequence is 
not present in the genomic DNA. In Figure 4.7 panel D, wild-type BeIx+/+ mice were 
crossed (7011 male crossed to 5125 female) and aIl of the offspring contain a PCR 
product at 400 bp, which corresponds to the BeIx alleie. This PCR reaction is used in 
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tandem with the reaction shown in panel C to confirm heterozygosity of Bclx and also 
confirm the quality of the DNA extracted from the mice. Using these PCR reactions, 
the genotype of aIl of the mice used in the experiment are confirmed. 
At this point, TgBSHI mice are at breeding 7, where Tg(BSHt'+Bclx+'- mice have 
been screened by quantitative PCR for likely homozygosity and then backcrossed to 
wild-type mice (Tg(BSR/-)Bclx+'+ mice to confirm their homozygous TgBSH status 
and heterozygous Bclx+'- status. A male is being bred to a TgBSHI +'+Bclx+'+ female 
mice to generate adequate numbers of TgBSHI +'+Bclx+'- mice to be used for breeding 
8. Breeding 8 will result in TgBSHI +'+Bclx-
'
- offspring. Sorne of these breedings will 
be allowed to go to termination and offspring kept to see if the presence of the 
transgene rescues the embryolethal phenotype of the Bclx-'- mice. In addition, the 
female parent will be euthanized at embryo day 12 and the offspring genotyped and 
examined quantitatively for neuronal death. The neuronal death will be compared to 
Tg(BSHr/-Bclx-'- (positive control), Tg(BSHr/-Bclx+'+ (negative control) as weIl as 
other transgenic mice generated i.e. Tg(BSHt'+Bclx+
'
- and Tg(BSHt'-Bclx+'- and 
Tg(BSHt'-Bclx-'- mice. The second line of mice TgBSH2 is currently at breeding 3. 
Heterozygous mice TgBSH2+'- have been crossed and possible homozygous offspring 
identified by quantitative PCR. Likely homozygous animaIs have been backcrossed 
to wild-type mice (breeding 3) and thus far, one male mou se and one female mouse 
have been confirmed as homozygous Tg(BSH)2+
'
+. This line has however, had 
problems breeding with smaIllitters, and very high post-natal mortality, leading us to 
suspect that the homozygous state may have seriously reduced fertility_ The third line 
of mice TgBSH3 as it began from a chimeric mouse, is only at breeding 2, where 
heterozygous TgBSH3+
'
- mice have been identified and are being crossed to establish 
a homozygous line. These offspring are being screened by quantitative PCR and will 
be subsequently crossed as in breeding 3 to confirm their homozygous status_ Based 
on the time that is required for the generation of the mice, 1 would expect that it will 
be another 18 months before adequate mice are available from aIl 3 lines to test the 
hypothesis. 
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4.4.5 Protein Expression 
The mice selected for use in the protein expression experiments were approximately 
20 weeks of age, which corresponds to the time of maximum Bclx mRNA (Grillot et 
al. 1997). Sorne of the protein expression results are shown in Figure 4.8 and Figure 
4.9 below. 
In Figure 4.8 panel A, immunoprecipitation results are shown. In the far right lane 
i.e. SHaPrP + Null Control lane, the signal from large amounts of SHaPrP is present 
as a smear between the 26 kDa and 36 kDa markers. However, no SHaPrP signal is 
present in the TgBSH1, TgBSH2, PrP+1+ or PrpO/O lanes. In Figure 4.8 panel B, the 
western blot results are shown. In the far right i.e. SHaPrP + Null Control lane, the 
signal from a large amount of SHaPrP is present as a smear between the 26 kDa and 
36 kDa markers. However, no SHaPrP signal is present in the TgBSH1, TgBSH2, 
PrP+1+, or PrpOlO lanes. These results indicate that the TgBSH1, TgBSH2, Prp+/+ and 
PrpO/O mice are not expressing SHaPrP at a level that can be detected either by 
immunoprecipitation with 3F4 antibody or by western blotting with 3F4 antibody. 
A previous experiment using immunoprecipitation of 1000 !Ag of protein from a 
SHaPrpOexp mouse brain yielded a less intense signal than a western blot of 100 !Ag of 
brain protein from the same sample (data not shown). Therefore, we decided to 
continue to check protein expression using western blots. Dr. Lingappa's laboratory 
kindly provided us with an antibody (13A5) that is specific for SHaPrP and does not 
recognize either human PrP or mou se PrP. Results in our laboratory have confirmed 
that this antibody is specific for SHaPrP and provides excellent results when used for 
western blots. Therefore, subsequent experiments to demonstrate protein expression 
used this antibody. 
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Legend Figure 4.7; PCR amplification from mouse genomic DNA to confirm 
mouse genotypes. Run on 1 % agarose gels, stained with ethidium bromide. 
Panel A; The first litter of TgBSH+'- male mouse (5398) crossed to a TgBSH+'- female 
mouse (5395) producing offspring Al to A5. The product at 565 bp corresponds to 
Mouse Ring Finger 1 (Mrf-1) housekeeping gene and is present in aIl mice. The 
product at 890 bp corresponds to the transgene (T gBSH). A2, A3 and A5 aIl have a 
product at 890 bp and so contain the transgene. A 1 and A4 do not have a product at 
890 bp and do not contain the transgene. Panel B; The first litter of a suspected 
homozygous transgenic male mouse (5369) backcrossed to a wild-type female mouse 
(7031). AIl of the offspring Alto A 7 contain a product at 565 bp corresponding to 
the Mrf-1 housekeeping gene and a product at 890 bp corresponding to the transgene 
(TgBSH). Panel C; The first litter of a Bclx+'+ male mouse (5369) crossed to a Bclx+'-
female mouse (7031). Offspring A3, A5, A6 and A7 all have a product at 600 bp, 
which corresponds to the Bclx knockout alleie. Offspring Al, A2 and A4 do not have 
a product at 600 bp and so do not contain the knockout alleie. Panel D; The first 
litter of a wild-type male mouse (Bclx+'+ 7011) crossed to a wild-type female (Bclx+'+ 
5125). AlI of the offspring (Al to A8) contain a product at 400 bp, which 
corresponds to the Bclx alleie. 
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In Figure 4.9 panel A, the results of the western blot probed with 13AS antibody are 
shown. In the far right lane Le. SHaPrP + Null Control lane, the signal from a large 
amount of SHaPrP is present as a smear between the 26 kDa and 36 kDa markers. 
However, no SHaPrP signal is present in the TgBSHl, TgBSH2, TgBSH3, PrP+/+, 
PrpOlO or empty lanes. In panel B, the expression of mou se beta-actin is present in ail 
of the lanes that were loaded with mou se brain protein extract, as a loading control. 
These results indicate that the TgBSHl, TgBSH2, TgBSH3, PrP+/+ and PrpOlO mice are 
not expressing SHaPrP at a level that can be detected by western blotting and probing 
with 13AS antibody. 
4.4.6 Messenger RNA extraction 
As outlined in the methods section 4.3.2.1.2 Messenger RNA extraction, mRNA was 
extracted from transgenic mou se brains, reverse transcribed to cDNA and the cDNA 
amplified by PCR to verify the presence of SHaPrP mRNA. Unfortunately, initial 
experiments did not yield definitive results either demonstrating the expression of or 
demonstrating the absence of the ShaPrP mRNA, due to contamination with genomic 
DNA. Subsequent experiments are ongoing, and at the present time, have also not 
yielded definitive results. 
182 
Legend Figure 4.8; Immunoprecipitation and western blot of brain protein 
extracts to verify expression of SHaPrP protein in transgenic mice. Run on 15% 
polyacrylamide gels. 
Panel A; Immunoprecipitation of SHaPrP with 3F4 antibody from brain prote in 
extracts from the first 2 lines of transgenic mice (TgBSH1, TgBSH2), as weIl as 
PrP+'+, PrpOlO negative controls and a SHaPrP protein expressing positive control. The 
signal in the positive control lane (SHaPrP + Null control) corresponds to SHaPrP. 
Panel B; Western blot of SHaPrP probed with 3F4 antibody from brain protein 
extracts from the first 2 lines of transgenic mice (TgBSH1, TgBSH2), as weIl as 
PrP+'+, PrpOlO negative controls and a SHaPrP protein expressing positive control. The 
signal in the positive control lane (SHaPrP + Null control) corresponds to SHaPrP. 
For each western blot 100 ~g of protein was loaded per lane, for the positive control 
98 ~g of PrpO'o brain protein and 2 ~g of SHaPrP brain protein was loaded. 
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Legend Figure4.9; Western blot probed with 3F4 antibody, of brain protein 
extracts to verify expression of SHaPrP protein in transgenic mice. Run on a 
15% polyacrylamide gel. 
Brain protein extracts from three lines of transgenic mice (TgBSH1, TgBSH2, 
TgBSH3), as weIl as PrP+1+, PrpO/O negative control s, an empty lane and a SHaPrP 
protein expressing positive control. Panel A; The signal in the positive control 
(SHaPrP + Null control) lane corresponds to SHaPrP. Panel B; The signal present in 
aIl lanes where protein has been loaded corresponds to mou se beta-actin. For each 
lane, 100 fAg of protein was loaded. For the positive control, 98 fAg of PrpO/O protein 
and 2 fAg of SHaPrP protein was loaded. 
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4.5 Discussion 
Our results demonstrate that the transgene promoter is active in vitro, and the 
transgene construct does not contain any mutations. In Figure 4.5, the results of an 
autoradiography experiment in N2a cells are shown. RISS antibody does not 
discriminate between mouse and hamster PrP and so N2a cells were selected, since 
they express very little endogenous mou se PrP, which is confirmed when transfected 
with the empty vector. The PrP promoter has a heat shock element within it, and so 
we would expect that cells stressed by being transfected with pEGFP to produce a 
foreign protein may express more PrP than background, as is the case here. N2a cells 
transfected with the vector containing the transgene express more PrP than either the 
empty vector or the transfection control. This increased PrP is therefore the product 
of the transgene and corresponds to SHaPrP. This experiment confirms that the 
transgene is expressed in vitro in mouse N2a celIs, albeit at low levels. We therefore 
felt confident that the construct was adequate to progress to the creation of the 
transgenic mouse. 
The transgene has been injected into embryos and 3 tines of transgenic mice created. 
These mice are currently in various stages of breeding to generate the final breeding 
of Tg(BSHr/+Bclx+
'
- X Tg(BSHr/+Bclx+
'
- to generate Tg(BSHr/+BeIx-
'
- mice in order 
to test our hypothesis that expression of SHaPrP under the murine BeIx promoter will 
rescue neuronal death in BeIx-'- mice. Unfortunately, the results do not confirm the 
presence of SHaPrP in brain protein extracts at the level of sensitivity of a western 
blot in aIl 3 tines or at the level of sensitivity of an IP in lines 1 and 2. Within the 
celI, gene expression is regulated at many steps. Perhaps most importantly, it is 
regulated at the level of transcription, but can also be regulated at the level of RNA 
processing (e.g. splicing), RNA transport into the cytoplasm or even in selecting 
which mRNAs in the cytoplasm are translated (Darnell et al. 1982). The stability of 
the mRNA is obviously another factor in regulating the amount of protein that is 
produced (Darnell et al. 1982). Our findings suggest that either via one or more of 
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these mechanisms, the amount of protein produced is below the level of detection by 
a western blot or that the promoter is very weak and it does not promote the 
generation of enough protein to be detected on a western blot. The original work 
identifying the sequence and activity of the mou se Bclx promoter was by Grillot et al. 
(1997) and in this paper, only the mRNA and not protein expression was reported. 
Roth et al. (1999) reported BclxL protein expression in vivo VIa 
immunohistochemistry in mouse embryos at EI2.5. They found that the protein was 
expressed diffusely in immature but post-mitotic neurons and not in neuronal 
precursors still capable of mitosis. Gonzalez-Garcia et al. (1994) also reported that 
mRNA is present in both the developing mouse brain and in the mature nervous 
system. These findings suggest that it may be more efficient to demonstrate tissue 
expression of BclxL by mRNA and that protein expression may be at a very low level. 
This suggests that the promoter may in fact be very weak in the brain in vivo. 
The weakness of the promoter is of considerable significance for the rest of the 
project. The Bclx-I- mice have massive neuronal death at embryo day 12 (Motoyama 
et al. 1995), however, the se mice are also PrP+1+. The expression of PrP is easy to 
demonstrate by western blot from brain homogenate in mice (see Figure 2.3) and this 
high background level of PrP is insufficient to protect the neurons in the Bclx-I- mice 
from Bax-mediated cell death. Therefore, if we add to this, SHaPrP at the level of 
expression driven by the murine Bclx promoter, which we cannot detect via a western 
blot, it seems unlikely that we will be adding enough PrP to the transgenic mice to 
test our hypothesis. 
It appears that BclxL is diffusely expressed in immature but post-mitotic neurons in 
the developing nervous system (Roth et al. 1999), and is therefore able to counteract 
the effect of Bax when it is expressed to induce apoptotic death of neurons that fail to 
make appropriate synaptic connections during the period of synaptogenesis, however, 
the endogenously expressed PrP may not be expressed in a similar manner. Mironov 
et al. (2003) have demonstrated that cytosolic PrP is only present in a subset of 
neurons in the adult mou se brain. It is therefore possible, that levels of endogenous 
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mou se PrP may be very low in neurons that fail to make the appropriate synaptic 
connections in the developing nervous system and if so, perhaps only a very smaU 
amount of PrP expressed under the Bclx promoter may be enough to have a 
neuroprotective effect at the critical stage. 
In order to determine if a low level of expression of PrP under the Bclx promoter at 
the appropriate stage of development may be enough to prevent neuronal apoptosis, it 
will be necessary to breed each of the 3 transgenic lines to breeding 8, 
Tg(BSHt+Bclx+
'
- X Tg(BSHt'+Bclx+'- and examine the Tg(BSHr'+Bclx-'- offspring. 
This is expected to take another 18 months to complete. 
4.6 Conclusions 
At this point, we have cloned and tested the efficiency of the murine Bclx promoter in 
vitro in N2a and HEK293 ceUs. We have sequenced the Bclx promoter-SHaPrP 
cDNA construct and found that there were no mutations generated in the cloning 
procedure. We have transfected N2a ceUs and have shown expression of SHaPrP. In 
addition, we have generated 3 lines of transgenic mice containing the transgene 
construct. These 3 lines are at various stages of breeding towards generating 
TgBSH+'+Bclx-'- mice in order to test our hypothesis that SHaPrP expressed under the 
murine Bclx promoter will protect neurons from Bax-mediated ceU death during 
embryonic development. Unfortunately, we have not been able to demonstrate the 
presence of SHaPrP in brain protein extracts in our transgenic mice, at the level of 
detection of a western blot. This does not necessarily me an that the protein is not 
expressed, only that if it is expressed, it may be so at a level below the sensitivity of a 
western blot. We do not know if expression of the protein at this level will be 
protective or not. There is the possibility that only a smaU amount of protein 
expressed at the right time may be enough to have a significant effect. 
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We have attempted to check brain extracts for rnRNA generated from our transgene 
construct. Thus far, due to contamination with genomic DNA, we have not been able 
to confirm the presence or absence of mRNA. These experiments are ongoing. 
The expression of BclxL has been confirmed in vivo in the mou se in post-mitotic 
neurons via immunohistochemistry. Therefore, it would seem logical to attempt to 
demonstrate the expression of SHaPrP in vivo via immunohistochemistry, to see if it 
is present in the transgenie mouse brains. There are currently 2 available antibodies 
that are able to discriminate between the endogenous mouse PrP and our introduced 
Syrian Hamster PrP (3F4 and 13A5). 
In addition, it is also possible to transfect cell lines with the transgenic construct and 
examine them for the presence of mRNA via RT -PCR. This would not tell us if the 
transgenic miee are expressing mRNA but would provide more confidence that the 
mRNA may be there at low levels. Obviously, the process of sacrificing a mouse, 
removing the brain and homogenizing it to extract the mRNA and subsequent reverse 
transcription to cDNA is not 100% efficient and so there is a threshold of mRNA that 
must be there in order to be detected. We do not know if a small number of copies, 
below the threshold of detection, could have an impact on Bax-mediated cell death. 
Another possibility is to use in situ hybridization using a probe to detect mRNA from 
the transgene. This could be done on tissue sections from the brain and is also a very 
sensitive technique available to detect mRNA. However, due to the effect of fixation 
and tissue preparation for in situ hybridization, it is also not a 100% efficient and so 
there would be a threshold level of mRNA required to be detected. 
Therefore, for the transgenic expression of SHaPrP under the murine BeIx promoter 
in miee experiment, we cannot make any firm conclusion regarding the effect of 
SHaPrP against developmental physiologie neuronal death. Further experimentation 
is required to confirm that the transgene is being expressed and further breeding is 
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required to obtain the required genotype to test our hypothesis that SHaPrP protects 
against Bax-mediated cell death in the developing mouse brain. 
Chapter 5 General Conclusions 
The prion protein is a highly conserved, widely expressed protein that is a critical 
component of, or perhaps the only component of an infectious agent that is associated 
with neurodegenerative diseases. These diseases are classified as acquired, sporadic 
or if associated with familial mutations in the prion protein, familial in humans. 
Similar diseases of acquired form have been identified in a wide variety of 
mammalian species. The recent epidemic of Bovine Spongiform Encephalopathy in 
Europe has been linked to approximately 200 cases of fatal neurological disease in 
humans and attests to the transmissibility of the disease. Despite the recognition that 
a normal ho st protein, PrpC is a critical component of the infectious agent over 20 
years ago, it is still unknown how this normal protein either causes or contributes to 
the pathogenesis of the disease, only that an abnormal form of the protein is 
associated with the disease. Surprisingly, it is also unknown what physiological role 
this protein plays in the organism. 
A basic tenet of pathology, is that in order to understand abnormal you must have a 
good understanding of normal. In other words, in order to understand the 
pathogenesis of the transmissible spongiform encephalopathies, it is logical to have a 
good understanding of the physiological function of Prpc. We should keep in mind 
that somewhere during its normal "life" cycle, Prpc is subverted to become a protein 
with partial resistance to proteinase K and detergents, which is associated with 
uniformly fatal neurodegenerative disease. Over 20 years of intense investigation has 
thus far, not elucidated the pathogenesis of the disease. In my opinion, part of the 
reason lies in the predominant focus on the middle of the pathway i.e. conversion of 
PrpC to Prpes rather than the beginning of the pathway, the physiological role of Prpc. 
Starting at the beginning makes more sense th an starting somewhere in the middle. 
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Numerous studies have investigated potential roles for Prpc in vitro. These potential 
roles indude; copper metabolism and a role as an anti-oxidant, a role in signal 
transduction and growth, a role in regulating calcium metabolism and regulating 
neuronal activity, a role in nucleic acid binding, and a role in cell survival as a natural 
antagonist of Bax, which is the focus of this thesis. 
Observations in primary neuronal cultures and certain neoplastic cell lines in our 
laboratory have demonstrated that PrpC is able to protect against Bax-mediated cell 
death in these in vitro systems. Thus far, nobody has definitively confirmed a role for 
Prpc in vivo, although transgenic mou se studies indicate that the reintroduction of 
PrpC provides neuroprotection in sorne mutations. Our objective was to test the 
hypothesis that Prpc protects against Bax-mediated cell death in vivo. We planned on 
testing our hypothesis using two paradigms. The first paradigm involved an external 
stimulus i.e. ethanol injection to stimulate Bax-mediated cell death. The second 
paradigm involved a physiologic stimulus i.e. developmental Bax-mediated cell 
death. 
Using the first paradigm, we found that ethanol injection stimulates large amounts of 
neuronal death and we noted a trend that the PrpOlO mice had more neuronal death than 
the Prp+/+ mice, although the difference between genetic backgrounds was not 
statistically significant. This variability may be due to individual mou se variation, 
possible differences in maturity among mice, possible differences in the peak of Bax 
activation and subsequent caspase 3 activation, which we were using as an end point, 
and also the possibility that the ethanol injection may induce more Bax activation 
than the endogenous Prpc can protect against or that Prpc may only be present at high 
enough levels in a subset of neurons. 
We subsequently examined the first paradigm using a different end point i.e. Bax 
activation directly or mitochondrial cytochrome c release as a marker of apoptosis. 
Again, we were not able to detect specific trends. We now believe that our model 
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using ethanol injection to induce Bax-mediated cell death may not be ideal to 
evaluate the possible neuroprotective role of Prpc against Bax-mediated cell death. 
We now know that in vitro Prpc only protects against Bax-mediated cell death and 
not against Bak or tBid-mediated cell death, and we do not know if ethanol also 
induces cell death via Bak or tBid. It is also possible that the ethanol insult may 
induce more Bax than endogenous PrpC can protect against. However, our in vivo 
results are consistent with numerous in vitro studies that show a potential 
neuroprotective role for Prpc. We believe that the trend that we have observed is 
biologically significant, although not statistically significant using our paradigm. 
The second paradigm involves creating a transgenic mou se expressing Prpc under the 
mouse BeIx promoter in the absence of endogenous BeIxL and protect neurons from 
developmental Bax-mediated cell death. In this paradigm, both Prpc and Bax should 
be expressed at physiologic levels. At this point, we have created 3 lines of mi ce 
carrying the transgene (murine BeIx promoter and SHaPrP cDNA) and they are in 
various stages of breeding to generate the Tg(BSHtl+BeIx-'- genotype that we will 
need to test our hypothesis that Prpc expressed under the BeIx promoter will protect 
against developmental Bax-mediated neuronal death. We thus far have not been able 
to definitively demonstrate either protein expression or mRNA from the transgene in 
vivo. Further experiments to demonstrate mRNA in vivo via RT -peR, to demonstrate 
protein via immunohistochemistry in vivo or to demonstrate mRNA in vivo via in situ 
hybridization are being considered. 
The work presented in this thesis highlights sorne of the problems inherent with in 
vivo studies. With in vitro studies, the experimenter has more direct control over the 
experimental conditions, whereas in vivo studies do not allow the same degree of 
control. For example, the researcher has to attempt to standardize ages of the mice 
and time from experimental treatment to sample collection, but has no control over 
other factors that may affect the results, such as relative maturity of the mice, relative 
stress experienced by the mice etc. Therefore, variability among mice is an inherent 
problem with in vivo studies, which is particularly evident in these studies. 
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More information is now available regarding the role of Prpc against Bax, which was 
not available at the beginning of the study. For example, results in our laboratory 
suggest that cytosolic PrP may be the protective moi et y, however, we now know that 
cytosolic PrP is only present in a small subset of neurons in the mou se brain, at least 
in mature mice. Based on work in our laboratory, Prpc may be protecting via an as 
yet unknown signal transduction pathway, and so a more specific insult may be a 
better model. We have also found that PrpC protection is specific for Bax and we do 
not know if ethanol induced neuronal death is also specific for Bax or if it also 
induces tBid or Bak-mediated cell death. The testing of the hypothesis that PrpC 
protects against Bax-mediated cell death was entirely appropriate at the beginning of 
this work, however, as new information is available, it may be that more detailed 
knowledge of the role of Prpc against Bax is required to select the most appropriate 
model to test it. 
Recently, work in our laboratory has suggested that the interaction between PrP and 
Bax is an indirect one, mediated via an as yet unidentified signaling pathway. In 
future in vivo experiments, it would be worthwhile pursuing our hypothesis with a 
more specific experimental paradigm. It may be possible to find a proapoptotic 
stimulus that involves a pathway that may be inhibited by PrP. If so, this would 
provide us with both a specific stimulus and a limited number of proteins that could 
be specifically evaluated to test our hypothesis. For example, recent evidence 
suggests that the ethanol insult increases JNK kinases and decreases Akt, Erk1l2 and 
PKAa kinases and the authors proposed that this results in phosphorylation of Bad 
and its release from 14-3-3, which binds to Bclx and thereby removes sorne of the 
inhibition of proapoptotic Bax (Han et al. 2006). If future results in our laboratory 
suggest that PrP is protecting via a similar effect of kinases and the release of Bad etc, 
this may provide a more refined paradigm to test our hypothesis in vitro and then in 
vivo. The work of Han et al. suggests that these kinases can be measured in ex vivo 
mouse brains (they did not report Bax directly or cytochrome c). If a specific 
stimulus is available that can produce a specific effect in vivo, for example, 
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phosphorylation of Bad, we may be able to confirm both that PrP protects against Bax 
in vivo and the mechanism by which it might accomplish this. 
Clearly, any future studies with the transgenic mice that we have created depend on 
first demonstrating the presence of the protein. As previously discussed, 
immunohistochemical staining is likely the most practical way of doing so. If the 
protein is expressed and protects against Bax-mediated neuronal death at E12, then 
we have proven our hypothesis. Potential complicating factors such as level of 
expression and regional differences in expression of PrP and Bax will also make any 
result that is not definitive difficult to interpret. If protein expression cannot be 
demonstrated, it may be difficult to relate any differences noted between groups to 
PrP and either prove or disprove our hypothesis. 
In my opinion, the work presented in this thesis shows a trend that supports our 
hypothesis that PrP protects against Bax-mediated cell death in vivo, but does not 
prove it. The work demonstrates that there is a great deal of variability inherent in in 
vivo studies and that our experimental paradigms need to be refined in order to 
adequately test the hypothesis. 
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Appendix 1 
Mouse genotyping using tail DNA by Polymerase Chain Reaction (PCR) 
For detecting: 730 bp aminoglycoside phosphotranspherase allele 
880 bp wild-type mouse Prnp allele 
Primer sequences: 
RK1: 5' TCAGCCTAAATACTGGGCAC 
RK2: 5' GCCTAGACCACGAGAAATGC 
RK3: 5' GCATCAGCCATGATGGATAC 
Working solution ofRK1:RK2:RK3 
For 10 20llL reactions: 
Master Mix: 
Distilled water 
lOX PCR Buffer 
10X dNTP (2mM) 
50 mM MgC12 
10X primer mix (1 OIlM) 
DNA Polymerase 
3' 
3' 
3' 
1:1:1 
20 ilL added to each reaction tube and 1 ilL of DNA extracted from the tail (DNA < 1 
Ilg/IlL) 
Conditions: 
94°C 3 minutes 1 cycle 
94°C 15 s 62°C 15 s 2:30 42 cycles 
72°C 7 minutes 
4°C soak 
222 
Appendix 1 continued 
For detecting: 530 bp fragment of ShaPrnp transgene allele 
Primer sequences: 
DW190: 5' GCCfTTGAATTGAGTCCATCACGGGCCA 3' 
DW191: 5' 
GGCCGCGGAGAAATGAAGAAACGCCAAGCGCCGTGACf 3' 
Working solution of each primer 10 f!M 
For 8 20f!L reactions: 
Master Mix: 
Distilled water 
lOX PCR Buffer 
10X dNTP (2 mM) 
50 mM MgCl2 
DW190 (10 f!M) 
DW191 (10 f!M) 
DNA Polymerase 
19 f!L added to each reaction tube and 1 f!L of DNA extracted from the tail (DNA < 1 
f!g/f!L) 
Conditions: 
94°C 3 minutes 1 cycle 
94°C 20 s 68°C 20 s 45 s 42 cycles 
72°C 7 minutes 1 cycle 
4°C soak 
223 
Appendix 1 continued 
For amplifying: 1200 bp portion of Murine BclxL promoter from mouse genomic 
DNA 
Primer sequences: 
NheIlBclx/-1207to-1179: 5' 
AAAGCf AGCGCCGCCfTGGGCfCGGCCfC 3' 
BglII/Bclx/-19to-46: 5' AAAAGATCfCfCAACCAGTCCATTGTCC 3' 
Working solution of each primer 10 !-lM 
For 2 50!-lL reactions: 
Master Mix: 
Distilled water 
lOX PCR Buffer 
dNTP (2.5 mM) 
NheIlBclx primer (10 !-lM) 
BglII/Bclx primer (10 !-lM) 
50 mM MgCl2 
DNA « 1 !-lg/!-lL) 
DNA Polymerase 
50 !-lL added to each of 2 reaction tubes 
Conditions: 
94°C 3 minutes 1 cycle 
62.6 !-lL 
94°C 1 minute 62°C 1 minute 72°C 
72°C 7 minutes 1 cycle 
4°C soak 
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2 minutes 42 cycles 
Appendix 1 continued 
For amplifying: 790 bp SHaPrnp from Tg(SHaPrnp)7 genomic DNA 
Primer sequences: 
BglII/HaPrP/-22to+1O: 5' 
AAAAGATCTGGGCTTTGTGGCTATGTGGACTG 3' 
XhoIlHaPrP/+79lto+755: 5' 
AAACTCGAGCCACAAGAACGAGGAAGTACAAGCAGGG 3' 
Working solution of each primer 10 flM 
For 3 40flL reactions: 
Master Mix: 
Distilled water 
lOX PCR Buffer 
dNTP (2.5 mM) 
BglII/HaPrP primer (10 flM) 
XhoIlHaPrP primer (10 flM) 
DNA « 1 flg/flL) 
12 flL 
9.6 flM 
6 flL 
6 flL 
6 flL 
40 flL added to each of 3 reaction tubes 
84.52 flL 
DNA Polymerase 0.6 flL added to each tube via hot start 
Conditions: 
94 oC 6 minutes 1 cycle 
94°C 1 minute 55°C 1 minute 72°C 40s 42 cycles 
72°C 10 minutes 
4°C soak 
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Appendix 1 continued 
For amplifying: 891 bp BclxSHaPrP transgene from Tg(BSH) genomic DNA and 
565 bp Mouse Ring Finger (Mrfl housekeeping gene) gene from mouse genomic 
DNA 
Primer sequences: 
TgBclx/SHaPrP-F: 5' CCCAT ACCTCCGTGAGAGTTCTCCTGACTCCCAG 3' 
TgBclx/SHaPrP-R: 5' GCCCCCATGTGCCGCCACCCTGAG 3' 
Working solution of each primer 1 f-tM 
ORP-Pl: 5' GGAAATGCACAATTTTGAGGAAGA 3' 
ORP-P2: 5' ACTGGAGAACGGCTTCCTTATCG 3' 
Working solution of each primer 10 f-tM 
For 17 20 f-tL reactions: 
Master Mix: 
DistiHed water 
Extract-N-Amp PCR Reaction Mix 
TgBclx/SHaPrP-F (1 f-tM) 
TgBclx/SHaPrP-R (1 f-tM) 
ORP-Pl (10 f-tM) 
ORP-P2 (10 f-tM) 
51 f-tL 
170 f-tL 
34 f-tL 
34 f-tL 
17 f-tL 
17 f-tL 
19 f-tL added to each reaction tube and 1 f-tL of DNA extracted from the tail (DNA < 
1 f-t g/ f-tL ) 
Conditions: 
3 minutes 1 cycle 
30 s 60°C 30 s 1 minute 42 cycles for 
genotyping, 33 cycles for quantitative PCR 
72°C 7 minutes 1 cycle 
4°C soak 
REDExtract-N-Amp PCR Reaction Mix (Sigma-Aldrich, St. Louis, Missouri) 
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Appendix 1 continued 
For amplifying: 600 bp Beix knockout allele from mouse genomic DNA and 400 
bp Beix allele from mouse genomic DNA 
Primer Sequences: 
Wild-type allele: 
NM4: 5' GTGCCATCAATGGCAACCCAT 3' 
NM5: 5' CCGCCGTTCTCCTGGATCCAA 3' 
Knockout allele: 
KO-1: 5' GCCT ACCCGCTTCCATTGCTCAGC 3' 
KO-4: 5' GAAACGCGGGGAGAACTTGCTGCTCTC 3' 
Working solution for each primer is 10 ~M 
For 10 20 ~L reactions: 
Distilled water 
Extract-N-Amp 
Primer 1 10 ~M 
Primer 2 1 0 ~M 
100 ~L 
lO~L 
lO~L 
19 ~L of reaction mix is added to each reaction tube with 1 ~L of DNA extracted 
from the tail ( < 1 ~g/~L) 
Conditions: 
5 minutes 1 cycle 
1 min 68°C 1 min 30 s72°C 1 min 42 cycles 
5 minutes 1 cycle 
soak 
The Wild-type allele reaction (NM4 and NM5) is mn separately from the knockout 
reaction (KO-1 and KO-4), as when they are mn together the reaction yields another 
band that is close in size to the KO product. 
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Appendix 2 
Individual mouse anti-active Csp3 cell counting data: 
al Number Genotype Treatment Section Replicate1 Replicate2 Replicate3 Animal Mean Animal Total Grol 
3197/319682 Null ethanol 3,1 124 107 124 118.33 950.97 
4,1 95 87 85 89 
5,1 106 106 94 102 
7,2 89 84 90 87.66 
8,1 74 82 79 78.33 
8,2 90 84 88 87.33 
9,1 119 120 109 116 
9,2 89 92 79 86.66 
10,1 133 135 114 127.33 
10,2 62 55 58 58.33 
3197/319681 Null ethanol 2,1 124 111 123 119.33 1283.97 
2,2 132 119 132 127.66 
3,1 84 78 90 84 
3,2 85 74 90 83 
4,1 149 154 147 150 
4,2 134 126 132 130.66 
5,1 124 119 115 119.33 
5,2 140 154 151 148.33 
6,1 158 180 166 168 
6,2 149 158 154 153.66 
3197/319686 Null ethanol 1,1 241 234 243 239.33 1794.29 
3,1 121 133 123 125.66 
3,2 95 92 89 92 
4,1 104 109 103 105.33 
4,2 86 92 88 88.66 
6,1 149 174 155 159.33 
8,1 358 327 330 338.33 
9,1 177 213 221 203.66 
10,1 267 284 311 287.33 
10,2 232 249 259 246.66 
3175/3168A1 Null ethanol 1,1 75 74 77 75.33 675.3 
1,2 65 50 46 53.66 
2,1 108 103 105 105.33 
2,2 68 73 72 71 
3,1 60 65 53 59.83 
4,1 82 81 81 81.33 
4,2 57 61 52 56.66 
9,1 58 66 60 61.33 
9,2 54 49 45 49.33 
10,1 75 74 77 75.33 
3175/316884 Null ethanol 2,1 53 58 55 55.33 681.64 
2,2 59 58 60 59 
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3197/3196B9 null 
4103/4101A4 null 
4104/4102A5 null 
4103/4101A2 null 
4104/4102A2 null 
ethanol 
ethanol 
ethanol 
ethanol 
ethanol 
8,1 
8,2 
9,1 
9,2 
10,1 
10,2 
11,1 
11,2 
1,1 
1,2 
2,1 
2,2 
5,1 
5,2 
7,1 
7,2 
9,1 
9,2 
1,1 
1,2 
3,1 
3,2 
5,1 
5,2 
7,1 
7,2 
9,1 
9,2 
1,2 
2,1 
2,2 
3,1 
4,1 
5,1 
5,2 
6,1 
10,1 
10,2 
1,1 
2,1 
5,1 
5,2 
6,1 
7,1 
7,2 
8,1 
8,2 
10,1 
1,1 
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58 
66 
125 
95 
57 
35 
83 
55 
72 
68 
56 
30 
58 
57 
68 
40 
77 
69 
40 
37 
31 
26 
75 
43 
54 
36 
36 
25 
36 
41 
36 
35 
31 
35 
39 
33 
34 
36 
33 
28 
55 
27 
27 
31 
38 
42 
35 
30 
25 
62 
57 
126 
108 
58 
33 
79 
55 
68 
72 
57 
32 
56 
63 
66 
39 
78 
66 
44 
39 
34 
28 
77 
47 
52 
36 
34 
21 
40 
40 
42 
39 
32 
39 
44 
38 
30 
30 
33 
22 
44 
25 
29 
27 
32 
42 
32 
40 
23 
57 
63 
110 
96 
62 
36 
69 
57 
65 
65 
56 
24 
62 
60 
60 
39 
75 
61 
40 
44 
29 
25 
73 
41 
51 
33 
30 
25 
36 
44 
41 
37 
38 
29 
32 
27 
31 
29 
31 
27 
54 
31 
32 
32 
30 
40 
32 
35 
24 
59 
62 
120.33 
99.66 
59 
34.66 
77 
55.66 
68.33 
68.33 
56.33 
28.66 
58.66 
60 
64.66 
39.33 
76.66 
65.33 
41.33 
40 
31.33 
26.33 
75 
43.66 
52.33 
35 
33.33 
23.66 
37.33 
41.66 
39.66 
37 
33.66 
34.33 
38.33 
32.66 
31.66 
31.66 
32.33 
25.66 
51 
27.66 
29.33 
30 
33.33 
41.33 
33 
35 
24 
586.29 
401.97 
357.95 
338.64 
350.62 
3,1 70 65 62 65.66 
3,2 33 36 37 35.33 
4,1 39 33 38 36.66 
4,2 29 31 32 30.66 
5,1 39 32 35 35.33 
6,1 32 33 37 34 
9,1 28 30 31 29.66 
10,1 31 25 24 26.66 
10,2 30 35 33 32.66 
3186/3180B1 lM. ethanol 3,1 109 99 110 106 639.64 
3,2 35 39 36 36.66 
4,1 65 57 59 60.33 
4,2 51 51 52 51.33 
6,1 88 89 85 87.33 
6,2 32 30 26 29.33 
7,1 75 68 64 69 
7,2 48 48 39 45 
10,1 84 81 85 83.33 
10,2 75 71 68 71.33 
3186/3180B4 lM. ethanol 1,1 129 130 134 131 947.65 
1,2 125 131 115 123.66 
2,1 85 89 90 88 
2,2 67 71 78 72 
4,1 86 72 73 77 
4,2 70 68 68 68.66 
5,1 72 88 83 81 
5,2 45 53 46 48 
7,1 150 143 136 143 
7,2 109 120 117 115.33 
3220/3187B2 lM. ethanol 1,1 201 193 182 192 1238.98 
1,2 155 147 142 148 
3,1 129 119 117 121.66 
3,2 104 109 102 105 
4,1 111 100 108 106.33 
8,1 83 76 78 79 
8,2 119 118 129 122 
9,1 151 142 153 148.66 
9,2 113 116 104 111 
10,1 108 107 101 105.33 
3208/3199A 1 lM. ethanol 3,1 23 20 21 21.33 285.64 
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3,2 19 13 19 17 
5,1 20 22 25 22.33 
5,2 18 22 18 19.33 
6,1 55 56 60 57 
6,2 35 35 33 34.33 
7,1 46 42 43 43.66 
7,2 27 32 28 29 
8,1 28 23 25 25.33 
8,2 17 15 17 16.33 
3208/3199A5 wt ethanol 3,2 49 50 48 49. 369.64 
4,2 39 43 42 41.33 
5,1 35 33 41 36.33 
5,2 39 38 34 37 
6,1 41 42 48 43.66 
6,2 28 27 32 29 
8,1 56 58 58 57.33 
8,2 35 30 35 33.33 
9,1 24 17 22 21 
9,2 23 18 24 21.66 
3220/3187C2 wt ethanol 2,1 42 43 43 42.66 527.64 
2,2 41 39 34 38 
3,1 48 44 40 44 
3,2 47 38 33 39.33 
4,1 44 37 42 41 
4,2 43 45 40 42.66 
5,1 43 43 43 43 
5,2 54 62 57 57.66 
10,1 95 97 102 98 
10,2 76 82 86 81.33 
5134/5130A1 wt ethanol 1,1 26 34 34 31.33 300.63 
1,2 23 27 33 27.33 
4,2 28 27 31 23.33 
7,1 33 35 38 35.33 
7,2 22 26 22 23.33 
8,1 40 46 54 46.66 
8,2 22 29 33 28 
9,1 35 38 44 39 
10,1 21 26 23 23.33 
10,2 17 16 19 17.33 
3220/31 8766 wt ethanol 1,2 64 63 64 63.66 710.96 
5,1 56 51 59 55.33 
5,2 53 49 48 50 
6,1 120 115 115 116.66 
6,2 90 102 98 96.66 
7,1 92 99 91 94 
7,2 78 86 77 80.33 
8,2 61 67 60 62.66 
9,2 48 56 48 50.66 
10,1 41 42 40 41 
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3145/3135A 1 wt ethanol 1,1 37 39 35 37 476.63 
1,2 29 30 27 26.66 
3,1 55 52 54 53.66 
3,2 36 44 45 42.3 
5,1 76 62 90 62.66 
5,2 71 71 64 66.66 
9,1 62 42 50 51.33 
9,2 23 26 25 25.33 
10,1 46 46 41 45 
10,2 36 47 49 44 
5134/5130A2 wt ethanol 1,1 29 27 31 29 279.31 
1,2 24 26 29 26.33 
2,1 35 26 34 32.33 
4,1 53 57 50 53.33 
4.2 14 17 14 15 
5,2 30 25 26 27 
7,1 23 21 24 22.66 
7,2 31 29 25 26.33 
6,1 26 22 20 23.33 
9,1 15 21 16 16 
3155/3104A7 Heter HaPrP ethanol 1,1 76 76 60 77.33 794.3 
4,1 72 70 71 71 
4,2 57 66 73 65.33 
6,2 25 21 26 24.66 
6,1 76 75 76 77 
6,2 73 76 71 73.33 
9,1 109 117 115 113.66 
10,1 104 112 102 106 
10,2 71 74 75 73.33 
3126/3104A9 Heter HaPrP ethanol 1,1 64 75 63 60.66 661.3 
1,2 77 69 74 73.33 
3,2 30 30 30 30 
4,1 51 53 52 52 
6,1 96 67 92 91.66 
6,2 65 52 5956,66 
9,1 77 79 70 75.33 
9,2 62 56 55 57.66 
10,1 65 91 BB BB 
10,2 70 79 73 74 
3149/3157A1 Heter HaPrP ethanol 1,1 126 143 131 134 1030.96 
1,2 123 126 131 126.66 
2,1 112 121 114 115.66 
3,1 66 92 96 92 
3,2 66 66 66 66.66 
4,1 74 61 73 76 
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3149/3157A8 Heler HaPrP elhanol 
3156/3102A3 Heler HaPrP elhanol 
3156/3102A8 Heler HaPrP elhanol 
3008215133A8 Heler HaPrP elhanol 
30083/4830A 12 Heler HaPrP ethanol 
5,1 
5,2 
9,1 
9,2 
1,1 
3,1 
3,2 
4,1 
4,2 
5,1 
5,2 
7,1 
9,1 
9,2 
3,1 
3,2 
4,1 
4,2 
6,1 
7,1 
7,2 
9,1 
10,1 
10,2 
1,1 
6,1 
6,2 
7,1 
7,2 
8,1 
9,1 
9,2 
10,1 
10,2 
1,1 
1,2 
2,1 
2,2 
5,1 
5,2 
6,1 
6,2 
7,1 
7,2 
1,1 
1,2 
2,1 
3,1 
3,2 
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72 
104 
104 
120 
112 
74 
63 
66 
56 
76 
43 
97 
127 
88 
49 
74 
89 
79 
95 
72 
72 
80 
88 
78 
72 
63 
66 
46 
64 
62 
52 
39 
56 
38 
68 
76 
93 
64 
69 
83 
106 
86 
38 
40 
68 
66 
55 
57 
51 
78 
122 
122 
128 
111 
81 
62 
74 
62 
74 
53 
101 
132 
96 
47 
65 
85 
70 
100 
79 
67 
73 
85 
76 
73 
65 
59 
43 
65 
59 
53 
41 
57 
38 
75 
84 
89 
75 
72 
82 
105 
78 
33 
35 
63 
62 
56 
54 
46 
71 
106 
112 
121 
116 
71 
69 
66 
53 
84 
44 
117 
137 
90 
47 
73 
81 
70 
90 
81 
77 
70 
80 
71 
72 
58 
60 
43 
63 
65 
56 
44 
63 
38 
71 
81 
96 
70 
62 
88 
102 
79 
33 
38 
62 
66 
55 
51 
45 
73.66 
110.66 
112.66 
123 
113 
75.33 
64.66 
68.66 
57 
78 
46.66 
105 
132 
91.33 
47.66 
70.66 
85 
73 
90 
77.33 
72 
74.33 
84.33 
75 
72.33 
62 
61.66 
44 
64 
62 
53.66 
41.33 
58.66 
38 
71.3 
80.3 
92.6 
69.6 
67.6 
84.3 
104.3 
81 
34.6 
37.6 
64.3 
64.6 
55.3 
54 
47.3 
831.64 
754.31 
557.64 
723.2 
527.4 
5,1 58 51 54 54.3 
7,1 42 37 39 39.2 
7,2 41 40 33 38 
10,1 57 53 55 55 
10,2 52 56 5B 55.3 
30082/5133A3 Heler HaPrP elhanol 1,1 49 55 53 52.3 487.9 
1,2 46 47 44 45.6 
2,1 68 63 63 64.6 
2,2 48 46 45 46.3 
5,1 37 41 36 38 
5,2 44 47 42 44.3 
7,1 61 68 62 63.6 
7,2 51 47 40 46 
8,1 40 42 37 39.6 
8,2 51 48 44 47.6 
483214186A5 Heler HaPrP elhanol 1,1 43 42 43 42.6 349.7 
1,2 45 49 44 46 
2,1 33 33 28 31.3 
2,2 26 20 20 22 
3,1 36 33 36 35 
6,1 32 27 30 29.6 
6,2 31 25 27 27.6 
7,1 28 20 24 24 
1'0,1 51 53 53 52.3 
10,2 41 42 35 39.3 
3197/319683 Null saline 1,1 47 49 43 46.33 444.3 
1,2 45 48 47 46.66 
3,1 19 24 24 22.33 
3,2 26 32 36 31.33 
5,1 35 30 29 31.33 
5,2 13 16 20 16.33 
6,1 85 72 74 77 
6,2 56 58 56 56.66 
7,1 62 55 58 58.33 
7;2 57 62 58 59 
3197/319684 Null saline 1,1 25 30 27 27.33 356.63 
1,2 27 29 32 29.33 
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3197/319685 null 
3175/3168A2 null 
3175/316882 null 
3197/319688 null 
4103/4101A3 null 
saline 
saline 
saline 
saline 
saline 
1,3 
2,2 
3,1 
3,2 
5,2 
6,3 
7,1 
7,2 
1,3 
2,1 
2,2 
4,1 
4,2 
5,1 
5,2 
6,1 
6,2 
7,1 
1,1 
1,2 
2,1 
2,2 
5,1 
5,2 
7,2 
9,1 
10,1 
10,2 
2,1 
4,2 
5,1 
5,2 
6,1 
6,2 
8,2 
9,1 
9,2 
11,2 
1,1 
1,2 
2,1 
2,2 
3,1 
3,2 
8,1 
8,2 
10,1 
10,2 
2,1 
235 
15 
32 
28 
27 
11 
49 
80 
63 
41 
29 
32 
44 
47 
43 
30 
78 
83 
55 
27 
18 
19 
11 
31 
17 
25 
5 
22 
19 
37 
28 
29 
28 
37 
28 
45 
34 
13 
30 
14 
4 
16 
17 
13 
7 
13 
12 
12 
7 
10 
18 
24 
34 
27 
12 
44 
75 
58 
47 
35 
34 
44 
51 
46 
35 
65 
75 
47 
26 
19 
19 
9 
28 
13 
20 
3 
24 
14 
35 
28 
23 
28 
31 
23 
39 
36 
11 
33 
14 
5 
13 
16 
9 
5 
9 
14 
14 
10 
9 
17 
27 
34 
24 
15 
46 
82 
58 
52 
33 
30 
42 
45 
38 
36 
64 
86 
49 
26 
16 
15 
8 
28 
12 
20 
4 
20 
15 
42 
33 
34 
28 
32 
24 
44 
34 
11 
30 
14 
7 
18 
22 
10 
10 
14 
16 
13 
7 
8 
16.66 
27.66 
32 
26 
12.66 
46.33 
79 
59.66 
46.66 
32.33 
32 
43.33 
47.66 
42.33 
33.66 
69 
81.33 
50.33 
26.33 
17.66 
17.66 
9.33 
29 
14 
21.66 
4 
22 
16 
38 
29.66 
28.66 
28 
33.33 
25 
42.66 
34.66 
11.66 
31 
14 
5.33 
15.66 
18.33 
10.66 
7.33 
12 
14 
13 
8 
9 
478.63 
177.64 
302.63 
118.31 
105.97 
4104/4102A1 Null saline 
4103/4101A8 Null saline 
4104/4102A4 Null saline 
3186/3180B2 lM. saline 
3,1 
4,2 
5,2 
6,1 
6,2 
9,1 
9,2 
10,1 
10,2 
3,1 
3,2 
4,1 
4,2 
5,1 
5,2 
6,2 
7,2 
9,1 
9,2 
1,2 
2,2 
3,1 
3,2 
5,1 
5,2 
6,1 
6,2 
9,1 
9,2 
1,1 
2,1 
2,2 
5,1 
5,2 
7,1 
8,1 
8,2 
10,1 
10,2 
2,1 
4,1 
4,2 
5,1 
236 
6 
14 
3 
15 
18 
14 
16 
5 
3 
20 
8 
17 
8 
11 
2 
15 
12 
16 
11 
5 
15 
10 
7 
28 
15 
24 
22 
15 
23 
12 
9 
6 
14 
5 
14 
11 
16 
16 
7 
44 
28 
19 
36 
4 
17 
3 
18 
20 
19 
11 
2 
3 
26 
10 
18 
9 
14 
5 
17 
17 
15 
11 
6 
14 
12 
7 
34 
13 
27 
22 
18 
25 
16 
13 
5 
16 
7 
14 
19 
22 
23 
7 
48 
27 
17 
41 
7 
14 
4 
13 
24 
16 
15 
3 
4 
22 
7 
16 
13 
11 
4 
18 
12 
21 
13 
4 
15 
9 
5 
28 
16 
28 
22 
17 
27 
12 
11 
4 
13 
7 
20 
13 
18 
24 
11 
49 
28 
18 
41 
5.66 
15 
3.33 
15.33 
20.66 
16.33 
14 
3.33 
3.33 
22.66 
8.33 
16.66 
10 
12 
3.66 
16.66 
13.66 
17.33 
11.66 
5 
14.66 
10.33 
6.33 
30 
14.66 
26.33 
22 
16.66 
25 
13.33 
11 
5 
14.33 
6.33 
16 
14.33 
18.66 
21 
8.33 
47 
27.66 
18 
39.33 
132.62 
165.97 
138.31 
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3186/318083 wt 
3220/318781 wt 
3208/3199A3 wt 
3208/3199A4 wt 
3220/318784 wt 
saline 
saline 
saline 
saline 
saline 
5,2 
6,2 
7,1 
7,2 
8,1 
11,2 
1,1 
1,2 
2,1 
2,2 
3,1 
3,2 
4,1 
4,2 
5,1 
5,2 
1,1 
1,2 
2,1 
2,2 
3,1 
3,2 
3,3 
4,1 
4,2 
7,2 
1,1 
1,2 
2,1 
2,2 
3,1 
3,2 
4,1 
4,2 
7,1 
7,2 
1,1 
1,2 
4,1 
4,2 
8,1 
8,2 
9,1 
9,2 
10,1 
10,2 
1,1 
1,2 
2,1 
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20 
30 
41 
21 
26 
21 
49 
32 
32 
24 
24 
17 
15 
23 
25 
33 
18 
15 
18 
28 
23 
24 
15 
41 
65 
36 
9 
14 
30 
20 
19 
15 
16 
15 
16 
11 
18 
11 
13 
13 
17 
13 
23 
16 
17 
15 
7 
19 
11 
21 
35 
43 
21 
25 
25 
53 
36 
30 
24 
23 
17 
17 
23 
34 
36 
26 
20 
14 
31 
24 
22 
14 
44 
56 
36 
6 
11 
23 
23 
17 
10 
14 
16 
16 
10 
18 
13 
12 
12 
17 
16 
26 
15 
18 
16 
7 
12 
12 
21 
39 
44 
25 
27 
26 
52 
34 
30 
30 
21 
13 
14 
23 
30 
32 
25 
17 
15 
32 
23 
16 
13 
51 
55 
37 
6 
12 
26 
18 
15 
11 
14 
17 
12 
10 
12 
13 
9 
10 
19 
19 
24 
18 
17 
18 
7 
12 
14 
20.66 
34.66 
42.66 
22.33 
26 
24 
51.33 
34 
30.66 
26 
22.66 
15.66 
15.33 
23 
29.66 
33.66 
23 
17.33 
15.66 
30.33 
23.33 
20.66 
14 
45.33 
58.66 
36.33 
7 
12.33 
26.33 
20.33 
17 
12 
14.66 
16 
14.66 
10.33 
16 
12.33 
11.33 
11.66 
17.66 
16 
24.33 
16.33 
17.33 
16.33 
7 
14.33 
12.33 
281.96 
284.63 
150.64 
159.3 
92.64 
2,2 9 7 8 8 
3,1 6 7 6 6.33 
3,2 4 6 3 4.33 
4,1 15 11 15 13.66 
4,2 7 8 6 7 
8,1 13 15 13 13.66 
8,2 4 8 6 6 
3145/3135A3 lM. saline 1,1 19 18 13 16.66 198.29 
1,2 12 14 11 12.33 
3,1 24 27 26 25.66 
3,2 22 23 21 22 
4,1 23 28 18 23 
4,2 22 26 21 23 
5,1 17 19 14 16.66 
5,2 19 23 23 21.66 
9,1 20 21 21 20.66 
9,2 17 17 16 16.66 
3220/3187C5 lM. saline 2,1 25 30 26 27 212.98 
2,2 23 28 24 25 
4,1 20 23 24 22.33 
4,2 12 13 12 12.33 
6,1 12 16 12 13.33 
6,2 15 14 12 13.66 
8,1 28 21 26 25 
8,2 25 19 25 23 
10,1 29 33 32 31.33 
10,2 16 22 22 20 
51 34/5130A4 lM. saline 1,1 8 8 6 7.33 96.63 
1,2 4 6 3 4.33 
4,2 14 15 13 14 
5,1 15 17 12 14.66 
5,2 8 9 8 8.33 
7,1 13 14 10 12.33 
8,2 14 9 12 11.66 
9,1 11 7 6 8 
9,2 2 3 2 2.33 
10,2 15 14 12 13.66 
5134/5130A6 lM. saline 1,1 21 18 18 19 130.31 
1,2 9 10 8 9 
2,2 15 16 14 15 
4,1 16 16 17 16.33 
7,1 12 10 13 11.66 
7,2 10 11 13 11.33 
9,1 16 10 13 13 
9,2 8 7 10 8.33 
10,1 14 16 12 14 
10,2 13 14 11 12.66 
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3128/31 04A3 Heler HaprP saline 1,1 49 51 47 49 481.31 
2,1 60 63 69 64 
2,2 53 46 52 50.33 
3,2 33 35 35 34.33 
4,1 47 52 51 50 
7,1 64 59 68 63.66 
7,2 32 36 40 36 
8,2 49 43 42 44.66 
9,1 52 55 55 54 
9,2 33 38 35 35.33 
3155/3104A10 Heler HaPrP saline 1,1 14 10 1.1 11.66 151.61 
1,2 12 10 10 10.66 
6,1 9 10 7 8.66 
6,2 24 20 19 21 
7,1 18 18 20 18.66 
7,2 12 10 7 9.66 
8,1 20 21 24 21.66 
8,2 12 11 12 11.66 
10,1 31 28 29 29.33 
10,2 10 9 7 8.66 
3149/3157A4 Heler HaPrP saline 1,1 46 48 43 45.66 356.63 
1,2 41 39 46 42 
3,2 51 55 55 53.66 
4,1 44 44 45 44.33 
4,2 46 44 49 46.33 
5,1 22 25 24 23.66 
5,2 11 12 9 10.66 
6,1 26 29 26 27 
6,2 32 36 35 34.63 
7,1 27 30 30 29 
3149/3157A5 Heler HaPrP saline 2,1 18 17 23 19.33 264.3 
2,2 30 29 30 29.66 
4,1 35 35 39 36.33 
4,2 24 24 28 25.33 
6,1 29 27 33 29.66 
6,2 20 20 21 20.33 
7,1 35 32 35 34 
8,1 23 21 24 22.66 
8,2 22 24 23 23 
10,1 22 28 22 24 
3156/3102A6 Heler HaPrP saline 1,1 10 11 10 10.33 144.29 
1,2 10 12 10 10.66 
2,1 21 22 24 22.33 
2,2 15 18 15 16 
4,1 20 20 24 21.33 
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3156/3102A5 Heler HaPrP saline 
3008215133A4 Heler HaPrP saline 
30083/4830A9 Heler HaPrP saline 
30082/5133Al Heler HaPrP saline 
483214186Al Heler HaPrP saline 
4,2 
5,1 
5,2 
8,1 
8,2 
1,1 
1,2 
4,1 
4,2 
5,1 
5,2 
9,1 
9,2 
10,1 
10,2 
2,2 
5,1 
5,2 
6,2 
7,2 
8,1 
9,1 
9,2 
10,1 
10,2 
4,1 
4,2 
5,1 
5,2 
7,1 
7,2 
8,1 
8,2 
10,1 
10,2 
3,1 
3,2 
4,1 
4,2 
5,1 
5,2 
6,1 
6,2 
8,1 
8,2 
4,1 
5,1 
5,2 
6,1 
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5 
8 
13 
14 
17 
6 
8 
26 
17 
11 
9 
18 
5 
22 
21 
39 
34 
20 
33 
45 
44 
38 
41 
48 
36 
19 
19 
25 
19 
22 
20 
32 
24 
17 
15 
39 
21 
38 
28 
22 
18 
39 
35 
41 
26 
19 
15 
11 
23 
7 
12 
16 
13 
21 
8 
10 
29 
18 
15 
11 
15 
8 
27 
19 
42 
29 
19 
34 
50 
47 
41 
41 
47 
38 
23 
18 
19 
22 
23 
16 
36 
21 
19 
14 
40 
22 
34 
31 
27 
15 
36 
30 
33 
26 
25 
15 
9 
21 
8 
8 
15 
11 
23 
8 
10 
28 
21 
16 
13 
18 
6 
22 
20 
39 
28 
20 
35 
52 
46 
43 
37 
50 
35 
21 
24 
21 
21 
23 
17 
36 
25 
18 
12 
33 
21 
36 
30 
23 
13 
36 
31 
33 
30 
20 
11 
8 
19 
6.66 
9.33 
14.66 
12.66 
20.33 
7.33 
9.33 
27.66 
18.66 
14 
11 
17 
6.33 
23.66 
20 
40 
30.3 
19.6 
34 
49 
45.6 
40.6 
39.6 
48.3 
36.3 
21 
20.3 
21.6 
20.6 
22.6 
17.6 
34.6 
23.3 
18 
13.6 
37.3 
21.3 
36 
29.6 
24 
15.3 
37 
32 
35.6 
27.3 
21.3 
13.6 
9.3 
21 
154.97 
383.3 
213.2 
295.4 
158.7 
6,2 16 15 19 16.6 
7,1 20 19 18 19 
7,2 19 19 17 18.3 
8,2 14 9 9 10.6 
9,2 14 13 15 14 
10,2 18 13 14 15 
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Anti-active caspase 3 
Anti-GFAP 
Anti-NeuN 
Appendix 3 
List of Antibodies Used 
Cell Signaling ASP175 1: 1000 IRC 
Chemicon International MAB 3402 1 :2000 IRC 
Chemicon International MAB377 1 :5000 IRC 
Donkeyanti-rabbit AffiniPure, Jackson Immunoresearch 711-035-1521: 1000 IRC 
Donkeyanti-mouse AffiniPure, Jackson Immunoresearch 715-035-1511:2000 IRC 
Anti-active Bax 6A 7 BD Pharmingen 556467 1 :500 WB, 1: 125 IP 
Anti-Bax N20 Santa Cruz Biotechnology sc-493 1:1000 WB 
Anti-cytochrome C BD Pharmingen 556433 1:500 WB 
Anti-beta tubulin Sigma-Aldrich T3526 1:250 WB 
Anti-beta actin Sigma-Aldrich AC-15 1 :5000 WB 
Cytosolic RSP70 Stressgen SPA-81O 1:500 WB 
Mitochondrial RSP70 Affinity BioRegents MA3-028 1 :500 WB 
Anti-PrP 3F4 (anti-hamster) hybridoma cellline 1: 1000 WB 
Anti-PrP R155 (anti-mouse) anti-sera made in our laboratory 1:1000 WB 
Anti-PrP 13A5 (anti-hamster) Laboratory of Dr. Lingappa 1:800 WB 
Donkeyanti-rabbit AffiniPure, Jackson Immunoresearch 711-035-1521:3000 WB 
Donkeyanti-mouse AffiniPure, Jackson Immunoresearch 715-035-1511:5000 WB 
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Appendix 4 
AH of the mi ce used in this research were housed in accordance with McGill 
University protocol number 4383 and the guidelines of the Canadian Council on 
Animal Care, and were housed at the Animal Facility at the Lady Davis Institute for 
Medical Research, 3755 chemin de la Cote-Sainte Catherine, Montreal, QC H3T -IE2. 
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